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I ZUSAMMENFASSUNG 
Trotz intensiver medizinischer und wissenschaftlicher Forschung sind Lungentransplantationen 
häufig immer noch die einzige therapeutische Möglichkeit zur Behandlung vieler 
Lungenerkrankungen im Endstadium. Das Langzeitüberleben vieler Organempfänger wird durch 
das Auftreten einer chronischen Dysfunktion der Lunge, der sogenannten „chronic lung allograft 
dysfunction“ (CLAD) stark limitiert, die zu einer Sterberate von 90% der Patienten innerhalb der 
ersten zehn Jahren führt. Unter CLAD werden verschiedene Arten von Lungendysfunktionen 
zusammengefasst, wobei das Bronchiolits obliterans Syndrom (BOS) die häufigste Form darstellt. 
BOS ist charakterisiert durch einen Verschluss der kleinen Atemwege, verursacht durch luminale 
Fibrose, begleitet von großflächiger Zerstörung der Bronchialepithelzellen und einem massiven 
Einwandern von Leukozyten. Dendritische Zellen (DCs) gehören zu den antigenpräsentierenden 
Leukozyten, die durch Aktivierung des adaptiven Immunsystems eine entscheidende Rolle bei der 
BOS-Pathogenese spielen. Des Weiteren wurde bei dieser Erkrankung eine Beteiligung von 
spezifischen Enzymen, den sogenannten Matrix Metalloproteinasen (MMPs) nachgewiesen, die an 
der Regulierung der Migration, der Zytokinspiegel sowie diverser weiterer Zellfunktionen beteiligt 
sind. Murine pulmonale DCs exprimieren im Vergleich zu anderen Leukozyten unter 
Ruhebedingungen vor allem MMP-12 und -13. Über ihre Funktion in DCs, ihre Rolle in 
Entzündungsprozessen und ihre Beteiligung bei der Pathogenese von BOS ist jedoch wenig 
bekannt.  
Ziel dieser Dissertation war es spezifische immunbiologische Funktionen von ausgewählten 
MMPs, vornehmlich MMP-12 und -13, in DCs zu identifizieren und deren Einfluss auf die 
Pathogenese des experimentellen BOS zu analysieren. 
Für die funktionalen in vitro Analysen wurden DCs aus dem Knochenmark von Mäusen generiert 
(“bone marrow-derived DCs“ (BMDCs)). Die Expression von MMP-12 und -13 konnte in den 
generierten BMDCs auf mRNA- und Proteinebene bestätigt sowie deren Aktivität in 
Zellüberständen quantifiziert werden. Die Behandlung der BMDCs mit Lipopolysaccharid (LPS) 
erhöhte die Expression von MMP-13 sowie dessen Aktivität. Funktionale Analysen mit einem 
spezifischen Inhibitor für MMP-13 zeigten eine verringerte Kapazität der BMDCs zur Endozytose 
von löslichem Ovalbumin (OVA), wohingegen Reifung und Migration der Inhibitor behandelten 
Zellen nicht beeinflusst wurden. Weiterhin konnte gezeigt werden, dass eine MMP-13-Inhibition 
die Oberflächenexpression des Haupthistokompatibilitätskomplex der Klasse I (MHC-I) auf 
BMDCs und in Folge die Aktivierung von T-Zellen verringerte. Ein verändertes Zytokin- und 
Chemokin-Profil der BMDCs nach Inhibition von MMP-13 unterstrich weiterhin den regulierenden 
Einfluss den MMP-13 auf die DC-Funktion besitzt. Besonders Zytokine wie Interleukin (IL) -12, 
IL-23 und IL-6, welche vor allem eine Rolle bei der Regulierung und Polarisierung von T-Zellen 
spielen, waren signifikant reduziert (Manuskript in revision).  
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Des Weiteren wurde die Rolle von MMP-13 für die Pathogenese von BOS in vivo untersucht. 
Hierfür wurde das Tiermodell der subkutanen Tracheatransplantation, das sogenannte “heterotopic 
trachea transplant (HTT) model“, etabliert und verwendet. Die Transplantate allogen 
transplantierter Tiere zeigten den typischen BOS-Phänotyp mit luminalem Tracheenverschluss, 
epithelialen Veränderungen sowie massivem Leukozyteneinstrom. Im Vergleich zu den syngen 
transplantierten Tieren zeigten die Tracheen der allogen transplantierten Tiere einen Anstieg an 
MMP-13 mRNA. Zudem konnte MMP-13 in Gewebeschnitten der Tracheen mit Hilfe der 
Immunfluoreszenzfärbung (IF) lokalisiert werden. In einer Pilotstudie, in welcher der MMP-13 
Inhibitor allogen transplantierten Mäusen verabreicht wurde, konnte ein milderer BOS-Phänotyp 
festgestellt werden. 
Die vorliegende Studie beschreibt somit, dass MMP-13 über die Beeinflussung wichtiger DC-
Funktionen, z.B. der Antigenpräsentation und der Sekretion von Zytokinen und Chemokinen, einen 
regulierenden Einfluss auf die T-Zellaktivierung hat. Weiterhin deuten die Ergebnisse darauf hin, 
dass MMP-13-Inhibition ein möglicher Therapieansatz bei immunbiologischen Prozessen im 
Allgemeinen und bei BOS im Besondern sein könnte. 
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II SUMMARY 
Despite intensive medical and scientific research, lung transplantation is often the only therapeutic 
option for end-stage pulmonary diseases. Long-term survival after lung transplantation is 
dramatically limited due to the occurrence of chronic lung allograft dysfunction (CLAD), which 
leads to death in 90% of the patients within the first ten years. Bronchiolitis obliterans syndrome 
(BOS) is the most frequent subgroup of CLAD. BOS is characterized by occlusion of the airways 
caused by luminal fibrosis, epithelial damage, and influx of leukocytes. Dendritic cells (DCs) are 
antigen-presenting cells among the leukocytes which can activate the adaptive immune system and, 
thereby, participate in the pathogenesis of BOS. Matrix metalloproteinases (MMPs) are enzymes 
that are important for the regulation of diverse cellular functions and are reported to participate in 
the development of experimental BOS. It is published that murine pulmonary DCs express specific 
MMPs, such as MMP-12 and -13, but little is known about their functions in DCs and their role in 
inflammatory conditions. 
The objective of the thesis was to identify specific functions of selected MMPs, mainly MMP-12 
and -13, in DC immunobiology and to determine the contribution to the pathogenesis of 
experimental BOS.  
For the functional cell assays, bone marrow-derived DCs (BMDCs) were generated. MMP-12 
and -13 expression was quantified in BMDCs at mRNA and protein level and, furthermore, their 
activities were investigated. It was observed that treatment with the pro-inflammatory stimulus 
lipopolysaccharide (LPS) strongly enhanced MMP-13 mRNA expression and activity, indicating 
an important role of MMP-13 in inflammatory processes. Functional cell-based assays revealed 
that the capacity of BMDCs to endocytose soluble ovalbumin (OVA) was significantly decreased 
by inhibition of MMP-13, while BMDC migration and maturation remained unchanged. 
Furthermore, inhibition of MMP-13 reduced the surface expression of the Major Histocompatibility 
Complex class I (MHC-I) and lowered the capability of murine BMDCs to activate CD8+ T cells. 
Alterations in the BMDC cytokine/chemokine profile after inhibition of MMP-13, in particular the 
reduction of T cell targeting cytokines such as interleukin (IL) -12, IL-23, and IL-6, further 
emphasized the role of MMP-13 in the regulation of BMDC immunobiology (manuscript in 
revision).  
To study the relevance of MMP-13 in vivo, a murine heterotopic trachea transplant (HTT) model 
was established. Allogeneic transplanted animals revealed the typical BOS-phenotype showing 
luminal occlusion, epithelial damage, and leukocyte influx. Increased MMP-13 mRNA expression 
was detected in allografts compared to syngrafts suggesting a role of MMP-13 in the pathogenesis. 
Furthermore, MMP-13 was localized in transplanted tracheas by the use of immunofluorescence 
(IF) staining. Finally, a pilot treatment study using the specific MMP-13 inhibitor revealed an 
attenuated BOS-phenotype in allografts.  
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In summary, the present study describes a novel role of MMP-13 in regulating DC functions 
including antigen presentation, cytokine/chemokine secretion, and T cell activation by BMDCs and 
indicates that inhibition of MMP-13 might be a promising therapeutic approach to moderate 
inflammatory processes in general and to alleviate the pathogenesis of BOS in particular. 
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 INTRODUCTION 1
1.1 Dendritic cells (DCs) and their role in the immune system 
The host defense by the mammalian immune system is based on the interplay of the innate 
nonspecific immune response and the specific adaptive immune response1-3. Dendritic cells (DCs), 
natural killer (NK) cells, macrophages, and granulocytes belong to the innate immunity and permit, 
together with complement and interferons, a rapid protection against pathogens. Furthermore, they 
are able to communicate the danger of pathogen invasion to the adaptive immune system and, 
thereby, provoke a cascade of defense mechanisms4. The adaptive immune system consists of 
T and B cells. The generation of a large diversity of highly antigen-specific clones and the 
development of an immunological memory are the characteristics of the adaptive immune system. 
The cells which orchestrate and regulate this highly sophisticated and potent system are the 
antigen-presenting cells (APC). B cells, macrophages, and DCs are professional APCs 
constitutively expressing the major histocompatibility complex (MHC) class II proteins, while 
other cell types such as fibroblasts, epithelial cells, glia cells, and vascular endothelial cells are 
classified as non-professional APCs5. Among APCs, DCs are unique, as they can initiate primary 
immune responses6-9.  
1.1.1 The immunobiology of DCs 
The life cycle of a DC starts in the bone marrow. DC progenitors leave the bone morrow and 
circulate as precursors through blood and the lymphatic system. They are resident in peripheral 
tissues as immature DCs and build up a defense line serving as guards against pathogens10,11. 
Attracted by cytokines and chemokines, they follow signals of tissue damage, take up foreign and 
self antigens, and migrate to the lymphoid organs where they meet and activate naïve T cells 
through antigen presentation12. Beside antigen presentation, another important ability of DCs is the 
release of specific cytokines and chemokines to direct the T cell response towards a specific type, 
such as T helper cells type (Th)1/Th2 cells, or to attract other immune cells (schematized in Figure 
1.1).  
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Figure 1.1: Schematic overview of DC function.  
[1] DCs migrate as precursors from the blood system to the area of infection, baited by danger signals, which 
are recognized by a panel of Toll-like receptors (TLR). These signals include typical microbial signals, such 
as lipopolysaccharide (LPS), viral dsRNA, as well as endogenous danger signals, such as heat-shock 
proteins, tumor necrosis factor (TNF)-α, and interleukin-1β (IL-1β), released by stressed and necrotic cells of 
damaged tissue. [2] In addition, DCs themselves secret cytokines and chemokines to bait other immune cells. 
At the area of pathogen invasion [3], DCs take up antigens, for instance by endocytosis (e.g. via mannose 
receptor (MR)), phagocytosis, or pinocytosis. At this functional stage, DCs express a variety of different 
endocytic receptors, including fragment crystallizable (Fc)-receptors, lectin-like receptors, and receptors for 
complement binding. While immature DCs express endocytic receptors strongly, they are poor in MHC-II 
surface expression. This phenotype changes after antigen uptake. [4] DCs migrate with the trapped antigen to 
the lymph nodes, [5] process the antigen, and [6] present it on MHC-I or -II to cytotoxic or helper T cells. 
Following the chemokine (C-C motif) ligand (CCL)21 gradient, they migrate through the lymphatic system 
to the lymph nodes. [7] At this stage, DCs express a variety of co-receptors, like cluster of differentiation 
(CD)40, CD80, CD86, and increase the MHC-II surface expression dramatically to interact optimally with 
T lymphocytes. [8] Binding of a MHC/peptide-complex on the surface of DCs to the specific T cell receptor 
on T lymphocytes initiates the adaptive immune response. (Figure adapted and modified from Vermaelen and 
Pauwels, 2004)13. 
 
1.1.1.1 Migration, antigen uptake, and maturation of DCs 
DCs do not reside at one place. They migrate through the endothelium to the infected area and 
further to the lymphoid organs to activate the adaptive immune system. At the area of pathogen 
invasion, DCs take up antigens, for instance by endocytosis14, phagocytosis15,16, or pinocytosis14. 
DCs undergo dramatically morphological and functional changes, defined as maturation, which 
enable them to operate optimal at the different stages during their life cycle17-19. As immature cells, 
DCs express receptors which are required to capture antigens14,20, whereas mature DCs 
downregulate these receptors and upregulate co-stimulatory molecules, such as cluster of 
differentiation (CD)40, CD58, CD80, and CD8621. Furthermore, mature DCs show an increased 
surface expression of MHC-II molecules22 as well as a shift in lysosomal compartments with an 
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increase in DC lysosome-associated membrane protein (DC-LAMP)6,17,23 (Figure 1.1). Altogether, 
these phenotypic and functional changes facilitate the optimal processing and presentation of 
antigens. DC maturation can be induced by various pathogen-derived molecules, such as 
lipopolysaccharides (LPS)24, bacterial DNA25-29, as well as double-stranded RNA29. Additionally, 
T cell-derived signals and the balance between pro-inflammatory and anti-inflammatory cytokines 
in the DC microenvironment contribute to the regulation of the DC maturation process.  
1.1.1.2 Antigen processing and presentation by DCs 
DCs present the antigen-derived peptides to T cells in one of the following three pathways17. 
Endogenous proteins are routinely degraded in the cytosol by the proteasome and loaded on MHC-I 
in the endoplasmic reticulum (ER) for the final presentation to CD8+ cytotoxic T lymphocytes30-32 
(Figure 1.2 left, MHC-I pathway).  
Exogenous proteins, internalized for example by endocytosis, are degraded in endosomal 
compartments and loaded on MHC-II to activate CD4+ T cells20-22,33-40 (Figure 1.2 right, MHC-II 
pathway). 
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Figure 1.2: Antigen processing and presentation on MHC-I or MHC-II.  
(Left) MHC-I pathway: Endogenous proteins, like those of viruses, are degraded in the cytosol by the 
proteasome. The degraded antigens enter the ER as peptides through the transporter associated with the 
antigen processing (TAP). Peptides of 8-10 amino acids in length (depicted in black) find a place in the 
binding groove of the MHC-I molecule. Once the peptide is loaded onto the MHC class I molecule, the 
complex leaves the ER through a secretory pathway to reach the cell surface. The surface peptide-MHC-I 
complex can now be recognized by the T cell receptor (TCR) on CD8+ T cells in combination with the CD8 
co-receptor. 
(Right) MHC-II pathway: Exogenous proteins are internalized by endocytosis and degraded in the endosome. 
The MHC-II complex is synthesized in the ER. In the ER the invariant chain (depicted in black and light 
blue) binds to the MHC-II molecule to stabilize the MHC-II complex and to avoid unspecific peptide biding. 
After passing from the ER to the Golgi, the MHC-II molecule enters the late endosome that contains the 
degraded proteins. The invariant chain is broken down by a protease called cathepsin leaving a small 
fragment named CLIP (depicted in blue) in the MHC-II binding groove until it is replaced by the exogenous 
peptide (depicted in red). Typically, peptides of 15-24 amino acids in length are presented by the MHC-II 
molecule. On the surface, the MHC-II-peptide complex can be recognized by CD4+ T cells with the help of 
the CD4 co-receptor (Figure adapted and modified from Villadangos and Schnorrer, 2007)41.  
 
In 1976, Michael J. Bevan first described a third mechanism named cross-presentation, where 
exogenous proteins could also be presented on MHC-I and stimulate CD8+ T cells32. The 
“cytosolic” and the “vacuolar” pathway have been reported as the two main pathways in cross-
presentation42. In case of the “cytosolic” pathway, internalized proteins access the cytosol, are 
degraded by the proteasome, and loaded on MHC-I molecules43-48. In contrast, in the “vacuolar” 
pathway, antigens are processed within the phagosome by endocytic proteases and loaded on 
MHC-I directly in the phagosome49,50. Cross-presentation is thought to be crucial for the defense 
against viruses that do not directly infected APCs and against tumor cells51,52.  
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1.1.1.3 Interaction of DCs with T and B cells  
DC-T cell interaction is based on an antigen-specific T cell receptor (TCR) on T cells that 
recognizes its corresponding peptide bound on MHC-I or -II on DCs. In vivo, this interaction takes 
place in lymphoid organs where immunity is primed53,54. The TCR-MHC recognition is known as 
”signal one” and is supported by multiple adhesion molecules, such as integrin β1 and β2 as well as 
members of the immunoglobulin superfamily (lymphocyte function-associated antigen (LFA)-2, 
intercellular adhesion molecules (ICAM)-3, ICAM-1, and LFA-3)7,8,55. If a TCR interacts with its 
cognate peptide-MHC complex, the adhesion between the two cells becomes tightened, thereby 
enabling the interaction of co-stimulatory molecules on the DC with the corresponding ligands 
expressed on the T cell55,56. The recognition of the co-stimulatory molecules is known as ”signal 
two” and facilitates T cell activation. For instance, the interaction of the co-stimulatory molecule 
CD40 on DCs with its ligand (CD40-L) on T cells activates DCs, increases the expression of 
further co-stimulatory molecules, such as CD80 and CD86, and promotes specific cytokine 
release20,57-60. The interface between the DC and the T cell is known as immunological synapse61.  
Beside T cell activation, DCs are also able to activate naïve and memory B cells. The secretion of 
interleukin (IL)-12 in combination with IL-6 by DCs supports the differentiation of B cells into 
plasma cells62,63. Furthermore, DCs can regulate effectors of the innate immunity, such as NK cells 
and NK T cells, either via direct cell contact or by modulating cytokines. IL-12, IL-15, and IL-18 
are typical cytokines that promote NK or NK T cell activation64,65.  
Depending of the maturation state and the surrounding microenvironment, DCs play not only a role 
in the induction but also in the suppression of immunity. DCs induce peripheral T cell tolerance by 
continuously presenting self- or harmless antigens to T cells in the absence of co-stimulatory 
molecules and/or activating cytokines66. As part of their tolerogenic function, DCs were further 
reported to induce regulatory T cells in vitro67. However, how important DCs are for the process of 
regulatory T cells induction in vivo remains to be fully elucidated.  
1.1.1.4 Release of specific cytokines by DCs 
As mentioned before, DCs release a variety of cytokines and chemokines depending on their 
maturation state and the local microenvironment. These cytokines can either activate or dampen the 
immune response or direct immune cells to differentiate into a specific cell type.  
IL-12, IL-23, and IL-6 are typical pro-inflammatory cytokines. IL-12, beside interferon (IFN)-γ, is 
known to be the main cytokine regulating Th1 differentiation68 and, thereby, serves as a critical 
mediator of CD8+ T cell activation by driving the necessary CD4+ T cell help towards a Th1 
phenotype69-72. Furthermore, IL-12 is reported to induce T and NK cells to secrete cytokines, such 
as IFN-γ, tumor necrosis factor (TNF)-α, macrophage colony-stimulating factor (M-CSF), 
granulocyte macrophage colony-stimulating factor (GM-CSF), IL-2, IL-3, IL-8, and IL-2369,73-76 
and to increase expansion and survival of effector/memory T cell populations by reducing 
apoptosis in CD4+ and CD8+ T cells68,76. IL-12 comprises of two subunits, p35 and p40 and shares 
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the same p40 subunit with IL-23. IL-23 is another related heterodimeric cytokine that consists of a 
different second subunit (p19)77.  
IL-23 also induces proliferation and IFN-γ production but preferentially stimulates naïve 
CD4+ T cells and Th17 memory T cell populations78. The two subunits, p19 and p35, show 
homology with IL-6, another cytokine that baits T cells, regulates T cell apoptosis, and is known as 
a downstream factor of IL-2378. Beside the release of these three described cytokines, DCs further 
secret typically anti-inflammatory cytokines, such as IL-10 and transforming growth factor 
(TGF)-β and, moreover, cytokines that promote Th2 differentiation, for instance, IL-4 and IL-579. 
In addition to cytokines, DCs express a variety of chemokines, such as chemokine (C-C motif) 
ligand (CCL)3, CCL4, CCL5, chemokine (C-X-C motif) ligand (CXCL)1, CXCL2, and 
lipopolysaccharide-induced CXC chemokine (LIX), which function as chemoattractants for various 
cells, such as neutrophils and basophils80,81. In general, DC-derived cytokines and chemokines 
promote leukocyte differentiation and attraction.  
1.1.2 DC subsets in human and mice 
In general and as outlined above, DCs are a heterogeneous group of cells whose several 
subpopulations differ in phenotype and function. Furthermore, they vary between species, such as 
between human and mice82.  
Four different DC subsets have been identified in human blood: the CD123+ plasmacytoid DC 
(pDC) subset, which produces large quantities of type I interferons83 and three myeloid DC (mDC) 
types encompassing the CD1c+, CD16+, and CD141+ DC subsets84. In human tissue, five DC types 
have been described so far which are grouped in CD1c+ conventional DCs (cDCs) type 1, 
CD141+ cDCs type 285 (formerly termed mDCs type 1 and 2), CD209+ monocyte-derived DCs86, 
CD303/304+ pDCs, and Langerhans cells87-89. 
In mice, DCs are classified into similar subtypes as in humans encompassing the myeloid-derived 
CD11b+ cDCs type 1 and CD8α+ cDCs type 2 as well as mPDCA1+ pDCs, monocyte-derived DCs, 
and Langerhans cells88,90. These five subsets show differences in phenotype, localization, and 
function and display comparable functions to those in humans. Murine cDCs express high levels of 
CD11c and in mature state high levels of MHC-II and co-stimulatory molecules, such as CD80, 
CD86, and CD40, similar to the human system91-94. CD8α+ cDCs are specialized in 
cross-presentation of exogenous antigens on MHC-I molecules to CD8+ T cells95, whereas pDCs 
express high levels of IFN-α in response to IL-12 and are reported to prime allogeneic T cells less 
efficiently than CD8α+ cDCs96.  
Murine classical DCs can be generated in vitro by culturing bone marrow-derived precursor cells 
with GM-CSF97-100. This method is widely used to gain large numbers of naïve DCs for in vitro 
analyses. DCs can also be derived from blood monocytes by culturing them in GM-CSF and 
IL-4101,102. This is the main method to generate DCs in the human setting where bone marrow cells 
are difficult to obtain.  
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1.1.3 The role of DCs in disease settings 
Taking their central role as regulator of immunity, DCs are intensively studied in various human 
disease settings, such as autoimmune disease103,104, tumor development105,106, transplant 
dysfunctions107, virus infections108, and allergy109 as well as in different lung diseases, such as 
chronic obstructive pulmonary disease (COPD)110, asthma111,112, and bronchiolitis obliterans 
syndrome (BOS)113,114. As DCs play a role in the induction of both, immunity and tolerance, they 
are clinically used to manipulate the immune response in the intended direction. For instance, ex 
vivo tumor antigen-loaded DCs are used to stimulate tumor-reactive T cells in vivo to control 
cancer106. In addition, the induction of tolerance by in vitro expansion of DCs that induce antigen-
specific regulatory T cells (Tregs) is an approach to treat autoimmune disease or asthma115.  
Besides cancer and autoimmune diseases, DCs are reported to play a role in the development of 
various lung diseases, such as COPD and BOS. Here, progression of the disease is often 
interrelated with extensive remodeling and repair processes of the lung. In these pathological 
pulmonary remodeling processes, specific enzymes, so-called matrix metalloproteinases (MMPs), 
are reported to be involved. Therefore, interplay between DCs and MMPs may contribute to the 
pathogenesis of inflammatory lung diseases.  
1.2 Matrix metalloproteinases (MMPs) 
1.2.1 Function of MMPs 
MMPs belong to the family of zinc-dependent endopeptidases. The first MMP was discovered by 
Gross and Lapiere in 1962 in the regressing tadpole tail116. Since then, more and more MMPs have 
been described. The MMP family currently includes 25 secreted as well as cell-anchored 
enzymes117. By degrading different structural matrix and non-matrix proteins, MMPs are involved 
in diverse biological and pathological processes, such as embryogenesis and differentiation, wound 
healing, tissue repair and remodeling, as well as cancer development and inflammatory diseases118-
120
. As such, these enzymes are mainly known to degrade extra cellular matrix proteins. Recent 
studies, however, indicate an involvement of MMPs in various other cellular processes. Based on 
the new discovered ability of MMPs to modify cytokines/chemokines and their receptors, they play 
important roles in innate immunity and in inflammatory processes121.  
1.2.2 Structure of MMPs 
MMPs usually consist of a pro-domain, a catalytic domain, and a C-terminal hemopexin-like 
domain (Figure 1.3). The highly conserved pro-domain, with a length of around 80 amino acids, 
typically contains the consensus sequence PRCXXPD. The catalytic domain (170 amino acids) 
contains a zinc ion in the active site, linked to three histidine residues. Furthermore, MMPs have a 
proline-rich hinge region that connects the catalytic domain with a carboxy-terminal 
hemopexin-like domain (200 amino acids), which is important for substrate recognition (Figure 
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1.3). The majority of MMPs are secreted, with the exception of MMP-14, -15, -16, -17, -25, 
and -24, which are membrane-anchored121-123. 
 
Figure 1.3: Basic structure of MMPs.  
The basic structure of MMPs consists of a N-terminal signal peptide (depicted in dark grey), a pro-domain 
(depicted in magenta) that is linked to a zinc ion of the catalytic domain (depicted in red) via a thiol group, 
and a carboxy-terminal hemopexin-like domain (depicted in grey). The bonding between the thiol group and 
the zinc ion (both depicted in yellow) ensures the inactive state of the pro-peptide. (Figure adapted and 
modified from Song et al.)124 
 
1.2.3 Regulation of MMPs 
MMPs can be regulated on transcriptional level as well as through the activation of the pro-enzyme 
and the inactivation of the active MMP. MMPs are generated as pro-peptides that are kept in a 
catalytically inactive state. This inactivity is sustained by the bonding between the thiol group of a 
cysteine residue of the pro-domain and the zinc ion of the catalytic domain (Figure 1.3). A process 
known as cysteine-switch mechanism activates the pro-enzyme by proteolysis of the pro-domain or 
by rearrangement of the cysteine thiol group122,125,126. MMPs can be activated by plasmin and 
urokinase type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA)127 as well 
as by other MMPs, oxidants128,129, and chemicals, such as 4-aminophenylmercuric acetate 
(APMA)130. Activated MMPs are tightly regulated to prevent host damage by their protease 
activities. Active forms of MMPs are inhibited by their natural inhibitors, named tissue inhibitors 
of metalloproteinases 1-4 (TIMPs) and by the general proteinase inhibitor α2-macroglobulin131. 
The overall shape of the TIMP molecule is “wedge-like”. The N-terminal residues of TIMPs bind 
into the entire length of the active site cleft of their cognate MMPs and form a 1:1 complex that 
leads to inhibition132,133. Beside the general proteinase inhibitor α2-macroglobulin and TIMPs, 
small inhibitors of metalloproteinase (IMPs) and large inhibitors of metalloproteinase (LIMPs) are 
two additional groups of MMP inhibitors134. However, TIMPs are the major natural inhibitors and 
are, therefore, often studied in association with MMPs. Besides these natural occurring MMP 
inhibitors, more than 50 pharmaceutical produced specific or broad spectrum inhibitors are 
described to inhibit MMP functions135. 
1.2.4 MMP-12 and -13 
MMP-12, also named macrophage metalloelastase as it is mainly produced by macrophages, is 
expressed as a 53 kDa pro-enzyme. For activation, it is processed into a 45 kDa form, followed by 
modification into the final active form of 22 kDa. Mouse and human MMP-12 share 64% 
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homology and are rarely expressed in healthy adult tissue136. MMP-12 is strongly induced in 
developing and remodeling processes which occur in the placenta as well as in inflammatory 
processes137. Targets of MMP-12 are various proteins like elastin136, gelatin, myelin basic proteins, 
pro-TNF-α138, type IV collagen, fibronectin, vitronectin, entactin, laminin, aggrecan139, 
proteoglycan, α1-proteinase inhibitor140, α2-macroglobulin141, fibrinogen, factor XII142, and 
urokinase-type plasminogen activator receptor (uPAR)143.  
MMP-13 (collagenase-3) belongs together with MMP-1 and MMP-8 to the subgroup of 
collagenases. It is expressed as a pro-peptide of 60-65 kDa that is further processed into an 
intermediate 50-55 kDa form and finally into the 48 kDa active form144,145.  
The catalytic domain of human MMP-13 has 97% homology to mouse MMP-13146,147. As known 
so far, active MMP-13 cleaves collagen I-III148, IV, IX, X, XIV, fibronectin, tenascin, 
osteonectin149, gelatin150, collagen telopeptides, casein151, aggrecan152, α2-macroglobulin153, 
complement factor Clq154, fibrinogen, and factor XII142. Furthermore, active MMP-13 can also 
cleave other MMPs, such as pro-MMP-2 and -9155 or cytokines and chemokines, such as MCP-3, 
pro-TGF-β, pro-TNF-α, SDF-1156, and CXCL12122. MMP-13 can further be activated by other 
MMPs, such as MMP-2, -3, and membrane-type1 (MT1) -MMP155. It plays a major role in skeletal 
development, tissue remodeling, wound healing, and angiogenesis157-160. MMP-13 was first cloned 
from human breast tumor145 but is expressed also during remodeling processes by plasma cells161, 
fibroblasts162,163, chondrocytes164-166 osteoblasts, vascular smooth muscle cells167, neurons168, 
endothelial cells157, and also in a variety of neoplastic cells155,158,169. 
Interestingly, recent studies have shown that MMP-12 and -13 are also expressed in murine bone 
marrow-derived dendritic cells (BMDCs)170 as well as in murine pulmonary DCs171. 
For both MMPs, knock-out (ko) mice are available which exhibit a normal lifespan with no 
prominent phenotypic abnormalities indicating that theses enzymes do not serve vital functions in 
development or homeostasis117. However, MMP-12 ko mice reveal reduced elastolytic capacity of 
macrophages and a diminished ability of macrophages to migrate172. MMP-13 ko mice reveal 
defects in the growth plate cartilage with a marked increase in the hypertrophic chondrocyte zone. 
Furthermore, two MMP-13 ko lines, described in the literature, display a delay in primary 
ossification160,173,174. 
1.2.5 MMP-12 and -13 in normal immune responses and in diseases 
When invading organisms attack the host immune system, MMPs participate in the immune 
response by degradation of extracellular matrix (ECM) components and by modulation of 
cytokines and chemokines. They play important roles in leukocyte recruitment by proteolysis of the 
basement membrane175,176 and by modulating the cytokine/chemokine gradient177,178 as well as by 
the destruction of bacteria by defensin activation179. While controlled MMP activity is required for 
the normal immune response, uncontrolled activity can harm the host intensively resulting in tissue 
damage and chronic inflammation. Given their important role in tissue homeostasis and 
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remodeling, MMPs are reported to participate in a wide range of diseases. Dysregulation of 
MMP-12 has been shown to be associated with inflammatory skin diseases180,181, atherosclerosis182, 
aneurysms183, and cancers184,185 as well as in inflammatory pulmonary diseases, such as 
COPD186,187. The influence of MMP-12 in COPD was demonstrated by MMP-12 ko mice which 
appeared to be protected against smoking-induced emphysema188. 
Apparently due to its ability to degrade a wide range of ECM components, dysregulation of 
MMP-13 leads to extensive degradation of the collagenous ECM, detected in osteoarthritis and 
rheumatoid arthritis173,189, periodontitis190, as well as in malignant tumors, such as breast 
carcinomas145,191,192, various squamous cell carcinomas193-195, cutaneous basal cell carcinomas194, 
and chondrosarcomas196.  
1.2.6 MMPs in the lung 
Various studies explicitly reported the participation of different MMPs in the development and 
remodeling process of the lung from the very beginning of lung bud formation throughout the 
alveolarization processes. In contrast, very little is known about the involvement of MMPs in the 
regeneration of the lung after injury and tissue destruction. In animal models of inflammatory lung 
diseases, a clear correlation between the onset of inflammation and increased MMP levels was 
reported197. Therefore, a large effort has been devoted to determine the exact role of MMPs in 
different inflammatory lung diseases. Involvement of MMPs was reported in most human lung 
diseases, such as idiopathic pulmonary fibrosis198, COPD199,200, asthma199, cystic fibrosis201, and 
especially in BOS202-204. In humans, increased MMP-9 levels are reported to correlate with 
progression of BOS202,203,205 whereas in murine studies various MMPs, such as MMP-2, -8, -9, and 
MT1-MMP are reported in the development of experimental BOS206-208. These reports support the 
notion that MMPs might be potential targets for therapeutic treatment. However, the participation 
of specific MMPs and their exact function in BOS is poorly understood.  
1.3 Bronchiolitis obliterans syndrome (BOS) 
Lung transplantation is the only therapeutic option for end-stage pulmonary disorders. Whereas 
short-term survival after lung transplantation could be improved due to surgical techniques and 
immunosuppressive therapy209, long-term survival is still limited by the occurrence of chronic lung 
allograft dysfunction (CLAD). The two main subgroups of CLAD are BOS and the restrictive 
allograft syndrome (RAS)210,211. Five years after transplantation, the survival rate of the patients is 
approximately 50%, whereas the 10-year-survival rate is only 26%212. Furthermore, the median 
survival after the diagnosis of BOS is only three years as most patients response poorly to 
immunosuppression213. A progressive decline in the forced expiratory volume 1 (FEV1), 
progressive dyspnea, and cough are the clinical features that lead to the diagnosis of BOS214,215. 
Histopathologically, BOS is characterized by fibroproliferative lesions of bronchioles. It is 
accompanied by luminal fibrosis, epithelial damage, and influx of lymphocytes, histiocytes, and 
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plasma cells, which finally leads to luminal occlusion of the airways216-221. In some patients 
vascular sclerosis of the pulmonary arteries and veins is although observed221. The pathogenesis of 
BOS is very complex and heterogenic. Acute rejection, lymphocytic bronchitis, and infections are 
reported as strong risk factors for BOS222-224. Different studies suggest that excessive 
fibroproliferation due to abnormal tissue remodeling and defects in the regeneration of the 
epithelium are the result of epithelial and subepithelial airway injury. It is reported that this airway 
injury may occur due to alloimmune-dependent and -independent mechanisms225. Therefore, a 
pivotal role of the adaptive immune system in the pathogenesis of BOS seems to be indicated. 
However, the exact mechanisms and the underlying molecular pathways leading to BOS remain 
elusive.  
1.3.1 Participation of DCs in BOS 
BOS is reported to result mainly from chronic presentation of donor-derived antigens to recipient 
T cells via a self-MHC-donor peptide complex226-228. Antigen presentation by DCs, which are the 
most potent APCs of the innate immune system, is considered to be important in the developmental 
process of BOS. In the early phase after transplantation, donor-derived DCs migrate to the lymph 
nodes of the recipient and induce the alloimmune response (direct pathway) that can lead to acute 
rejection229. Solari and co-workers could demonstrate in human kidney transplant patients that a 
depletion of DCs significantly reduced acute rejection230. In later stage after transplantation, 
recipient DCs take up and process damaged donor cells and present the foreign peptides on 
self-MHC to T cells (indirect pathway)231. While the direct pathway dominates the early 
posttransplant period, the indirect pathway remains active during the whole life of transplant and is, 
therefore, considered to drive BOS. As DCs are thought to substantially contribute to the 
pathogenesis of BOS, different groups investigated the role of DCs in CLAD. In 1990 the group of 
Yousem found an increase in DC numbers in lung allografts that were chronically rejected114. In 
contrast, eight years later, Milnes and colleagues reported a decline in the amount of CD1a+ DCs in 
lung allografts232. In 2000, Leonard and co-workers suggested that the importance of DC numbers 
in BOS is underestimated due to the usage of inappropriate DC markers. Using the typical dendritic 
morphology and MHC-II instead of CD1a expression for DC detection, they confirmed an increase 
in DCs in patients with worsening BOS compared to stable patients113. In general, due to the lack of 
a unique marker for pulmonary DCs, contradicting reports exist in the literature on the correlation 
of DC number and the pathogenesis of BOS. However, in a BOS animal model, increased numbers 
of DCs were reported by Kleinjan et al.233. They showed that blocking of critical co-stimulatory 
molecules expressed on DCs prevents the development of the BOS phenotype. This report indicates 
that DCs are key players in the pathogenesis of murine experimental BOS. However, further 
research effort is necessary to identify the precise role of DCs in this disease. 
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1.3.2 The role of MMPs in BOS 
The development of BOS is associated with extracellular matrix remodeling and inflammatory 
activity. In both of these processes, MMPs are known to play a pivotal role as outlined in section 
1.2. Therefore, efforts were made to determine the role of MMPs in the pathogenesis of BOS and, 
furthermore, to verify MMPs as sensitive markers for BOS. Different groups reported an increase 
of MMP-9 relative to TIMP-1 in sputum205 and bronchoalveolar lavage fluid202,203. Therefore, 
MMP-9 was assumed to serve as indicator of BOS. However, Smith and coworkers suggested that 
the increased levels of MMPs are due to ischemia reperfusion injury after transplantation or the 
result of an acute rejection234.  
Different animal models have been developed to study the pathogenesis of experimental BOS in 
vivo. The heterotopic trachea transplant (HTT) model is often used to explore the pathogenesis of 
BOS as it mimics the development of BOS quickly and robustly. This model is less technically 
demanding in comparison to whole lung transplant models and, therefore, reduces variability 
within experimental studies235. Furthermore, it better reflects the chronic changes, whereas models 
of orthotopic lung transplantation lead to acute rejection phenotypes. Different reports suggest an 
involvement of specific MMPs, such as MMP-2, -8, -9, and MT1-MMP in the development of 
experimental BOS in the HTT model206-208.  
Specific MMPs, such as MMP-9 mentioned above, have been already intensively studied in BOS 
and its inhibition ameliorated the progression of experimental BOS. However, the disadvantage of 
pharmaceutical MMP-9 inhibition is the broad expression of MMP-9 in a variety of cells, e.g. 
neutrophils, and, thereby, the occurrence of severe side effects in the host. Therefore, there is 
significant interest to find other proteases of the MMP family that would serve as more specific 
pharmacological targets. To consider the utilization of specific MMP inhibitors as therapeutic 
option in patients, detailed knowledge of MMP function is essential. Nowadays, MMPs are no 
longer just considered as enzymes that only degrade extracellular matrix components, but instead, 
are also important in inflammatory processes, e.g. in the regulation of cytokines/chemokines177,178, 
in migration175,176, and likely other functions of immune cells. In DC biology, MMP-12 and -13 are 
reported to be highly expressed in murine pulmonary DCs compared to macrophages and 
monocytes171 and thus, may contribute to the function of pulmonary DCs, possibly influencing the 
progression of BOS.  
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1.4 Objectives of this thesis 
DCs and MMPs are both reported to participate in the pathogenesis of BOS. Current evidence 
suggests that the activity of MMPs is no longer limited to a role in the degradation of EMC 
products but extends beyond that to including regulatory activities in various other cell functions 
and inflammatory processes. Murine pulmonary DCs have been shown to express specific MMPs, 
such as MMP-12 and -13171, but little is known about their functions in DCs and their role in 
inflammatory conditions. 
The first aim of the thesis was to establish various functional assays to identify the role of selected 
MMPs (mainly MMP-12 and -13) in the immunobiology of DCs. The second aim was to correlate 
these specific MMPs to the pathogenesis of BOS in vivo.  
To achieve these aims, murine DCs were generated from bone marrow cells and analyzed for their 
MMP expression profile under inflammatory condition. BMDCs were further used to study the 
involvement of identified MMPs in DC migration, OVA-endocytosis, antigen presentation, T cell 
activation, and cytokine profile by using specific MMP-12 and -13 inhibitors.  
For the in vivo studies, the HTT model was established and used to localize the identified MMPs 
(MMP-12 and -13) in the grafts and to analyze alterations of these MMPs between syngrafts and 
allografts. The HTT model was further used to analyze the effect of MMP-13 inhibition on the 
progression of experimental BOS in vivo. Therefore, MMP-13 inhibitor was administered 
intraperitoneal (i.p.) every second day and changes in the BOS phenotype were analyzed. 
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 MATERIAL AND METHODS 2
2.1 Material 
2.1.1 Antibodies 
Table 2.1: Antibodies for flow cytometry analysis 
Target name Host/Clonality Supplier Fluorochrome Catalog No. 
H-2Kb MHC-I 
  
Mouse/ 
monoclonal (mc) 
BioLegend; Fell, Germany 
 
PE 
 
#116507 
 
MHC-II Rat/mc BioLegend; Fell, Germany PerCP/Cy5.5 #107626 
CD80 
 
Hamster/mc 
 
BioLegend; Fell, Germany 
 
Pacific blue 
(PB)  #104723 
CD86 Rat/mc BioLegend; Fell, Germany PE #105007 
CD40 Rat/mc BioLegend; Fell, Germany PE/Cy7 #124621 
CD11c Hamster/mc BioLegend; Fell, Germany APC #117310 
H-2Kb bound  
to SIINFEKL  
Mouse/mc 
 
BioLegend; Fell, Germany 
 
PerCP/Cy5.5 
 
#141610 
 
CD11b 
 
Rat/mc 
 
BD Bioscience; Heidelberg,  
Germany 
PE 
 
#553311 
 
CD45 
 
Rat/mc 
 
BD Bioscience; Heidelberg,  
Germany 
FITC 
 
#553080 
 
Ly-6G/Ly-6C 
 
Rat/mc 
 
BD Bioscience; Heidelberg,  
Germany 
V450 
 
#560453 
 
F4/80 Rat/mc BioLegend; Fell, Germany APC/Cy7 #123118 
CD3 Rat/mc BioLegend; Fell, Germany PB #100213 
CD19 Rat/mc BioLegend; Fell, Germany PE #115508 
CD4  Rat/mc BioLegend; Fell, Germany PerCP/Cy5.5 #100539 
CD8α Rat/mc BioLegend; Fell, Germany APC/Cy7 #100713 
NK1.1 Mouse/mc BioLegend; Fell, Germany APC #108710 
 
Table 2.2: Isotypes for flow cytometry analysis 
Isotype name Host/Clonality Supplier Fluorochrome Catalog No. 
IgG2a, κ Mouse/mc BioLegend; Fell, Germany PE #400211 
IgG2b, κ Rat/mc BioLegend; Fell, Germany PerCP/Cy5.5 #400631 
IgG Hamster/mc BioLegend; Fell, Germany PB  #400925 
IgG2a, κ Rat/mc BioLegend; Fell, Germany PE #400507 
IgG2a, κ Rat/mc BioLegend; Fell, Germany PE/Cy7 #400521 
IgG Hamster/mc BioLegend; Fell, Germany APC #400911 
IgG2b, κ Mouse/mc BioLegend; Fell, Germany PerCP/Cy5.5 #400112 
IgG2b, κ 
 
Rat/mc 
 
BD Bioscience; Heidelberg,  
Germany 
PE 
 
#555848 
 
IgG2b, κ 
 
Rat/mc 
 
BD Bioscience; Heidelberg,  
Germany 
V450 
 
#560457 
 
IgG2a, κ Rat/mc BioLegend; Fell, Germany APC/Cy7 #400523 
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Table 2.3: Primary antibodies for immunofluorescence staining 
Target name Host/Clonality Supplier Fluorochrome Catalog No. 
CD45 
 
Rat/polyclonal 
(pc) 
Abcam; Cambridge, UK 
 
- 
 
#ab25386 
 
CD45 Rabbit/pc Abcam; Cambridge, UK - #ab10558 
CD3 Rabbit/pc Abcam; Cambridge, UK - #ab16669 
MMP-12 Rabbit/mc Abcam; Cambridge, UK - #ab52897 
MMP-13 
 
Mouse/mc 
 
Merck Millipore; Schwalbach, 
Germany 
- 
 
#IM78 
 
MMP-13 Rabbit/pc Abcam; Cambridge, UK - #ab75606 
CD11c 
 
Hamster/mc 
 
Angio-Proteomie; Boston, 
USA 
- 
 
#mAP-0047 
 
CD11c Hamster/mc BioLegend; Fell, Germany - #117301 
CD11c 
 
Rabbit/pc 
 
Santa Cruz; Heidelberg, 
Germany 
- 
 
#sc-28671 
 
MHC-II 
 
Mouse/mc 
 
Bio-Rad AbD Serotec; 
Puchheim, Germany 
- 
 
#MCA46GA 
 
MHC-II Rat/mc Abcam; Cambridge, UK - #ab 64528 
MHC-II 
 
Rat/mc 
 
eBioscience; Frankf. am Main, 
Germany  
- 
 
#14-5321 
 
α-SMA 
 
Mouse/mc 
 
Sigma-Aldrich; Taufkirchen, 
Germany 
- 
 
#A5228 
 
CD31 
 
Rabbit/pc 
 
Santa Cruz; Heidelberg, 
Germany 
- 
 
#sc-28188 
 
E-cadherin 
 
Mouse/mc 
 
BD Bioscience; Heidelberg, 
Germany 
- 
 
#610181 
 
Galectin3 
 
Rabbit/pc 
 
Santa Cruz; Heidelberg, 
Germany 
- 
 
#sc-20157 
 
Collagen I 
 
Rabbit/pc 
 
Rockland-inc.; Hamburg, 
Germany 
- 
 
#600-401-103 
 
 
Table 2.4: Isotypes for immunofluorescence staining 
Target name Host Supplier Fluorochrome Catalog No. 
IgG  Hamster BioLegend; Fell, Germany - #400901 
IgG1 
  
Mouse 
 
Merck Millipore; Schwalbach, 
Germany 
- 
 
#MABC002F 
 
 
Table 2.5: Secondary antibodies for immunofluorescence staining 
Target name Host Supplier Fluorochrome Catalog No. 
anti-hamster IgG Goat BioLegend; Fell, Germany DyLight 594 #405504 
anti-mouse IgG 
 
Goat 
 
Invitrogen, Life Technologies; 
Carlsbad, USA 
Alexa Fluor 
488  
#A11001 
 
anti-rat IgG (H+L) 
 
Goat 
 
Invitrogen, Life Technologies; 
Carlsbad, USA 
Alexa Fluor 
488 
#A11006 
 
anti-mouse IgG 
(H+L) 
Goat 
 
Invitrogen, Life Technologies; 
Carlsbad, USA 
Alexa Fluor 
568 
#A11004 
 
anti-rabbit IgG 
(H+L) 
Goat 
 
Invitrogen, Life Technologies; 
Carlsbad, USA 
Alexa Fluor 
568 
#A11011 
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2.1.2 Buffers and solutions 
DNA loading buffer (6x) (Fermentas, Thermo Fisher Scientific) 
Substance Concentration 
Tris/HCl, pH 7.6 10 mM 
Bromophenol blue 0.03% 
Xylene cyanol FF 0.03% 
Glycerol 60% 
EDTA 60 mM 
HEPES (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid) (Sigma-Aldrich): 
Substance Concentration 
HEPES 1 M 
Lämmli loading buffer (6x): 
Substance Concentration 
SDS 12% (w/v) 
Glycerol (87%) 60% (v/v) 
Bromophenol blue  0.06% (w/v) 
Tris/HCl, pH 6.8 375 mM 
Dithiothreitol (DTT) 600 mM 
PBS (Phosphatate buffered saline) pH 7.4 (10x): 
Substance Concentration 
NaCl 1.37 M 
KCl 27 mM 
Na2HPO4 100 mM 
KH2PO4 20 mM 
NaCl 1.37 M 
RIPA (radio-immunoprecipitation assay) buffer: 
Substance Concentration 
Tris-Cl pH 7.4 50 mM 
NaCl 150 mM 
NP40 1% (v/v) 
Na-deoxycholate 0.25% (v/v)  
SDS (sodium dodecyl sulphate) solution (20%) (w/v): 
Substance Volume/Weight 
SDS 200 g 
Millipore-H2O 1 L 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis)  
running buffer: 
Substance Concentration 
Tris/HCl, pH 7.4  250 mM 
Glycine 1.92 M 
SDS 1% (w/v) 
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SDS-PAGE separation gels (12%): 
Substance Volume 
Millipore-H2O 3.1 ml 
1.5 M Tris/HCl pH 8.8 2.25 ml 
SDS 20% 45 µl 
Acrylamide 3.6 ml 
APS 10% 30 µl 
TEMED 6 µl 
SDS-PAGE stacking gel (4%):  
Substance Volume 
Millipore-H2O 1.8 ml 
0.5 M Tris/HCl pH 6.8 750 µl 
SDS 20% 15 µl 
Acrylamide 400 µl 
APS 10% 15 µl 
TEMED 3 µl 
TBS (Tris-buffered saline) (10x): 
Substance Concentration 
Tris/HCl pH 7.4 10 mM 
NaCl 150 mM 
TBS-T (TBS with TWEEN®20) (1x): 
Substance Concentration 
TBS (10x) 10% (v/v) 
Tween®20 0.1% (v/v) 
Millipore-H2O 89.99% (v/v) 
Transfer buffer (10x): 
Substance Concentration 
Tris/HCl 250 mM 
Glycine 1.92 M 
Transfer buffer (1x): 
Substance Concentration 
Transfer Buffer (10x) 10% (v/v) 
Methanol 10% (v/v) 
Millipore-H2O 80% (v/v) 
2.1.3 Cell lines 
Table 2.6: Murine cell lines 
Name Description  Supplier 
B3Z 
 
 
CD8+ T cell hybridoma cell line specific for OVA257-264-
peptide (SIINFEKL), expresses β-galactosidase under control 
of the IL-2 promoter 
Nilabh Shastri (Department of 
Molecular and Cell Biology, 
University of California) 
DOBW 
 
 
CD4+ T cell line specific for OVA323-339-peptide 
 
 
Cliff Harding (Washington 
University School of Medicine, 
Department of Pathology)  
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2.1.4 Laboratory equipment and software 
Table 2.7: Laboratory equipment 
Product Manufacturer 
-80°C freezer U570 HEF New Brunswick; Hamburg, Germany 
-20°C freezer MediLine LGex 410 Liebherr; Biberach, Germany 
Agarose gel running chamber Biorad; Hercules, USA 
Analytical scale XS20S Dual Range Mettler Toledo; Gießen, Germany 
Autoclave DX-45 Systec; Wettenberg, Germany 
Autoclave VX-120 Systec; Wettenberg, Germany 
Cell culture work bench Herasafe KS180 Thermo Fisher Scientific; Darmstadt, Germany 
Centrifuge MiniSpin plus Eppendorf; Hamburg, Germany 
Centrifuge Rotina 420R Hettich; Tuttlingen, Germany 
Centrifuge with cooling, Micro200R Hettich; Tuttlingen, Germany 
CO2 cell incubator BBD6620 Thermo Fisher Scientific; Darmstadt, Germany 
Demineralized water Thermo Fisher Scientific; Darmstadt, Germany 
Deparaffination machine microm HMS740 Thermo Fisher Scientific; Darmstadt, Germany 
Dispenser, Ceramus 2-10ml Hirschmann Laborgeräte; Eberstadt, Germany 
Dry ice container Forma 8600 Series, 8701 Thermo Fisher Scientific; Darmstadt, Germany 
Electronic pipet filler Eppendorf; Hamburg, Germany 
Embedding machine, Microm EC350 Zeiss; Oberkochen, Germany 
Film developer Curix 60 AGFA; Morsel, Belgium 
Fridge MediLine LKv 3912 Liebherr; Biberach, Germany 
Gel electrophoresis chamber MINIeasy Carl Roth; Karlsruhe, Germany 
Gel imaging system ChemiDoc XRS+ Biorad; Hercules, USA 
Ice machine ZBE 110-35 Ziegra; Hannover, Germany 
Intelli-Mixer RM-2 Schubert & Weiss Omnilab; Munich, Germany 
Light Cycler LC480II Roche Diagnostics; Mannheim, Germany 
Liquid nitrogen cell tank BioSafe 420SC Cryotherm; Kirchen/Sieg, Germany 
Liquid nitrogen tank Apollo 200 Cryotherm; Kirchen/Sieg, Germany 
LSR II (flow cytometer) BD Bioscience; Heidelberg, Germany 
Magnetic stirrer KMO 2 basic IKA; Staufen, Germany 
Mastercycler gradient Eppendorf; Hamburg, Germany 
Mastercycler Nexus Eppendorf; Hamburg, Germany 
Micro-Dismembrator Sartorius Thermo Fisher Scientific; Darmstadt, Germany 
Microscope Axio Imager M2 (fluorescence) Zeiss; Jena, Germany 
Microscope Axiovert 40 Zeiss; Jena, Germany 
Microscope LSM 710 (confocal) Zeiss; Jena, Germany 
Microtom, Hyrax M55 Zeiss; Jena, Germany 
Multipette stream Eppendorf; Hamburg, Germany 
Nalgene® Freezing Container (Mr. Frosty) Omnilab; Munich, Germany 
NanoDrop 1000 PeqLab; Erlangen, Germany 
pH meter InoLab pH 720 WTW; Weilheim, Germany 
Pipettes Research Plus Eppendorf; Hamburg, Germany 
Plate centrifuge 5430 Eppendorf; Hamburg, Germany 
Plate reader Tri-Star LB941 Berthold Technologies; Bad Wildbach, Germany 
Plate reader Sunrise Tecan; Crailsheim, Germany 
Roll mixer VWR International; Darmstadt, Germany 
Power Supply Power Pac HC Power Supply Biorad; Hercules, USA 
Scale XS400 2S Mettler Toledo; Gießen, Germany 
MATERIAL AND METHODS 
20 
Shaker Duomax 1030 Heidolph; Schwabach, Germany 
Tissue processor Microm STP420D Thermo Fischer Scientific; Waltham, USA 
Thermomixer compact Eppendorf; Hamburg, Germany 
Ultrapure water supply MilliQ Advantage A10 Merck Millipore; Darmstadt, Germany 
LSM Top table centrifuge MCF-2360 Schubert & Weiss Omnilab; Munich, Germany 
Vortex Mixer IKA; Staufen, Germany 
Vacuum pump NO22AN.18 with switch 2410 KNF; Freiburg, Germany 
Water bath Aqua Line AL 12 Lauda; Lauda-Königshofen, Germany 
 
Table 2.8: Software 
Software Producer 
Axio Imager Software Zeiss; Jena, Germany 
Endnote X6 Thomson Reuters; San Francisco, USA 
GraphPad Prism 5 GraphPad Software; La Jolla, USA 
FlowJo  Tree Star; Ashland, USA 
Image Lab Version Biorad; Hercules, USA 
LightCycler® 480 SW 1.5 Roche Diagnostics; Mannheim, Germany 
Magellan Software Tecan; Crailsheim, Germany 
Tri-Star MicroWin 2000 Berthold Technologies; Bad Wildbach, Germany 
 
2.1.5 Chemicals and consumables 
Table 2.9: Chemicals 
Product Manufacturer  
Ammonium peroxodisulfate (APS) AppliChem; Darmstadt, Germany  
Bovine serum albumin (BSA) Sigma-Aldrich; Taufkirchen, Germany 
Bromphenolblue-Sodiumsalt AppliChem; Darmstadt, Germany  
CCL19 PeproTech; Hamburg, Germany  
Chloroform AppliChem; Darmstadt, Germany  
Collagen G Biochrom; Berlin, Germany  
Complete® Mini without EDTA (Protease-
inhibitor) 
Roche Diagnostics; Mannheim, Germany 
 
Coomassie Brilliant Blue R-250 staining solution BioRad; Hercules, USA 
CountBright™ counting beads Invitrogen, Life Technologies; Carlsbad, USA 
Chlorophenol red-β-D-galactopyranoside 
(CPRG) 
Roche Diagnostics; Mannheim, Germany 
 
Cultrex Collagen IV R&D systems; Wiesbaden-Nordenstadt, Germany 
Cutasept Bode science center; Heidenheim, Germany 
DAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich; Taufkirchen, Germany 
Desoxyribonucleotide mix (dNTPs) Thermo Fisher Scientific; Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Carl Roth; Karlsruhe, Germany 
Dithiothreitol (DTT) AppliChem; Darmstadt, Germany 
ECL Plus Western Blotting Substrate Pierce, Thermo Fisher Scientific; Schwerte, Germany 
Eisenhämatosylin, Weigert's, Reagent A Carl Roth; Karlsruhe, Germany  
Eisenhämatosylin, Weigert's, Reagent B Carl Roth; Karlsruhe, Germany  
Eosin Alcoholics Carl Roth; Karlsruhe, Germany  
Eosin G 0.5%  Carl Roth; Karlsruhe, Germany  
Acetic acid AppliChem; Darmstadt, Germany  
Ethanol (p.a.) AppliChem; Darmstadt, Germany  
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Fetal bovine serum (FBS) "GOLD", heat 
inactivated PAA, GE Healthcare; Cölbe, Germany 
Fluorescence mounting medium Dako; Hamburg, Germany 
Gamunex® (10%)  Grifolds; Barcelona, Spain  
Glycine, molecular biology grade AppliChem; Darmstadt, Germany  
GM-CSF (murine) PreproTech; Hamburg, Germany  
Haemalaun solution Mayers Carl Roth; Karlsruhe, Germany  
Haematoxylin solution Gill Carl Roth; Karlsruhe, Germany  
HANKs' Balanced Salt Solution Modified Sigma-Aldrich; Taufkirchen, Germany  
Heparin AppliChem; Darmstadt, Germany 
HEPES, 1 M AppliChem; Darmstadt, Germany 
Isopropanol, (p.a.) AppliChem; Darmstadt, Germany 
Light Cycler 480 SybrGreen I Master Mix Roche Diagnostics; Mannheim, Germany 
LPS  
(Lipopolysaccharides, Escherichia coli K-235) Sigma-Aldrich; Taufkirchen, Germany  
Magnesiumchlorid-Hexahydrat MB AppliChem; Darmstadt, Germany  
Magnetic Lumines Screening Assay R&D systems; Wiesbaden-Nordenstadt, Germany  
Methanol, (p.a.) AppliChem; Darmstadt, Germany  
MMP-12 inhibitor 408 Merck; Grafing, Germany  
MMP-12 protein, recombinant mouse  R&D systems; Wiesbaden-Nordenstadt, Germany  
MMP-13 protein, recombinant mouse  MyBioSourceMerck; Grafing, Germany   
MMP-13 inhibitor (CL82198) Tocris Bioscience, Biozol, Eching, Germany  
Non-fat dried milk powder AppliChem; Darmstadt, Germany  
Nonidet P-40 AppliChem; Darmstadt, Germany  
OVA323-339-peptide  AnaSpec; Seraing, Belgium  
OVAAlexa 488  Invitrogen, Life Technologies; Carlsbad, USA 
Ovalbumin grade VI Sigma-Aldrich; Taufkirchen, Germany 
Paraformaldehyde Sigma-Aldrich; Taufkirchen, Germany 
Penicillin-Streptomycin (10000 U/ml) Gibco, Life Technologies; Carlsbad, USA 
Poly-L-Lysine (0.01% solution) Sigma-Aldrich; Taufkirchen, Germany 
Protein marker V Peqlab; Erlangen, Germany 
Random hexamers Life Technologies; Carlsbad, USA 
Rotiphorese Gel 30 (37,5:1) 500ml Carl Roth; Darmstadt, Germany 
SIINFEKL-peptide Sigma-Aldrich; Taufkirchen, Germany 
Sodium chloride AppliChem; Darmstadt, Germany 
Sodium Deoxycholate VWR; Ismaning, Germany 
Sodium dodecyl sulphate (SDS) pellets Carl Roth; Darmstadt, Germany 
SuperSignal West Dura Duration Substrate Pierce, Thermo Fisher Scientific; Schwerte, Germany 
SuperSignal West Femto Substrate Pierce, Thermo Fisher Scientific; Schwerte Germany 
SuperSignal West Pico Substrate  Pierce, Thermo Fisher Scientific; Schwerte, Germany 
SybrSafe (10000x in DMSO) Invitrogen Life Technologies; Carlsbad, USA 
Tetramethylethylenediamine (TEMED) AppliChem; Darmstadt, Germany 
Tris base, buffer grade AppliChem; Darmstadt, Germany 
Triton X-100 AppliChem; Darmstadt, Germany 
Trypan blue Sigma-Aldrich; Taufkirchen, Germany 
Tween 20 AppliChem; Darmstadt, Germany 
UltraPure DNase/RNase-Free Distilled Water Invitrogen, Life Technologies; Carlsbad, USA 
Water soluble tetrazolium (WST) -1 Roche Diagnostics; Mannheim, Germany 
Xylol (Isomere) Carl Roth; Darmstadt, Germany 
β-Mercaptoethanol AppliChem; Darmstadt, Germany 
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Table 2.10: Consumables  
Product Manufacturer 
96 well MaxiSorp ELISA plate Nunc; Wiesbaden, Germany 
96 well plates, white, for luciferase assay Berthold Technologies; Bad Wildbad, Germany 
Whatman blotting paper 3 mm GE Healthcare; Freiburg, Germany 
Cell culture dishes Corning, Thermo Fisher Scientific; Schwerte, Germany 
Cell culture flasks Nunc; Wiesbaden, Germany 
Cell culture multi well plates TPP Techno Plastic Products; Switzerland 
Cell scraper/lifter Corning, Thermo Fisher Scientific; Schwerte, Germany 
Counting chamber Brand GmbH; Wertheim, Germany 
Cryo vials 1.5 ml Greiner Bio-One; Frickenhausen, Germany 
Cryo vials for microdismembrator 1.2 ml Nalgene, Thermo Fisher Scientific; Schwerte, Germany 
Falcon tubes (5 ml, 50 ml) BD Bioscience; Heidelberg, Germany 
Filter tips Biozym Scientific; Hessisch Oldendorf, Germany 
Glas Pasteur pipettes VWR International; Darmstadt, Germany 
Hyperfilm® ECL™ Film Amersham, GE Healthcare; Freiburg, Germany 
Measuring pipettes sterile, single use (2 ml, 5 ml, 
10 ml, 25 ml, 50 ml) 
VWR International; Darmstadt,  
Germany 
Nylon filters, pore size 70 µm, 40 µm BD Bioscience; Heidelberg, Germany 
Microscope slides, superfrost plus Thermo Fisher Scientific; Darmstadt, Germany 
Menzler-Gläser Thermo Fisher Scientific; Darmstadt, Germany 
PCR plates Kisker Biotech; Steinfurt, Germany 
Reaction tubes (0.5 ml, 1.5 ml) Eppendorf; Hamburg, Germany 
Stainless steel grinding balls (9 mm) Neolab; Heidelberg, Germany 
Sealing foil for PCR plates Kisker Biotech; Steinfurt, Germany 
Shaver, Med comfort Sanismart; Waltropp, Germany 
Tips Eppendorf; Hamburg, Germany 
Transwell, PC membrane, 5.0 µm pore size, 0.33 
cm2 surface area 
Corning, Thermo Fisher Scientific;  
Schwerte, Germany 
 
2.1.6 Kits 
Table 2.11: Kits 
Product Manufacturer Catalog number 
BCA Protein Assay kit Biochrom; Berlin, Germany #23221 
IL-2 ELISA Duo Set R&D systems; Wiesbaden, Germany #DY202 
PeqGold RNA kit Peqlab; Erlangen, Germany #12-3398 
RNase-Free DNase set Qiagen; Hilden, Germany #79254   
Sensolyte 520 MMP-13 Assay kit  Ana Spec; Fremont, USA #71156 
Sensolyte 520 MMP-12 Assay kit  Ana Spec; Fremont, USA #71157 
Sensolyte Plus 520 MMP-13 Assay kit  Ana Spec; Fremont, USA #72019 
 
2.1.7 Enzymes 
Table 2.12: Enzymes 
Product Manufacturer 
Collagenase I Biochrom; Berlin, Germany 
DNase I AppliChem; Darmstadt, Germany 
RNase inhibitor 20 U/µl Invitrogen, Life Technologies; Carlsbad, USA 
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2.1.8 Quantitative real-time polymerase chain reaction (RT-PCR) 
Primers for quantitative polymerase chain reaction (qPCR) were purchased from Eurofins MWG 
Operon; Ebersberg, Germany as desalted oligonucleotide lyophilisates and dissolved in 
DNase/RNase-free water to a concentration of 15 µM. 
Table 2.13: Mouse primer  
Gen   Sequence 5’ – 3’ 
MMP-2 fw TGATGCTTTTGCTCGGGCCTTA 
rev TTTACGCGGACCACTTGTCCTT  
MMP-9 fw CGTCGTGATCCCCACTTACT 
rev AACACACAGGGTTTGCCTTC 
MMP-12 fw TGATGCAGCTGTCTTTGACC 
rev GTGGAAATCAGCTTGGGGTA 
MMP-13 fw ATCCCTTGATGCCATTACCA 
rev AAGAGCTCAGCCTCAACCTG 
TIMP-1 fw GGCATCCTCTTGTTGCTATCACTG 
rev GTCATCTTGATCTCATAACGCTGG 
TIMP-2 fw GGCGTTTTGCAATGCAGACGTA 
rev ATCTTGCACTCACAGCCCATCT 
TIMP-3 fw TTCTGCAACTCCGACATCGTGA 
rev CAGGCGTAGTGTTTGGACTGAT 
α-enolase fw TTGCTTTGCAGGGATCCTACT 
rev GATCATCAGCTTGTCAATCTT 
 
2.2 Methods 
2.2.1 Generation of BMDCs 
Femur and tibia of female C57BL/6 mice were harvested and sterilized for 30 seconds in 4 ml of 
80% ethanol (AppliChem). Bones were transferred in a 15 ml Falcon tubes (BD Bioscience) and 
washed with 10 ml phosphatate buffered saline (PBS). Bone marrow cells were sterilely collected 
by cutting the edges of the bones with a scalpel blade and flushing out the cells with 2 ml DC 
medium. Cells were centrifuged for ten minutes at 1200 rpm at 4°C, followed by depletion of 
erythrocytes using 3 ml of lysis buffer. After washing with 10 ml of DC medium, cell pellets were 
resuspended in 10 ml DC medium and filtrated through a 40 µm nylon cell strainer (BD 
Bioscience). Afterwards, cells were centrifuged using the same conditions and counted with a 
Neubauer cell counting chamber. Cell viability was determined by trypan blue (Sigma-Aldrich) 
staining as described in section 2.2.4. Subsequently, 0.75 x 106 cells/ml were cultured in 24-well 
plates in DC medium supplemented with 1 µg/ml GM-CSF (PreproTech) at 37°C in a humidified 
cell incubator with 5% CO2. On day six, loosely and non-adherent cells were collected by carefully 
rinsing the wells with DC medium. Afterwards, cells were cultured in new 24-well plates and 
supplemented with fresh GM-CSF. On day seven, loosely- and non-adherent cells were harvested 
and re-suspended in DC medium for further experiments. To control the purity of BMDCs and their 
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maturation state, cells were analyzed on day seven for the surface expression of MHC-I, MHC-II, 
CD80, CD86, CD40, and CD11c (abs all from BioLegend) as described in section 2.2.9.9.1. The 
purity of CD11c+ BMDCs, which were used subsequently for experiments, was more than 70% 
with a similar maturation state. Beside the usage of wild-type (wt) C57BL/6 mice, MMP-12 ko 
mice were additionally used to generate MMP-12 ko BMDCs. Femur and tibia of female MMP-12 
ko mice172, kindly provided by the group of Marcus Mall (Department of Pneumology, University 
Hospital Heidelberg), were shipped on ice within 24 hours. BMDCs were generated as described 
above. 
Table 2.14: DC medium   
Reagent Concentration 
L-Glutamine, Penicillin-Streptomycin  500 µg/ml, 100 U/ml  
Inactive FBS  10% 
Na-Pyruvate 1 mM  
Non-essential amino acids 1x  
2-Mercaptoethanol 50 µM  
HEPES  10 mM 
Add 500 ml RPMI medium 
 
 
2.2.2 Cell culture of cell lines 
The CD8+ T cell hybridoma cell line B3Z was used, kindly provided by the group of Nilabh Shastri 
(Department of Molecular and Cell Biology, University of California), which is specific for 
OVA257-264-peptide (SIINFEKL) and expresses β-galactosidase under control of the IL-2 
promoter236. Additionally, the CD4+ T cell line DOBW was used which is specific for 
OVA323-339-peptide237, kindly provided by the group of Cliff Harding (Washington University 
School of Medicine, Department of Pathology).  
1 x 106/ml B3Z cells or 0.5 x 106/ml DOBW cells were cultured in T cell medium (cell culture 
flasks) at 37°C in a cell incubator with 5% CO2. Cells were split 1:10 every second day. Therefore, 
non-adherent and loosely adherent cells were collected in 50 ml tubes, centrifuged at 400 g for 
four minutes at room temperature (RT), counted (see section 2.2.4), and cultured in culture flasks.  
 
Table 2.15: T cell medium   
Reagent Concentration 
L-Glutamine, Penicillin-Streptomycin  500 µg/ml, 100 U/ml  
Inactive FCS  10% 
Add 500 ml IMDM medium 
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2.2.3 Preservation and defrosting of cells 
For freezing, 1 x 107 DOBW or B3Z cells were resuspended in 1 ml FBS supplemented with 10% 
dimethyl sulfoxide (DMSO) (Carl Roth) in a specific cryo tube and stored overnight in a Mister 
Frosty (Omnilab) at -80°C. For long-time storage, tubes were transferred to liquid nitrogen.  
To defrost cells, cryo tubes were briefly warmed in a 37°C water bath and quickly diluted in 5 ml 
T cell medium. Cells were centrifuged at 400 g for four minutes. Finally, cell pellets were 
resuspended in T cell medium and cultured as described in section 2.2.2. 
2.2.4 Cell counting and detection of dead cells 
To detect the amount of live and dead cells, the cell suspension was diluted and mixed 1:10 with 
trypan blue. This dye does not cross the cell membrane of living cells and, therefore, stains only 
dead cells. Four big squares of a Neubauer counting chamber were counted and living cells were 
calculated using the following formula.  
Concentration (c) [cells/ml] = counted cells/4 x dilution factor x 104 
 
2.2.5 Cell treatment 
As inflammatory stimulus and to mature BMDCs, cells were treated with LPS (Escherichia coli 
K-235, Sigma-Aldrich) on day seven. In addition, the protein OVA (Ovalbumin grade VI, 
Sigma-Aldrich) was used to study the process of antigen uptake and processing. If not stated 
otherwise, 10 µg/ml LPS or 1 mg/ml OVA was administered to BMDCs. For the functional 
analysis, MMP-13 inhibitor N-[4-(4-morpholinyl)butyl]-2-benzofurancarboxamide hydrochloride 
(CL82198) (Tocris Bioscience) or MMP-12 inhibitor (S)-2-(8-
(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408) 
(Merck) was used with following concentrations: MMP-12 inhibitor: 10 µM, 20 µM, 50 µM and 
MMP-13 inhibitor: 50 µM, 100 µM, 200 µM, and 500 µM.  
2.2.6 Detection of cell viability by WST-1 assay 
BMDCs were treated with the indicated inhibitor concentrations overnight and water soluble 
tetrazolium-1 (WST) assay was performed according to the manufacture`s protocol. This 
colorimetric assay is based on the cleavage of a tetrazolium salt, MTS, by mitochondrial 
dehydrogenases forming formazan in viable cells. Cells that are viable and metabolically active 
produce greater amount of formazan resulting in an accumulation of WST-1. Overnight was chosen 
as timeframe for the toxicity test as this was the longest period of co-incubation with the inhibitors 
during the functional assays. 
2.2.7 Functional analysis  
If not stated differently, all cells used in the below described functional analysis were centrifuged at 
400 g. 
MATERIAL AND METHODS 
26 
2.2.7.1 Migration assay through collagen I 
Collagen I gel was prepared on ice as follows: 0.7 M NaOH and 1 M HEPES buffer were mixed 
1:1 and transferred in a new tube. An equal amount of 10x PBS plus 20% FBS was added to the 
tube and mixed with collagen in the relation 1:5. Each transwell (PC membrane, 5.0 µm pore size, 
Corning) was filled with 50 µl of gel and allowed to polymerize for two hours at 37°C. Transwells 
were placed in 12-well plates filled with 600 µl RPMI plus 0.5% BSA supplemented with CCL19 
(10 µg/ml) (PeproTech) or with PBS as control. BMDCs were centrifuged at RT for 6 minutes and 
resuspended in RPMI plus 0.5% BSA. Subsequently, BMDCs were pre-treated with different 
concentrations of MMP-12 or MMP-13 inhibitor for one hour. Afterwards, 2 x 105 BMDCs in 100 
µl were seeded on top of each collagen-filled transwell and either treated with LPS (10 µg/ml) or 
left untreated. 24 hours later, 500 µl of the cell suspension was harvested from each bottom 
chamber and stained without washing step for CD11c and MHC-II. 25 µl CountBright™ absolute 
counting beads (Life Technologies) were added and the CD11c+ BMDCs that had migrated through 
the gel and reached the bottom chamber were counted using an LSR II flow cytometer (BD 
Bioscience) and FlowJo software (Tree Star). 
2.2.7.2 Migration assay through collagen IV 
Collagen IV (R&D) was diluted 1:5 with distilled Millipore-H2O. 100 µl of collagen IV gel was 
filled in each transwell and polymerized overnight at 37°C. Afterwards, the remaining liquid on top 
of the collagen-coated transwells was carefully aspirated and transwells were placed in 12-well 
plates filled with 600 µl RPMI plus 0.5% BSA supplemented with 10 µg/ml CCL19 or with PBS as 
control. BMDCs were placed on top of the transwells. Cells were further cultured as described in 
section 2.2.7.1 with minor differences. As collagen IV is a target substrate of MMP-12 but not of 
MMP-13, only MMP-12 dependent migration was analyzed here. Due to the lower thickness of 
collagen IV, the migration time was four hours until the cells were collected from the bottom 
chamber. In addition, to control that collagen IV was completely covering the transwells, BMDCs 
were seeded on top of transwells without collagen. 
2.2.7.3 Endocytosis assay 
2 x 105 BMDCs in 100 µl DC medium were transferred to specific polypropylene round-bottom 
tubes (FACS-tubes) (BD Bioscience) and pre-treated with indicated amounts of MMP-12 or 
MMP-13 inhibitor for one hour at 37°C, cooled down on ice for ten minutes, and incubated with 
OVAAlexa 488 (10 µg/ml) (Life Technologies) at 4°C (control) or 37°C (endocytosis). One hour later, 
the process of endocytosis was stopped with 2 ml of ice-cold PBS supplemented with 0.5% BSA. 
Cells were additionally washed three times with PBS-BSA buffer. Therefore, tubes were filled with 
1 ml PBS-BSA buffer, centrifuged at 4°C for ten minutes, and supernatant was discarded. Finally, 
cell pellets were resuspended in 70 µl PBS-BSA buffer, blocked with 10 µl Gamunex (Grifolds), 
and stained with 20 µl of ab-mix for DCs (Table 2.16). The intensity of OVA-uptake was analyzed 
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by flow cytometry. For detailed analysis, BMDCs were divided in different analysis groups based 
on their expression intensity of MHC-II.  
Table 2.16: Ab-mix for DCs 
Anti-mouse Ab Dilution Supplier Fluorochrome Isotype 
MHC-II 1:100 BioLegend PerCP/Cy5.5 Rat IgG2b, κ 
CD11c 1:50 BioLegend APC Hamster IgG 
 
2.2.7.4 T cell activation assay 
OVA cross-presentation and T cell activation was detected using the CD8+ T cell hybridoma cell 
line B3Z. 2 x 105 BMDCs in 200 µl DC medium was seeded in 96 well-plates. Cells were either 
not treated (group one) or pre-treated with indicated amounts of MMP-13 inhibitor for one hour at 
37°C (group two). Subsequently, cells were pulsed with 1 mg/ml soluble OVA grade VI or 1 µg/ml 
SIINFEKL-peptide as positive control, or PBS as negative control for three hours. Finally, BMDCs 
were centrifuged for 8 minutes at 540 g at 4°C and washed with 200 µl of ice-cold PBS. 
Afterwards, BMDCs were cultured with indicated amounts of inhibitor overnight in the presence of 
1 x 105 B3Z cells in 200 µl T cell medium without phenol red indicator to avoid erroneous results 
during the colorimetric LacZ assay. Cells were centrifuged and supernatant was harvested. The 
remaining cells on the 96-well plates were washed with 200 µl cold PBS and incubated for three 
hours with LacZ buffer at 37°C. Activation of B3Z cells was monitored by measuring IL-2 
accumulation in the cells by a colorimetric LacZ assay (absorbance 570/620 nm) and in the 
supernatant by an IL-2 enzyme-linked immunosorbent assay (ELISA) (R&D). Note that group one 
was subjected to the inhibitor only after the OVA-uptake was already completed, whereas group 
two was exposed to the inhibitor before the pulsing with OVA protein and once more after the 
pulsing, during the co-incubation with the T cells. To exclude direct influences of the inhibitor on 
B3Z cells, non-inhibitor-treated BMDCs were pulsed with SIINFEKL-peptide for two hours. 
Afterwards, they were washed with cold PBS and fixed in 1% paraformaldehyde (PFA) (Sigma-
Aldrich) for 30 minutes on ice. Finally, after a further washing step, BMDCs were co-incubated 
with B3Z cells in T cell medium together with indicated amounts of inhibitor.  
Peptide presentation via the classical MHC-II pathway and activation of CD4+ T cells was detected 
by using the CD4+ T cell hybridoma cell line DOBW instead of B3Z cells. Experiments were 
performed as described for B3Z cells with slight variations. 1 x 105 BMDCs were co-incubated 
with 2 x 105 DOBW cells in 200 µl T cell medium. To detect the influence of MMP-13 inhibition 
on DOBW cells, untreated DCs were pulsed with OVA323-339-peptide (AnaSpec) for two hours, 
subsequently fixed, washed, and co-incubated with indicated amounts of inhibitor and DOBW cells 
in 200 µl T cell medium. Activation of DOBW cells was monitored by measuring IL-2 secretion 
using an ELISA. 
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Table 2.17: LacZ buffer 
Reagent Concentration/Volume 
β-Mercaptoethanol 225 µl 
MgCl2 4.5 mM 
NP40 0.07% 
CPRG 0.046 mg/ml 
PBS add to 50 ml 
 
2.2.8  Molecular biology 
2.2.8.1 mRNA isolation 
Total RNA was isolated from cells or trachea tissue using pepGold total RNA kit (Peqlab) 
according to the manufacture`s protocol. Unless described differently, isolation was performed at 
RT. Briefly, cells were lysed and DNA was removed using a DNA removing column. 
Subsequently, RNA was precipitated by 70% ethanol and isolated by a PerfectBind RNA column. 
DNase digestion was made within 15 minutes with 73.5 µl DNase I Digestion Buffer and 1.5 µl 
RNase-free DNase I (20 units/µl) directly on the column and after diverse washing steps, mRNA 
was eluted with 40 µl of sterile RNase-free dH2O by centrifugation. Subsequently, reverse 
transcription was performed.  
For mRNA isolated from trachea tissue, mRNA elution was performed similarly, but with one 
additionally homogenization step. For tissue homogenization, frozen trachea tissue was grinded 
with a stainless steel ball in a cryo tube applying 3000 rpm for 30 seconds in the 
microdismembrator. In order to avoid thawing of the tissue, the homogenized material was snap 
frozen in liquid nitrogen before shaking another 30 seconds with 3000 rpm in the 
microdismembrator. The frozen powder was dissolved in 1 ml Roti-Quick 1 Solution and incubated 
for 20 minutes on ice before it was jolted for ten seconds with 3000 rpm in the microdismembrator. 
The lysate was transferred to another fresh tube and 1 ml of Roti-Quick-Solution 2, based on a 
Phenol-Chloroform solution, was added and mixed intensively. After ten minutes of incubation on 
ice, the mixture was centrifuged 15 minutes at 13000 rpm at 4°C and the upper aqueous layer was 
separated and transferred to a new tube. After this lysis procedure, samples were supplemented 
with 70% ethanol and further processed as described above. 
2.2.8.2 cDNA synthesis and qRT-PCR  
Reverse transcription was performed using the GeneAMP PCR kit (Applied Biosystems) together 
with random hexamers and 1 µg of isolated mRNA per reaction. Denaturation was performed in an 
Eppendorf Mastercycler (lid = 90°C, 70°C for 10 minutes, and 4°C for 5 minutes), followed by 
reverse transcription (Eppendorf Mastercycler: lid = 105°C, 20°C for 10 minutes, 42°C for 
60 minutes, and 99°C for 5 minutes).  
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Table 2.18: Mastermix for reverse transcription 
Reagent Stock concentration Volume [µl] 
MgCl2 5 mM 8 
10x Buffer 10 mM 4 
dNTPs 1 mM 4 
Random Hexamers 2.5 µM 2 
RNase Inhibitor 1 U/µl 2 
Reverse Transcriptase 2.5 U/µl 2 
Denat. RNA 1 µg 18 
Total   40 
 
cDNA was used subsequently for qRT-PCR or stored at -20°C. qRT-PCR reactions were 
performed in duplicates with SYBR Green I Master in a LightCycler® 480 II (Roche) with standard 
conditions: 95°C for five minutes followed by 45 cycles of 95°C for five seconds (denaturation), 
59°C for five seconds (annealing), and 72°C for 20 seconds (elongation). 
Table 2.19: Mastermix for qRT-PCR 
Reagent Stock concentration Volume [µl] 
SybrGreen I Master Mix 2x 5 
Primer Mix 15 µM each 0.5 
cDNA 8.33 ng/µl 3 
H2O  1.5 
Total   10 
 
For standardization of relative mRNA expression, target genes were normalized to α-enolase 
expression. Relative transcript abundance of a gene is expressed in ∆CT values (∆CT = CTreference – 
CTtarget). Relative changes of mRNA levels are presented as ∆∆CT values (∆∆CT = ∆CTtreated – 
∆CTcontrol). Mouse primer sequences were as detailed in Table 2.13.  
All primers for quantitative PCR were designed with NCBI’s PrimerBLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and tested for primer hybridization, 
primer-dimer, and hairpin formation by oligoanalyzer tool from Integrated DNA Technologies 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/#Structure%201). If possible, the 
following primer criteria were adhered to: amplicon size ≤ 500 bp, GC content ≈ 50%, TM (primer) 
≈ 60°C, and size of primer 18 - 24 bp. 
For determination of the RNA and DNA concentration, absorbance at 260 nm was measured using 
the NanoDropTM 1000 spectrophotometer. As blank, control H2O was measured. 
2.2.9 Protein biochemistry 
2.2.9.1 Protein isolation and concentration determination  
Cells were centrifuged at 400 g for 8 minutes and frozen at -80°C for later analysis. For protein 
isolation, cells were denaturated on ice for 30 minutes in 70 µl RIPA lysis buffer containing 
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protease/phosphatase inhibitors. Protein extracts were separated by centrifugation at 14000 g for 
15 minutes at 4°C. Protein concentrations were determined using BCA assay from 1:5 diluted 
samples according to the manufacture’s protocol. 
2.2.9.2 Protein analysis by Western blot 
Cell lysates were mixed with 6x Lämmli buffer and PBS to gain equal amounts of total proteins, 
denaturated for five minutes at 95°C, separated in 10% SDS-polyacrylamide gels, and blotted onto 
a nitrocellulose membrane. After blocking with 5% milk in TBST (0.1% Tween 20/TBS) for 
30 minutes, membranes were incubated with the respected primary antibody overnight at 4°C while 
shaking. After washing three times for ten minutes with TBST, membranes were incubated with 
HRP-conjugated secondary antibodies for one hour at RT. After washing three times with TBST, 
the membranes were incubated for five minutes with Dura Duration Substrate and bands were 
visualized by enhanced chemiluminescence. Signals were detected using x-ray films and 
automatically developed with the film developer Curix 60.  
2.2.9.3  Protein analysis by immunofluorescence (IF) staining 
Tracheas were fixed in 4% PFA and incubated overnight at 4°C. The next day tracheas were 
embedded in paraffin blocks using an embedding machine. After discarding 20 µm of the upper 
end of the embedded trachea, 2 µm thick pieces were cut in series with a microtome and collected 
on object slides. After drying the slides for 30 minutes at 60°C, the tissue was deparaffinated and 
cooked with Citrate buffer (pH 6.0) in a decloaking chamber for 30 seconds at 125°C and for 
ten seconds at 90°C. This step is important to get access to antibody binding sites that are covered 
due to the fixation and embedding process. Afterwards, slides were slowly cooled down and 
washed three times with Tris buffer. To block the endogen peroxidase, slides were put in 2% H2O2 
for 15 minutes. The washing step with Tris buffer was repeated three times and 100 µl of primary 
antibody in appropriated dilution was put on the tissue for one hour at RT. Slices were washed 
again three times with Tris buffer and 100 µl of the secondary antibody (1:250) was added for 
30 minutes at RT. To detect another protein on the same slice, the process was repeated with the 
corresponding primary and secondary antibody. Finally, slides were counterstained with DAPI 
(1:2500) for one minute in the dark and washed three times with Tris buffer. The slides were 
covered with fluorescence mounting medium, dried, and stored at 4°C in the dark or were directly 
taken for immunofluorescence images. Antibodies are listed in Table 2.3 - Table 2.5. 
2.2.9.4 Immunohistochemical analysis by H&E and Masson Trichrome staining 
Hematoxylin and eosin (H&E) staining 
Fixed tracheas were embedded, cut, and deparaffinated as described in section 2.2.9.3. The slides 
were incubated in Meyers` Hämalaun solution for 6 minutes, washed in distilled water, washed for 
15 minutes in running tap water, and finally washed two minutes in distilled water. Slides were 
immersed for ten minutes in 100 ml Eosin Y solution (0.5%), supplemented with one drop of acetic 
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acid, washed in running tap water for five minutes, and incubated in 80% ethanol for another 
five minutes. The tissues on the slides were dehydrated by incubating two times in 100% ethanol 
followed by two times in Xylene for five minutes. Finally, the slices were prepared for long-time 
storage by embedding in mounting medium (Entellan). Dried slices were stored at 4°C. 
Masson Trichrome staining 
Fixed tracheas were embedded, cut, and deparaffinated like described in section 2.2.9.3. Slides 
were incubated in equal amounts of Weigerts` iron hematoxylin A and B solution for ten minutes 
and afterwards put in Picric acid alcoholic stable solution for four minutes. After washing 
three seconds in distilled water, slides were immersed in acid solution E and incubated for 
ten minutes. Afterwards, slides were immediately incubated in light green solution F for five 
minutes and washed in distilled water. The tissue was dehydrated rapidly through ascending 
concentrations of ethanol by immersing the slides one minute at 90%, one minute at 95%, and one 
minute at 100% ethanol. Finally, the slides were cleared in Xylen for 20 minutes, embedded in 
mounting medium (Entellan), and stored at 4°C.  
2.2.9.5 MMP-12 activity assay 
To measure active MMP-12 in response to an inflammatory stimulus, BMDCs were cultured in the 
absence or presence of LPS (10 µg/ml). Active MMP-12 in the supernatant of BMDCs was 
measured three hours after LPS treatment using SensoLyte® 520 MMP-12 assay according to 
manufactures instructions (extinction = 490 nm; emission = 520 nm). The SensoLyte® 520 
MMP-12 assay is based on the same method as described in section 2.2.9.6 for SensoLyte® Plus 
520 specific MMP-13 assay but without the usage of the specific anti-MMP antibody. In contrast to 
MMP-13 there exists no commercially available specific MMP-12 activity assay. 
To quantify the efficacy of the MMP-12 inhibitor to inhibit murine MMP-12, recombinant murine 
MMP-12 protein (R&D Systems) was activated by the organomercurial derivate APMA for 
120 minutes at 37°C, incubated with MMP-12 inhibitor at different concentrations, and quantified 
by the same activity assay. In case of the recombinant MMP-12 protein, the SensoLyte® 520 
MMP-12 assay without specific antibody was sufficient. 
2.2.9.6 MMP-13 activity assay 
To detect active MMP-13, BMDCs were cultured in the absence or presence of LPS (10 µg/ml) or 
OVA (1 mg/ml). Active MMP-13 in the supernatant of BMDCs was measured three hours after 
LPS or OVA treatment using SensoLyte® Plus 520 specific MMP-13 assay according to 
manufactures instructions. Briefly, a specific anti-MMP-13 monoclonal antibody was used in 
combination with a MMP fluorogenic substrate (5-FAM/QXL®520 FRET peptide). The 
fluorescence signal was monitored (extinction = 490 nm; emission = 520 nm) upon MMP-13 
induced cleavage of the fluorescence resonance energy transfer (FRET) substrate.  
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To quantify the efficacy of the MMP-13 inhibitor to inhibit murine MMP-13, recombinant murine 
MMP-13 protein (Emelca Bioscience) was activated by APMA for 40 minutes at 37°C, incubated 
with MMP-13 inhibitor at different concentrations, and quantified by SensoLyte® 520 MMP-13 
assay (extinction = 490 nm; emission = 520 nm).  
2.2.9.7 IL-2 enzyme-linked immunosorbant assay (ELISA) 
Mouse IL-2 protein concentration in cell supernatants of B3Z cells or DOBW cells were analyzed 
with the IL-2 DuoSet ELISA from R&D Systems according to the manufacture’s protocol using 
Nunc MaxiSorp® flat-bottom 96-well plates. Supernatants were obtained by centrifugation of cells 
in 96-well plates at 540 g for 7 minutes at 4°C. Supernatant was stored at -80°C for later analysis. 
2.2.9.8 Cytokine screening by Luminex assay  
200 µl of 2 x 105 BMDCs in DC medium were cultured with 10-500 µM MMP-13 inhibitor for 
24 hours, followed by treatment with LPS (10 µg/ml). Supernatant of BMDCs was harvested three 
hours after LPS treatment. Cytokine and chemokine profile were analyzed using Luminex 
bead-based multiplex screening assay (R&D) according to manufactures instructions. The customer 
based assay detected the following chemokines and cytokines: CCL2/JE/MCP-1, CCL3/MIP-1α, 
CCL4/MIP-1β, CCL5/RANTES, CCL20/MIP-3α, CXCL1/KC, CXCL2/MIP-2, CXCL10/IP-
10/CRG-2, IFN-γ, IL-1β, IL-6, IL-10, IL-12p70, IL-13, IL-23p19, LIX, TNF-α, and 
CXCL12/SDF-1α. 
2.2.9.9 Flow cytometry analysis 
For all flow cytometry experiments the basic gating strategy was as follows: After separating the 
cell population of interest according to their size and granulation by forward (FSC) and side (SSC) 
scatter, dead cells were separated by Propidium iodide (PI) staining. PI is a fluorescent molecule 
that can only bind to DNA of dead cells whereas it is discharged in living cells. Afterwards, 
doublet cells were excluded by FSC-A/FSC-W gating, followed by gating on the different cell 
types by specific antibodies. 
2.2.9.9.1 Surface expression of DCs 
To determine the surface expression of MHC-I, MHC-II, CD80, CD86, CD40, and CD11c, (Table 
2.20 and Table 2.21) cells were treated with 10, 50, 100, 200, and 500 µM MMP-13 inhibitor 
overnight together with LPS (10 µg/ml) or OVA (1 mg/ml). Data were collected on LSR II and 
analyzed with FlowJo software.  
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Table 2.20: Ab-mix for maturation markers 
Anti-mouse ab Dilution Supplier Fluorochrome Isotype 
MHC-II 1:100 BioLegend PerCP/Cy5.5 Rat IgG2b, κ 
CD80 1:50 BioLegend PB  Hamster IgG 
CD86 1:100 BioLegend PE Rat IgG2a, κ 
CD40 1:50 BioLegend PE/Cy7 Rat IgG2a, κ 
CD11c 1:50 BioLegend APC Hamster IgG 
in 20 µl PBS + 2% FBS 
 
Table 2.21: Ab-mix for MHC-I presentation 
Anti-mouse ab Dilution Supplier Fluorochrome Isotype 
CD11c 1:50 BioLegend APC Hamster IgG 
H-2Kb MHC-I  1:50 BioLegend PE Mouse IgG2a, κ 
in 20 µl PBS + 2% FBS 
 
2.2.9.9.2 SIINFEKL-peptide presentation on MHC-I  
To determine the presentation of the specific SIINFEKL-peptide on MHC-I (Table 2.22), BMDCs 
were pre-treated with indicated amounts of MMP-13 inhibitor for one hour. Afterwards, BMDCs 
were pulsed with 1 mg/ml soluble OVA grade VI (Sigma) for three hours, followed by washing 
and further cultivation overnight in DC medium supplemented with inhibitor. SIINFEKL-peptide 
(1 µg/ml) (Sigma) was used as positive control. Finally, BMDCs were washed and stained for 
H-2Kb combined SIINFEKL. Data were collected on LSR II and analyzed with FlowJo software.  
Table 2.22: Ab-mix for quantification of SIINFEKL-peptide presentation   
Anti-mouse ab Dilution Supplier Fluorochrome Isotype 
CD11c 1:50 BioLegend APC Hamster IgG 
H-2Kb bound to 
SIINFEKL  1:50 BioLegend PerCP/Cy5.5 Mouse IgG2b, κ 
in 20 µl PBS + 2% FBS         
 
2.2.9.9.3 Detection of apoptotic and dead cells  
To detect apoptotic and dead cells by flow cytometry, PI/Annexin staining was performed 
according to the manufacture`s protocol. In the early phase of apoptosis the membrane 
phospholipid phosphatidylserine (PS) is translocated from the inner side of the plasma membrane 
to the outer side, thereby exposing PS to Annexin V, a calcium-dependent phospholipid-binding 
protein. Cells that are positive for Annexin V (FITC) and negative for PI are undergoing apoptosis. 
Cells that stain positive for both Annexin V and PI are either in the end stage of apoptosis, are 
undergoing necrosis, or are dead. 
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2.2.9.9.4 Surface expression of leukocyte populations in blood and lymph nodes of 
transplanted mice 
Blood, lymph nodes, and tracheas were collected from mice as will be described in 2.2.10.  
Tracheas  
Tracheas, collected in RPMI medium with 0.7 mg/ml Collagenase A plus 25 µg/ml DNase I were 
grinded with the punch of a syringe and incubated for 60 minutes at 37°C. Afterwards, the tissue 
was homogenized using a syringe and subsequently filtrated through a 70 µm cell strainer by 
adding 10 ml RPMI plus 10% FBS. After two times of washing, cells were resuspended in buffer 
and counted by trypan blue staining. (Ab-mixes listed in Table 2.23 -Table 2.24). 
Lymph nodes 
Four lymph nodes per animal (two brachial, two axillary) were collected in RPMI and centrifuged 
at 300 g for ten minutes at 4°C, followed by homogenization with the punch of a syringe and 
filtration through a 40 µm cell strainer by adding 500 µl RPMI. After centrifugation, cells were 
counted by trypan blue staining and stained for flow cytometry analysis. To characterize the murine 
HTT model in detail, the different distribution of myeloid and lymphocytic populations in the 
lymph nodes of syngen and allogen transplanted animals were analyzed on the day of sacrification.  
Blood 
Whole-blood staining was performed after depletion of erythrocytes using the automatic lysis 
program of coulters immunology workstation. To characterize the murine HTT model in detail, the 
same staining strategy was performed as described above for lymph nodes.  
Table 2.23: Ab-mix for myeloid cells 
Anti-mouse ab  Dilution Fluorochrome Isotype 
CD11b 1:100 PE Rat IgG2b, κ 
MHC-II 1:200 PerCP/Cy5.5 Rat IgG2b, κ 
CD45 1:20 FITC - 
Ly-6G/Ly-6C 1:20 V450 Rat IgG2b, κ 
F4/80 1:13 APC/Cy7 Rat IgG2a, κ 
CD11c  1:13 APC Hamster IgG 
in 20 µl PBS + 2% FBS 
 
Table 2.24: Ab-mix for lymphocytes 
Anti-mouse ab  Dilution Fluorochrome Isotype 
CD3 1:20 PB - 
CD19 1:200 PE - 
CD45 1:40 FITC - 
CD4  1:100 PerCP/Cy5.5 - 
CD8α 1:100 APC/Cy7 - 
NK1.1 1:40 APC - 
in 20 µl PBS + 2% FBS 
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2.2.10 Murine HTT model (mouse model) 
Female C57BL/6 mice and female BALB/c mice were obtained from Jackson Immuno-Research 
Laboratories and used at the age of 8-10 weeks. All experiments were conducted according to the 
guidelines of the Ethics Committee of the Helmholtz-Center Munich and approved by the 
Regierungspräsidium Oberbayern, Germany.  
Syngrafts and allografts were obtained by transplanting either C57BL/6 tracheas into C57BL/6 
recipient (syngraft) or BALB/c tracheas into C57BL/6 recipient (allograft).  
Donor mice were deeply narcotized with intraperitoneal (i.p.) administration of a mixture of 60% 
ketamine, 20% rompun, and 20% NaCl according to their body weight (around 0.6 ml) and 
sacrificed by cervical fracture. Skin of mice was sterilized with 70% ethanol and mice were fixed 
on a polystyrene plate. First, donor heart and lung were exposed via a midline incision through the 
skin and peritoneum extending through the rib cage and sternal notch. Second, thymus tissue was 
dissected away. Afterwards, the esophagus was separated from the trachea by blunt dissection and 
the trachea was then excised cephalad near the larynx and close to the hilu above the lung. Finally, 
the trachea was placed in PBS. Recipient mice were narcotized with i.p. administration of 
0.2 mg/ml medetomidin (Orion Pharma, Hamburg), 2.0 mg/ml midazolam (Roche Pharma, 
Mannheim), and 0.02 mg/ml fentanyl (Janssen-Cliag, Neuss) according to their body weight. Skin 
of mice was sterilized with Cutasept. After shaving of a 1 cm × 1 cm large area behind the head on 
the back, a 3 mm transverse incision was made through the dermis and a 1.5 cm × 1.5 cm large 
subcutaneous pouch was created via blunt dissection. One trachea was placed into each animal and 
the skin pocket was closed with size 5.0 degradable suture, sterilized with Cutasept, and covered 
with iodine. After the instillation procedure, the narcosis was antagonized subcutaneously with 
0.29 mg/ml atipamezol (Orion Pharma, Hamburg), 0.059 mg/ml flumazenil (Hexal, Holzkirchen), 
and 0.14 mg/ml naloxon (Actavis, Munich) according to the mouse body weight. Narcosis and 
antagonist was obtained through the Tierärztliche Hausapotheke of the Helmholtz Zentrum 
München. Mice which got the inhibitor were treated i.p. every second day with 25 µg (74 µM) (two 
animals per group) or with 100 µg (296 µM) (four animals per group) MMP-13 inhibitor (100 µl) 
or 100 µl NaCl as control. On day 14 and 21, syngrafts and allografts were harvested and collected 
either in 4% PFA for histology, or in RPMI (4°C) with 0.7 mg/ml collagenase A plus 25 µg/ml 
DNase I for flow cytometry, or were snap frozen in liquid nitrogen for RNA analysis. Additionally, 
blood and lymph nodes (axillary and branchial) were collected from each mouse on the day of 
sacrification and, subsequently, used for flow cytometry analyses. The blood (max. 0.8 ml) was 
collected from the abdominal aorta with a syringe wetted with heparin.  
To quantify the BOS phenotype, luminal occlusion and epithelial loss were calculated on 
histological slices. Epithelial loss was calculated by measuring the distance of destroyed epithelium 
in relation to intact epithelium. Luminal occlusion was determined by following formula adapted 
from Grove et al.238. 
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Luminal occlusion = area within cartilage - area within residual lumen x 100   
    area within cartilage 
 
2.2.11 Statistical analysis 
Statistical analysis was performed with GraphPad Prism 4 (GraphPad Software) using unpaired 
t-test, One-way Anova with Dunnett’s multiple comparison test, Anova with Kruskal-Wallis 
Dunn’s comparison test, or One-Sample t-test. Data are presented as mean ± S.D or median (25-75 
percentile with minimum (min.) to maximum (max.).  
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 RESULTS 3
DCs and MMPs are both considered to be important in the pathogenesis of BOS, as detailed in the 
introduction section. Whether the selected MMPs, MMP-12 and -13, are involved in BOS and 
whether they have specific immunobiological functions in DCs, which might promote the 
progression of BOS, have not been investigated so far. To elucidate possible immunobiological 
functions of MMP-12 and -13 in DC biology, experiments were performed with in vitro generated 
murine DCs. This knowledge should subsequently be applied to the in vivo mouse BOS model to 
gain insights how DC biology and MMPs might contribute to the pathogenesis of BOS in vivo. 
3.1 In vitro analysis of MMP-12 and -13 in DC immunobiology 
3.1.1 Analysis of generated bone marrow-derived DCs by flow cytometry 
To obtain enough cells for the diverse functional assays, murine DCs derived from bone marrow 
(BMDCs) were chosen as source of DCs for the in vitro study. As shown in Figure 3.1 and detailed 
in section 2.2.1., cells were generated from bone marrow cells within one week by adding GM-CSF 
and harvesting non-adherent cells.  
 
Figure 3.1: Generation of BMDCs in vitro. 
BMDCs were generated within one week by adding GM-CSF and by separating them from the majority of 
remaining cells by cell adherence. On day seven, cells were harvested and analyzed for their expression 
profile. 
 
To control the purity and the phenotype of generated BMDCs, cells were analyzed on day seven for 
the surface expression of CD11c, MHC-I, MHC-II, CD80, CD86, and CD40. First, cells were 
selected by forward and side scatter (Figure 3.2i), followed by exclusion of cell doublets (Figure 
3.2ii) and separation of dead cells by live-dead staining with PI (Figure 3.2iii). Afterwards, 
remaining cells were gated on CD11c+ cells (Figure 3.2iv-v) and either analyzed for MHC-I 
(Figure 3.2iv) or MHC-II expression (Figure 3.2v). The purity of CD11c+ BMDCs, which were 
used subsequently for experiments, was at least 70% with a homogenous maturation state of the 
cell population (Figure 3.2vii-ix). For the later performed endocytosis assay (see section 3.1.3.2), 
CD11c+ cells were further separated according to their MHC-II surface expression intensity (Figure 
3.2vi). Additionally, to control their maturation state, cells were stimulated 24 hours with LPS or 
left unstimulated, subsequently gated for CD11c+ BMDCs (Figure 3.2v), and further analyzed by 
three different maturation markers (CD40, CD80, and CD86). In line with previous reports239, 
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BMDCs stimulated with LPS increased CD40, CD80, and CD86 compared to non-stimulated ones 
(Figure 3.2vii-ix).  
 
Figure 3.2: Gating strategy of generated BMDCs. 
(i) Cells were gated according to their size and granulation followed by (ii) separation of doublets and (iii) 
dead cells. Afterwards, CD11c+ cells were further analyzed for their (iv) MHC-I or (v) MHC-II expression. 
(vi) The intensity of MHC-II expression was further divided in MHC-IIlow, MHC-IIdim, and MHC-IIhigh. The 
maturation state of BMDCs on day 7 was evaluated by the expression of the following markers: (vii) CD40, 
(viii) CD80, and (ix) CD86. To gain mature BMDCs, cells were stimulated on day seven with LPS for 24 h 
and analyzed subsequently for their maturation profile. Non-stimulated (n.s.). 
 
3.1.2 Expression analysis of MMPs and TIMPs in DCs 
To determine the importance of MMP-12 and -13 for the immunostimulatory function of DCs, 
expression of these MMPs was first verified in unstimulated immature BMDCs by qRT-PCR 
(Figure 3.3A). Expression of MMP-12 and -13 was detected with the following ∆CT(α-enolase-target) 
values of 6 ± 1.2 and -2.2 ± 1.7 (mean ± SD), respectively. In addition, expression of the natural 
MMP inhibitors TIMP-1, -2, and -3, was also determined in these cells (∆CT values of -4.3 ± 
0.9, -3.4 ±1.5, and -5.1 ± 1.4, respectively). For comparison, BMDCs were also analyzed for the 
expression of two already very intensely studied MMPs, namely MMP-2 and -9 (∆CT values 
of -3 ± 2.6 and 0.7 ± 1.1, respectively). In line with other studies170, all MMPs were detected at low 
expression level under baseline conditions with MMP-12 showing the highest expression level. 
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To test for MMP-12 and -13 expression on protein level, Western blot analysis was performed. The 
presence of the zymogen (54 kDa) and the active form of MMP-12 (45 kDa) as well as the different 
forms of the MMP-13 protein, pro-enzyme (60 kDa), active form (54 kDa), and cleaved fragments 
(48/34 kDa) were detected in unstimulated BMDCs (Figure 3.3B).  
 
Figure 3.3: MMP-12 and -13 expression in unstimulated BMDCs on RNA and protein level.  
(A) Total cell lysates of BMDCs were analyzed on day seven by qRT-PCR for the presence of MMP-12 and 
-13 as well as their TIMPs. Data are illustrated in a box plot (25 – 75 percentile with min. to max.) as ∆CT 
values (n = 13). (B) The zymogen (54 kDa) and the active form of MMP-12 (45 kDa) as well as the different 
forms of MMP-13, pro-enzyme (60 kDa), active form (54 kDa), and cleaved fragments (48/34 kDa) were 
validated by Western blot. Molecular weights of the protein marker are indicated (kDa). Results are 
representative of 5 independent experiments. 
 
To determine the expression of MMP-12 and -13 in response to a pro-inflammatory stimulus, 
BMDCs were stimulated with 10 µg/ml LPS. Three different time points, 0.5, 3, and 24 hours of 
LPS-treatment were chosen for the expression kinetics. The highest induction of MMP-13 
expression (7-fold) on mRNA level was found at three hours after LPS stimulation, which declined 
again over time within 24 hours (Figure 3.4). Regarding MMP-12 transcript levels no significant 
increase was detected. 
 
Figure 3.4: Expression kinetics of MMP-12 and -13 on RNA level. 
Kinetic of BMDCs were performed to determine the appropriate duration for LPS stimulation. Therefore, 
BMDCs were cultured with LPS for 0.5, 3, and 24 h and alterations in the transcript levels of MMP-12 
and -13 were analyzed by qRT-PCR. Data are shown as ∆∆CT values of LPS-stimulated BMDCs normalized 
to PBS-treated BMDCs for 11 independent experiments. Data are shown as box plot (25 – 75 percentile with 
min. to max.). Statistical analysis: Anova with Kruskal-Wallis Dunn’s Comparison Test. *p<0.05 and 
***p<0.001. 
 
As LPS most effectively induced MMP-13 three hours after stimulation, this time point was chosen 
for further experiments. Beside the usage of the inflammatory stimulus LPS, the antigen OVA was 
included for further analysis. Using OVA, alterations in the expression profile of MMPs could be 
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analyzed while the antigen processing takes place. Alterations of specific MMPs during antigen 
uptake via the endocytotic pathway and during antigen processing and presentation can be analyzed 
in this way.  
BMDCs treated either with LPS (∆∆CT(LPS-n.t.) = 2.5 ± 1.1 (mean ± SD)) or OVA (∆∆CT(OVA-n.t.) 
= 1.9 ± 0.3) displayed a significant increase of MMP-13 mRNA expression (Figure 3.5ii), whereas 
MMP-12 expression did not change significantly (Figure 3.5i). MMPs are controlled by their 
natural inhibitors. Therefore, TIMP-1, -2, and -3 were analyzed simultaneously for changes in their 
expression profile after LPS/OVA stimulation (Figure 3.5v-vii). TIMP-1 significantly increased 
only upon LPS stimulation (mean ∆∆CT(LPS-n.t.) = 1.484 ± 1) whereas TIMP-2 significantly 
decreased in response to both stimuli (∆∆CT(LPS-n.t.) = -0.8 ± 0.6 and ∆∆CT(OVA-n.t.) = -1.22 ± 0.7, 
respectively). The expression level of TIMP-3 did not display significant changes whereas MMP-2 
and MMP-9 mRNA expression increased after both stimuli (Figure 3.5iii-iv). 
 
Figure 3.5: Increased MMP-13 expression after inflammatory stimulus.  
BMDCs were stimulated with LPS (10 µg/ml) or OVA (1 mg/ml) for 3 h. Expression of different MMPs and 
TIMPs was analyzed by qRT-PCR. Data are shown as ∆∆CT values of LPS/OVA-stimulated BMDCs 
normalized to PBS-treated BMDCs for 11 (LPS) and 7 (OVA) independent experiments (box plot 25 – 75 
percentile with min. to max.). Statistical analysis: Anova with Kruskal-Wallis Dunn’s Comparison Test. 
**p<0.01 and ***p<0.001. 
 
After confirming the expression of MMP-12 and -13 on RNA and protein level, specific MMP 
activity assays were performed to investigate whether the activity state of MMP-12 or -13 also 
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changed during inflammatory LPS stimulation. Indeed, active MMP-12 (factor = 1.14 ± 0.07) and 
MMP-13 (factor = 1.3 ± 0.2) increased after LPS stimulation (Figure 3.6).  
 
Figure 3.6: Increased active MMP-12 and -13 after LPS stimulation. 
Active MMP-12 and -13 in the supernatant of BMDCs were determined 3 h after LPS stimulation by specific 
MMP assays. Data are displayed as box plot (25 – 75 percentile with min. to max.) with relative values of 
LPS-stimulated cells normalized to PBS-treated cells in percentages (n = 6). Statistical analysis: Unpaired 
t-test. **p<0.01 and ***p<0.001. 
 
Taken together, these results confirmed the expression of MMP-12 and -13 in BMDCs under 
baseline conditions and revealed a significant upregulation, especially of MMP-13, in response to 
the inflammatory stimulus LPS. 
3.1.3 Involvement of MMP-12 and -13 in BMDC functions  
In order to determine a role of MMP-12 and -13 for the phenotype and function of BMDCs, in 
particular concerning migration, endocytosis, cytokine release, antigen presentation, and T cell 
activation, various functional assays were performed using two specific MMP inhibitors. The 
specific small molecule inhibitor MMP408 for MMP-12 inhibition and the specific small molecule 
inhibitor CL82198 for MMP-13 inhibition were used, respectively.  
3.1.3.1 Efficacy and toxicity analysis of MMP-12 and -13 inhibitors  
In order to rule out toxic side effects of the applied doses of the chosen inhibitors, toxicity tests 
were performed. Therefore, BMDCs were treated with the indicated amounts of inhibitors 
overnight, followed by the cell viability assay WST-1. MMP-12 inhibitor showed no toxic effect up 
to a concentration of 50 µM (Figure 3.7). Beyond that concentration, a clear increase in 
metabolically stressed or dead cells were detected as indicated by a decrease of WST turnover. In 
case of the MMP-13 inhibitor, no strong increase in cell death could be detected up to a 
concentration of 500 µM (Figure 3.8). A threshold of metabolic activity of 80% was selected. 
Accordingly, in further experiments, MMP-12 inhibitor was used in a concentration up to 50 µM 
and MMP-13 inhibitor up to 500 µM. 
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Figure 3.7: Toxicity measurements of MMP inhibitors using WST-1 assay.  
WST-1 reagent was used to determine the toxic effect of MMP-12 and -13 inhibitors on BMDCs. Cells were 
treated with indicated amounts of inhibitors for 24 h followed by WST-1 assay. Data are shown as relative 
values of inhibitor-treated cells (inh.) normalized to non-treated (no inh.) cells in percentage (mean ± SD)  
(n = 8). 
 
In a second step, the efficacy of murine MMP inhibition was verified with murine recombinant 
MMP-12 or MMP-13 as these inhibitors were originally designed for human MMPs. As 
demonstrated in Figure 3.8, both inhibitors decreased active recombinant murine MMP-12 or -13, 
respectively, in a dose-dependent manner, with a mean inhibition efficacy of up to 91% ± 7% at the 
highest MMP-12 inhibitor concentration of 50 µM and 67% ± 13% at the highest MMP-13 
inhibitor concentration of 500 µM. 
 
Figure 3.8: Efficacy of inhibitor for murine MMP-12 or -13 protein. 
Recombinant murine MMP-12 or -13 protein was activated by 4-Aminophenylmercuric Acetate (APMA), 
incubated with the specific inhibitor at different concentrations, and quantified by specific MMP activity 
assays. Data are illustrated as relative values of active MMP-12 and -13 between inhibitor treated (inh.) and 
non-treated (no inh.) groups. (mean ± SD) (n = 4). Statistical analysis: Anova with Dunnett's Multiple 
Comparison Test. **p<0.01 and ***p<0.001. 
 
Altogether, functionality of the two MMP inhibitors for the respective murine MMPs was validated 
and the concentrations with the highest inhibitory potential, that revealed no toxic side effects, were 
identified. 
3.1.3.2 Involvement of MMP-12 and -13 in DC migration 
In the process of host defense, DCs must leave the periphery to reach the area of infection and later 
move on to the lymph nodes where they finally activate T cells. Hence, the capability to migrate is 
one of the central functions of DCs. To investigate whether MMP-12 or -13 is involved in BMDC 
migration, a 3D collagen migration assay was performed with CCL19 as chemoattractant (Figure 
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3.9). Depending on the specific target-substrate, MMP-12 dependent migration was analyzed 
through collagen I and IV whereas MMP-13 dependent migration was performed through collagen 
I gel. 
 
Figure 3.9: Design of the 3D migration assay. 
Schematically overview of the 3D migration assay design. 
 
First, the setup of the 3D migration assay was controlled without inhibitor application. As 
expected, no migration was detected through collagen I when the chemoattractant CCL19 was 
absent, independently of PBS/LPS treatment, validating CCL19 directed migration of BMDCs in 
the assay (Figure 3.10A). In case of collagen IV, 17% ± 8.5% (mean ± SD) of cells migrated even 
in the absence of CCL19 (Figure 3.10Bi).  
To control for complete coverage of the transwells with collagen IV, a negative control without 
collagen IV coating was run in parallel. In case of non-coated transwells, an increase of 29% ± 8% 
(mean ± SD) of migrated cells was observed compared to transwells coated with collagen IV 
(Figure 3.10Bii), indicating that the collagen IV layer had built up a barrier for the cells. In the case 
of the thick collagen I layer, the integrity could be confirmed by eye with microscopy.  
When comparing LPS stimulated and non-stimulated cells, LPS-stimulated BMDCs showed an 
increase of 36% ± 15% (mean ± SD) of migrated cells through collagen I compared to 
non-stimulated BMDCs (Figure 3.10A). In contrast, in case of collagen IV, 37% ± 17% (mean ± 
SD) fewer cells migrated after LPS stimulus (Figure 3.10Bi). The reason for this difference is 
unknown, but might be related to stronger cell adherence after LPS treatment. The adherence effect 
might lose its impact on the migration outcome during the elongated time frame of 24 hours in 
collagen I. 
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Figure 3.10: Control setting of the 3D migration assay.  
(A and Bi) Comparison of BMDCs stimulated with LPS or PBS as control as well as with or without CCL19 
as chemoattractant. (Bii) Analysis of collagen IV layer integrity by comparing DC migration through 
collagen coated or non-coated transwells. Statistical analysis: A and Bi: Anova with Dunnett's Multiple 
Comparison Test. ***p<0.001. Bii: Unpaired t-test. *p<0.05 
 
Concerning the CCL19-directed BMDC migration capacity, neither the inhibition of MMP-12 nor 
inhibition of MMP-13 influenced migration of LPS-stimulated or unstimulated DCs (Figure 3.11A 
and B), independently of the target-substrate. In order to confirm that MMP-12 inhibition does not 
alter BMDC migration, BMDCs generated from MMP-12 ko cells were analyzed. Even MMP-12 
ko BMDCs migrated similar compared to wt cells (Figure 3.11B right). The same analysis could 
not be performed for MMP-13 based migration as no MMP-13 ko animals were available. 
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Figure 3.11: No influence of MMP-12 or -13 inhibition on BMDC migration. 
Unstimulated or LPS-stimulated (-/+ LPS) BMDCs were incubated with MMP-12 or -13 inhibitor for 1 h or 
left untreated and seeded (A) overnight on collagen I, or (B) 4 h on collagen IV filled transwells. BMDCs 
which migrated towards the CCL19 into the bottom chamber were stained for CD11c and MHC-II, and 
counted with counting beads by flow cytometry. (A) Migration of DCs through collagen I after (i) MMP-12 
or (ii) MMP-13 inhibition. Data are shown as relative values between inhibitor-treated (inh.) and 
non-inhibitor-treated (no inh.) groups (mean ± SD) (n = 4). (B) Migration of (i) BMDCs treated with 
MMP-12 inhibitor or (ii) MMP-12 ko cells through collagen IV. Data are shown as relative values between 
(i) inhibitor treated and non-treated groups or (ii) ko cells normalized to wt cells (mean ± SD) (n = 4). 
Statistical analysis: Anova with Dunnett's Multiple Comparison Test.  
 
Taken together, these data suggest that MMP-12 and -13 do not have a strong role for BMDC 
migration. 
3.1.3.3 Analysis of endocytic capacity of MMP-12 ko and wt DCs after MMP-13 inhibition  
DCs take up foreign antigens to activate the antigen-specific T cell response. To determine whether 
MMP-12 or -13 influences the endocytic capability of BMDCs, MMP-12 ko cells and wt cells 
treated with the tested inhibitors were exposed to fluorochrome-labeled OVA. As shown in Figure 
3.12i and Figure 3.13, soluble OVA was efficiently taken up by CD11c+ BMDCs.  
As shown in Figure 3.12ii, a significant lower number of MMP-12 ko cells endocytosed OVA (6% 
± 2%). Concerning the amount of endocytosed OVA, as determined by the mean fluorescence 
intensity of OVA, a reduction of 38.5% ± 12% (mean ± SD) was detected in the MMP-12 ko group 
(Figure 3.12iii). In addition, the MHC-II surface expression profile of ko compared to wt BMDCs 
was analyzed. As documented in Figure 3.12iii, ko cells displayed higher MHC-II surface 
expression than WT cells.  
Using the specific MMP-12 inhibitor, a decreased OVA-uptake was observed, however the same 
effect was seen in the DMSO vehicle control groups (data not shown), thus, indicating that the 
effect of the MMP-12 inhibitor was unspecific. 
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Figure 3.12: Decreased endocytosis of soluble OVA in MMP-12 ko BMDCs.  
BMDCs were generated from MMP-12 ko mice or wt mice, cooled down on ice, then incubated with 
OVAAlexa 488 for 1 h at 4°C (control) or 37°C, followed by staining for CD11c and MHC-II, and flow 
cytometry analysis. Data represent uptake of OVAAlexa 488 by CD11c+ DCs. (i) Representative result of 5 
independent experiments. (? = control at 4°C, ─ = wt at 37°C, ─ = MMP-12 ko at 37°C). (ii) Box plot (25 – 
75 percentile with min. to max.) summary of 5 experiments illustrating the relative difference in number of 
cells that endocytosed OVA between MMP-12 ko and wt BMDCs. (iii) Quantification of the relative amount 
of internalized OVA and MHC-II between MMP-12 ko and wt BMDCs shown by MFI value. Statistical 
analysis: Anova with Dunnett's Multiple Comparison Test. **p<0.01. 
 
Regarding inhibition of MMP-13, endocytic capability of BMDCs decreased in a dose-dependent 
manner (Figure 3.13). Using the highest inhibitor concentration, a significant lower number of DCs 
endocytosed OVA (17% ± 16% less) (Figure 3.13ii) and, furthermore, MMP-13 inhibitor-treatment 
reduced the OVA+ cells of up to 16% ± 6% (mean ± SD) compared to the uninhibited DCs (Figure 
3.13iii).  
To further determine whether the observed effect can be correlated to a specific BMDC phenotype, 
CD11c+ BMDCs were grouped according to their MHC-II surface profile and subgroups were 
compared for their OVA-uptake. In line with other studies33, immature BMDCs with low MHC-II 
surface expression showed stronger capability to capture OVA compared to MHC-IIhigh BMDCs. 
As demonstrated in Figure 3.13iv-vi, the reduction in endocytosis by MMP-13 inhibition was 
detected in all BMDCs subgroups independent of MHC-II expression level, even though the 
MHC-IIhigh subgroup showed very low overall OVA-uptake.  
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Figure 3.13: Involvement of MMP-13 in endocytosis of soluble OVA in BMDCs.  
BMDCs were pre-treated with MMP-13 inhibitor for 1 h at 37°C or left untreated, cooled down on ice, then 
incubated with OVAAlexa 488 for 1 h at 4°C (control) or 37°C, followed by staining for CD11c and MHC-II, 
and flow cytometry analysis. Data represent uptake of OVAAlexa 488 by CD11c+ BMDCs. (i) Representative 
result of 9 independent experiments, showing two inhibitor concentrations exemplarily. (? = control at 4°C, 
─ = non-treated at 37°C, ---- = 100 µM MMP-13 inhibitor at 37°C, and ─ = 200 µM MMP-13 inhibitor at 
37°C). (ii) Box plot (25 – 75 percentile with min. to max.) summary of 9 experiments illustrating the relative 
difference in number of cells that endocytosed OVA between treated (inh.) and non-treated (no inh.) groups. 
(iii) Quantification of the relative amount of internalized OVA between treated and non-treated groups, 
shown by MFI values. Statistical analysis: Anova with Dunnett's Multiple Comparison Test. **p<0.01 and 
***p<0.001. (iv-vi) Representative results of BMDCs that endocytosed OVA classified according to their 
MHC-II expression intensity.   
 
These results indicate that MMP-13 participates in the regulation of soluble OVA endocytosis, 
resulting in reduction in the percentage of BMDCs that take up OVA as well as in the overall 
amount of endocytosed OVA when MMP-13 activity is inhibited. MMP-12 ko BMDCs revealed a 
decline in endocytosis but showed simultaneously a different MHC-II expression profile in 
comparison to wt BMDCs. 
3.1.3.4 MMP-13 involvement in T cell activation 
Another fundamental ability of DCs is the processing and presentation of antigens and, thereafter, 
the activation of the adaptive immune response. DCs treated with soluble OVA can either activate 
CD4+ T cells via the classical MHC-II pathway or CD8+ T cells by cross-presentation via the 
MHC-I pathway.  
As the only commercially available MMP-12 inhibitor showed side effects due to the solvent 
(DMSO) and the MMP-12 ko cells had a different MHC-II surface profile and were therefore not 
comparable to wt cells, the focus of further investigations was set on MMP-13.  
As the T cell activation assay includes besides BMDCs also the T cell line B3Z (CD8+ T cell 
hybridoma cell line specific for OVA257-264-peptide (SIINFEKL)), or the T cell line DOBW 
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(CD4+ T cell line specific for OVA323-339-peptide), the effect of MMP-13 inhibition was tested on 
the T cells. To exclude potential toxicity of MMP-13 inhibitor on these types of cells, PI/Annexin 
staining of inhibitor-treated T cells was performed. Apoptotic and dead cells were analyzed by flow 
cytometry. Cells that are positive for Annexin V (FITC) and negative for PI are undergoing 
apoptosis. Cells that stained positive for both Annexin V and PI are either in the end stage of 
apoptosis, are undergoing necrosis, or are dead. Using this assay, only a moderate increase in 
apoptotic cells was detected in both T cell lines after MMP-13 inhibitor treatment (Figure 3.14). In 
addition, PI/Annexin staining detected no apoptotic effects of the MMP-13 inhibitor on BMDCs 
confirming the previous results observed with the WST assay (Figure 3.7). 
 
Figure 3.14: No toxic effect of MMP-13 inhibitor on BMDCs, B3Z, or DOBW cells.  
PI/Annexin staining was used to determine the toxic effect of MMP-13 inhibitor on the different cell types. 
BMDCs, B3Z cells, or DOBW cells were treated with 10-500 µM MMP-13 inhibitor for 24 h. BMDCs (left), 
B3Z (center), and DOBW (right) cells were stained with Annexin V plus PI and analyzed by flow cytometry 
for percentages of dead and apoptotic cells. Results are representative of 3 independent experiments.  
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After excluding toxic side effects of the inhibitor on the two T cell lines, the T cell activation 
assays were performed. To elucidate a role of MMP-13 in the MHC-I pathway (cross-presentation) 
for T cell activation, OVA-treated BMDCs were co-cultivated with CD8+ T cells (B3Z T cells), 
followed by measurement of IL-2 production by T cells as readout for T cell activation. In addition, 
a colorimetric LacZ assay was performed for the detection of T cell activation because B3Z T cells 
express β-galactosidase under the control of the IL-2 promoter. It was observed that the capability 
of BMDCs to activate CD8+ T cells was significantly and strongly reduced in the presence of 
MMP-13 inhibitor in a dose dependent manner (Figure 3.15i-ii). To determine whether the 
observed effect is due to reduced endocytic capability of treated BMDCs (as shown in Figure 3.13), 
MMP-13 inhibitor was applied after the endocytosis phase. As depicted in Figure 3.15iii-iv, a 
similar reduction in T cell activation was detected, indicating that the reduction might be due to 
effects on processes subsequent to endocytosis. 
As the inhibitor was present during DC and T cell co-culture, the inhibition could be due to effects 
on the DCs, the T cells, or both. To exclude a direct effect of the inhibitor on the CD8+ T cells, 
BMDCs were pulsed with SIINFEKL-peptide in the absence of inhibitor, then fixed, and 
co-incubated with T cells in the presence of MMP-13 inhibitor. In this setting, where the inhibitor 
cannot alter DC function any longer, the previously observed reduction in IL-2 secretion was no 
longer detected (Figure 3.15v-vi), which excludes that MMP-13 inhibition manipulated the 
CD8+ B3Z cells. Thus, it has to be concluded that MMP-13 inhibition not only alters OVA 
endocytosis (as shown in Figure 3.13) but has additional effects in the MHC-I cross-presentation 
pathway following the endocytosis process, which affect T cell activation. 
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Figure 3.15: Decreased capacity of BMDCs to activate B3Z CD8+ T cells by MMP-13 inhibition.  
(i-ii) BMDCs were pre-treated with indicated amounts of MMP-13 inhibitor, followed by protein pulsing 
with OVA or PBS (3h), and cultured with indicated amounts of inhibitor overnight in the presence of 
CD8+ T cell (B3Z). (Top) Activation of CD8+ B3Z cells was monitored by measuring LacZ accumulation in 
a colorimetric assay (n =6 ) or (bottom) IL-2 secretion in the supernatant by ELISA (n = 5). (iii-iv) 
Experiments were performed as described above except that the inhibitor was added after pulsing with OVA 
(iii: n = 6, iv: n = 3). (v-vi) Untreated BMDCs were pulsed with SIINFEKL-peptide for 2 h, washed, fixed, 
and co-incubated with B3Z cells in the presence of indicated concentration of inhibitor overnight. (v: n = 4, 
vi: n = 3). Data are depicted as relative values between MMP-13 inhibitor treated (inh.) and non-treated (no 
inh.) groups (mean ± SD). Statistical analysis: Anova with Dunnett's Multiple Comparison Test. *p<0.05, 
**p<0.01, and ***p<0.001.  
 
To further define whether MMP-13 also has a role in the classical MHC-II pathway, experiments 
were performed as described above using CD4+ T cells. In the setting where the inhibitor was 
present during the whole experiment, a moderate reduction in CD4+ T cell activation was observed 
(Figure 3.16i). In the setting where untreated SIINFEKL-pulsed and fixed DCs were used and the 
inhibitor was added during the DC-T cell co-culture, a comparable reduction in IL-2 secretion was 
measured (Figure 3.16ii). Thus, it has to be concluded that the MMP-13 inhibitor has a direct effect 
on the DOBW CD4+ T cells and it cannot be discerned whether MMP-13 inhibition affects 
additional processes of the CD4+ T cell activation. 
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Figure 3.16: Inhibition does not affect BMDCs regarding activation of DOBW CD4+ T lymphocytes.  
Activation of DOBW CD4+ T cells via MHC-II pathway was detected by performing similar experiments as 
described in Figure 3.15 with slight modification. (Left) DCs were pre-treated with indicated amounts of 
inhibitor for 1 h or left untreated, followed by protein pulsing with OVA or PBS (as control) for 3 h, washed, 
and cultured with indicated amounts of inhibitor overnight with CD4+ T cells (DOBW cells). Activation of 
DOBW cells was monitored by measuring IL-2 secretion in the supernatant by ELISA (n = 5). (Right) 
Untreated BMDCs were pulsed with SIINFEKL-peptide for 2 h, washed, fixed, and then co-incubated with 
DOBW cells in the presence of indicated amounts of inhibitor (n = 3). Statistical analysis: Anova with 
Dunnett's Multiple Comparison Test. *p<0.05, **p<0.01, and ***p<0.001. 
 
In summary, these results suggest that MMP-13 plays a crucial role in DCs, facilitating the 
activation process of CD8+ T cells via the MHC-I pathway, whereas it seems to be less important 
or dispensable for the CD4+ T cell activation via the MHC-II pathway. 
3.1.3.5 Analysis of the MHC surface expression after inhibition of MMP-13 
To induce protective CD8+ T cell activation in vivo, sufficient peptide presentation by APCs is 
necessary. To determine the mechanism leading to reduced CD8+ T cell activation in our system, 
alterations in the capability of BMDCs to present peptides after inhibition of MMP-13 was 
analyzed. Therefore, BMDCs were incubated with OVA protein in the absence or presence of 
MMP-13 inhibitor followed by flow cytometry staining of the complex of the OVA peptide 
(SIINFEKL) bound to H-2Kb of MHC-I. As depicted in Figure 3.17, SIINFEKL-presentation on 
MHC-I by BMDCs was reduced significantly at the highest inhibitor concentration. 
 
Figure 3.17: Involvement of MMP-13 in peptide presentation.  
BMDCs were pre-treated with indicated amounts of MMP-13 inhibitor followed by treatment with OVA or 
PBS (control) for 3 h, washed, and cultured overnight in the presence of the MMP-13 inhibitor. Cells were 
washed and stained for CD11c and the complex of SIINFEKL bound to H-2Kb of MHC-I. (Left) 
Representative result of 11 independent experiments (? = isotype, ---- =PBS, ─ = OVA without MMP-13 
inhibitor, …… = OVA with 200 µM MMP-13 inhibitor, ─ = OVA with 500 µM MMP-13 inhibitor). (Right) 
Relative MFI values between inhibitor-treated (inh.) and non-treated (no inh.) CD11c+ BMDCs (mean ± SD). 
Statistical analysis: Anova with Dunnett's Multiple Comparison Test. **p<0.01. 
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This result suggests that MMP-13 is involved in generating the peptide/MHC-I complex required 
for T cell activation by either regulating the loading of exogenous peptides onto MHC-I or 
participating in the MHC-I surface expression. To analyze whether inhibition of MMP-13 leads to 
a general reduction of the overall MHC-I surface expression, BMDCs were treated with MMP-13 
inhibitor and OVA overnight, followed by flow cytometry analysis measuring total MHC-I surface 
molecules. In line with the reduced CD8+ T cell activation shown in Figure 3.15, surface 
expression of MHC-I was significantly reduced on BMDCs treated with inhibitor, whereas MHC-II 
remained unchanged (Figure 3.18).  
 
Figure 3.18: Decreased MHC-I surface expression on DCs after MMP-13 inhibition. 
BMDCs were pre-treated with indicated amounts of MMP-13 inhibitor and cultivated with OVA overnight. 
Cells were washed and stained for CD11c and surface MHC-I or MHC-II, followed by flow cytometry 
analysis. Representative MHC-I or -II surface expression (?= isotype, ─ = without inhibitor, …… = 500 µM 
of MMP-13 inhibitor) and quantification of 6 experiments, respectively. Data are shown as relative MFI 
values between treated (inh.) and non-treated (no inh.) CD11c+ BMDCs (mean ± SD). Statistical analysis: 
Anova with Dunnett's Multiple Comparison Test. **p<0.01 and ***p<0.001. 
 
Taken together, a decline in total surface MHC-I, including the specific SIINFEKL-peptide on 
MHC-I, was determined after MMP-13 inhibition. 
3.1.3.6 Analysis of the maturation profile and selectin expression after MMP-13 inhibition  
T cells are activated by DCs through the recognition of specific peptides on MHCs together with 
the help of co-stimulatory molecules, such as CD40, CD80, and CD86, which are upregulated 
during maturation21. To determine whether MMP-13 participates in the maturation process of 
BMDCs, analysis of MMP-13 inhibitor-treated cells were performed. As expected, CD40, CD80, 
and CD86 were strongly upregulated after LPS stimulation compared to non-stimulated control 
(Figure 3.2vii-ix) and this pattern was identical when MMP-13 was inhibited (Figure 3.19).  
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Figure 3.19: MMP-13 inhibition does not change the LPS-induced maturation profile of BMDCs.  
BMDCs were pre-treated with indicated amounts of MMP-13 inhibitor, followed by stimulation with LPS, 
and cultivation overnight. Cells were washed and stained for CD11c, MHC-II, CD80, CD86, and CD40. 
(Top) Representative surface expression of BMDCs treated with LPS and inhibitor (? = isotype, ─ = without 
inhibitor, …… = 500 µM of MMP-13 inhibitor). (Bottom) Quantification of 5 experiments illustrated as 
relative MFI values between inhibitor treated (inh.) and non-treated (no inh.) CD11c+ BMDCs. Statistical 
analysis: Anova with Dunnett's Multiple Comparison Test (mean ± SD).  
 
Next, alteration in the surface expression of the α-integrin CD11c after inhibition of MMP-13 was 
determined. Previous reports indicated that CD11c is involved in antigen presentation by DCs240. In 
the present study, inhibition of MMP-13 reduced the intensity of CD11c surface expression of 
BMDCs dose-dependently (Figure 3.20).  
 
Figure 3.20: Decreased CD11c surface expression after inhibition of MMP-13.  
Experiment was performed as described in Figure 3.19 and CD11c surface expression in response to inhibitor 
treatment was analyzed. (i) Representative surface expression of CD11c (? = isotype, ─ = without inhibitor, 
…… = 500 µM of MMP-13 inhibitor). (ii) Quantification of 5 experiments illustrated as relative MFI values 
between inhibitor treated (inh.) and non-treated (no inh.) cells. Statistical analysis: Anova with Dunnett's 
Multiple Comparison Test (mean ± SD). *p<0.05 and ***p<0.001. 
 
This observation indicated that MMP-13 does not participate in the maturation process of BMDCs 
but influences the CD11c surface expression. 
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3.1.3.7 Cytokine profile of BMDCs after inhibition of MMP-13 
A fundamental characteristic of DCs is the capability to release cytokines that determine the 
polarization of the innate and adaptive immune response81. Therefore, the participation of MMP-13 
in the cytokine profile of BMDCs was addressed. The release of 18 different cytokines and 
chemokines in response to LPS stimulation was analyzed by a Luminex cytokine/chemokine 
screening assay. Consistent with the literature81, all detectable cytokines (Figure 3.21A) and 
chemokines (Figure 3.21A, B, and C) were increased upon inflammatory stimulus. IL-13, CCL20, 
CXCL12, IL-10, IL-1β, and IFN-γ were below the detection limit. Therefore, the effect of 
inhibition of MMP-13 on these factors could not be determined. 
IL-12p70, IL-23p19, and IL-6, which are cytokines influencing T cell-mediated response, were 
significantly decreased by MMP-13 inhibition in a dose-dependent manner (Figure 3.21). 
Especially, IL-12p70 and IL-23p19 were strongly reduced at 500 µM MMP-13 inhibitor 
concentration with a reduction of 46% ± 12% (mean ± SD) (Figure 3.21A) and 49% ± 10% (Figure 
3.21B), respectively. IL-6 showed moderate but significant reduction of 11% ± 6% (Figure 3.21C). 
On the contrary, CXCL10 and TNF-α were increased after MMP-13 inhibition (Figure 3.21D and 
E). CXCL10 was strongly elevated at the highest inhibitor concentration with an increase of 92% ± 
49% (Figure 3.21D), whereas TNF-α increased moderately (6.1% ± 5.4%) (Figure 3.21E).  
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Figure 3.21: T cell-targeting cytokines/chemokines in response to LPS and after MMP-13 inhibition. 
BMDCs were cultured for 24 h followed by stimulation with LPS or PBS as control. Supernatant of BMDCs 
was harvested 3 h after stimulation. Cytokines and chemokines were analyzed using Luminex screening 
assay. Shown are: IL-12p70, IL-23p19, IL-6, CXCL10/IP-10/CRG-2, and TNF-α. Data are shown as 
(i) absolute cytokine/chemokine values (pg/ml) of PBS- or LPS-stimulated BMDCs and (ii) as relative values 
in percentage between LPS-stimulated BMDCs treated with (inh.) or without inhibitor (no inh.), or BMDCs 
stimulated with PBS instead of LPS (PBS) (n = 9). ? = + PBS, ? = + LPS. PBS stimulated samples were 
not treated with inhibitor. Statistical analysis: i: unpaired t test. ii: Anova with Dunnett's Multiple 
Comparison Test (mean ± SD). *p<0.05, **p<0.01, and ***p<0.001.  
 
In contrast, CCL5, a chemoattractant for basophils, eosinophils, and T cells as well as CXCL1 and 
LIX, activators of neutrophils, showed a moderate decline after inhibitor application (mean ± SD: 
10% ± 7%, 6.2% ± 6.4%, and 7.9 ± 7.7%, respectively), (Figure 3.22A-C). Typical cytokines 
targeting neutrophils, CCL3, CCL4, and CXCL2 remained unchanged after inhibition of MMP-13 
(Figure 3.22D-F).  
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Figure 3.22: Granulocyte-attracting chemokines in response to LPS and after MMP-13 inhibition. 
Experiments were performed and analyzed as described in Figure 3.21. (A-C) CCL5, CXCL1, and LIX are 
typical chemokines that attract granulocytes. (D-F) CCL3, CCL4, and CXCL2 are typical chemokines that 
attract neutrophils. Data are shown as (i) absolute cytokine/chemokine values (pg/ml) of PBS- or 
LPS-stimulated BMDCs, and (ii) as relative values in percentage between LPS-stimulated BMDCs treated 
with (inh.) or without inhibitor (no inh.), or BMDCs stimulated with PBS instead of LPS (PBS) (n = 9). ? = 
+ PBS, ? = + LPS. PBS stimulated samples were not treated with inhibitor. Statistical analysis: i: unpaired 
t test. ii: Anova with Dunnett's Multiple Comparison Test (mean ± SD). *p<0.05 and **p<0.01. 
 
Finally, CCL2, a chemokine that recruits monocytes, memory T cells, and DCs to the area of 
infection increased significantly at the highest inhibitor concentration (mean ± SD: 10.3% ± 9.2%) 
(Figure 3.23).  
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Figure 3.23: Monocyte- , memory T cell-, and DC-attracting chemokine in response to LPS and after 
MMP-13 inhibition. 
Experiments were performed and analyzed as described in Figure 3.21. CCL2 recruits monocytes, memory 
T cells, and DCs. Data are shown as (i) absolute chemokine values (pg/ml) of PBS- or LPS-stimulated 
BMDCs, and (ii) as relative values in percentage between LPS-stimulated BMDCs treated with (inh.) or 
without inhibitor (no inh.), or BMDCs stimulated with PBS instead of LPS (PBS) (n = 9). ? = + PBS, ? = 
+ LPS. PBS stimulated samples were not treated with inhibitor. Statistical analysis: i: unpaired t test. 
ii: Anova with Dunnett's Multiple Comparison Test (mean ± SD). *p<0.05 and p**<0.01. 
 
Together, these results suggest that MMP-13 plays a crucial role in maintaining or establishing the 
cytokine profile of BMDCs, whereby the inhibition of MMP-13 moderates mainly T cell-targeting 
cytokines.  
The in vitro results taken together reveal an involvement of MMP-13 in BMDCs regarding the 
capacity of endocytosis, MHC-I presentation, and cytokine profile. The reduction in the MHC-I 
surface expression after MMP-13 inhibition further causes an attenuation of CD8+ T cell activation. 
3.2 Ex vivo analysis 
After detecting MMP-13 as a regulator of DC function and thereby as a modulator of the innate and 
adaptive immune response in vitro, the aim was to determine whether these findings can be used 
for the treatment of inflammatory human diseases. Due to the broad impact of MMP-13 on the 
immune response, shown before in in vitro assays (section 3.1), it is conceivably that MMP-13 
could be a potential target in various diseases where the immune response must be attenuated.  
Other groups could already demonstrate an involvement of MMPs in the pathogenesis of BOS. 
These studies revealed the participation of MMP-2 and -9 in experimental BOS. However, little is 
known about the contribution of MMP-12 and -13 in BOS. Therefore, the aim was to address the 
potential role of MMP-12 and -13 in the development of experimental BOS and ask the question 
whether an inhibition of active MMP-13 could attenuate the disease. To answer this question, a 
mouse model was established. 
3.2.1 Establishment of the HTT model  
Different types of mouse models exist to study BOS. The heterotopic trachea transplant (HTT) 
model is very useful to determine the influence of the immune system in the outcome of BOS. In 
this model, the trachea of a donor mouse is transplanted under the skin on the back of a recipient 
mouse, schematized in Figure 3.24A and detailed in section 2.2.10. In case of syngeneic 
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transplantations, where the donor and recipient mice are of the same strains, no graft rejection 
occurs. On contrast, after organ transplantation of different strains (allograft), a graft rejection is 
visible that shows similar histologic features to that seen in human BOS (Figure 3.24B).  
 
 
Figure 3.24: The heterotopic trachea transplant model.  
Trachea of either C57BL/6 or Balb/c mice were transplanted in a pouch on the back of C57BL/6 mice to 
induce the phenotype of BOS. Syngeneic transplanted animals should reveal no BOS phenotype whereas 
allogeneic transplanted mice should develop the typical BOS phenotype in the transplanted trachea. 
(A) Schematically display of the operation procedure (Figure adapted and modified from Jungraithmayr 
et al241). (B) Overview of syngeneic vs. allogeneic transplanted animals. 
 
3.2.1.1 Characterization of the HTT model by H&E and Masson's Trichrome staining 
To validate the model and to judge effects of the specific treatment in the following experiments, 
syngrafts and allografts were characterized for differences. First, the histopathological changes 
were determined. According to the literature, Day 14 and 21 after transplantation were chosen as 
experimental end point for the analysis. Figure 3.25 shows H&E staining (Figure 3.25A) to 
visualize the architecture of the trachea and Masson's Trichrome (Figure 3.25B) staining to 
highlight general collagen deposition of syn- and allografts on day 14 and 21 post transplantation. 
The syngeneic transplanted tracheas revealed no evidence of BOS whereas the heterotopic 
transplanted tracheas demonstrated luminal occlusion and epithelial loss. This BOS phenotype 
worsened until day 21. After quantification of five animals per group with three different trachea 
slices per animal, significant differences were determined in epithelial loss and luminal occlusion 
(Figure 3.25C).  
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Figure 3.25: Lumina occlusion and epithelial damage can be detected in the allografts  
on day 14 and 21.  
Tracheas were explanted on day 14 and 21, embedded in paraffin, and (A) H&E and (B) Masson's Trichrome 
stainings were performed. Figure A and B show explanted tracheas on day 14 and 21, exemplarily. 
(C) Quantification of luminal obliteration and epithelial damage. Statistical analysis: Anova with Dunnett's 
Multiple Comparison Test (mean ± SD). * p<0.05, **p<0.01, and ***p<0.001.  
 
3.2.1.2 Analysis of collagen deposition and epithelial damage 
To validate that the alterations in the grafts, visualized in Figure 3.25, were caused by epithelial 
damage and collagen deposition, specific immunofluorescence staining was performed. As 
demonstrated in Figure 3.26, an intact epithelial layer with intact cilia (anti E-cadherin in green) 
was visualized in the control group whereas no epithelium was detected in the allografts, neither on 
day 14 nor on day 21. In addition, collagen deposition (red), narrowing the tracheas` lumen like a 
net structure, was highlighted by the immunofluorescence (IF) staining for collagen I. DAPI 
staining (blue) was used to visualize the nuclei (Figure 3.26). Isotype antibodies instead of specific 
antibodies were used as specificity control, revealing no staining beside DAPI (data not shown). 
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Figure 3.26: Epithelial loss and collagen deposition in explanted tracheas on day 14 and 21. 
Experiments were performed as described in Figure 3.25 with specific IF stainings. Nuclei are highlighted 
with DAPI staining (blue), collagen with ab against collagen I (red), and the epithelium with ab against 
E-cadherin (green). Images were recorded on Axio imager. 
 
3.2.1.3 Analysis of activated fibroblasts and vascularization 
Increased appearance of activated fibroblasts, which are the main producer of collagen deposition, 
is a typical characteristic of BOS. As no specific marker for murine fibroblasts exists, α-smooth 
muscle actin (SMA), together with the prominent shape of fibroblasts is generally used as a marker 
to visualize this cell type. In addition, CD31, a marker for endothelial cells was also used in this 
study to detect neovascularization of transplanted tracheas. Whereas syngrafts did not show signs 
of intraluminal cell infiltration, allografts demonstrated an intraluminal accumulation of fibroblasts 
with their characteristic shape, stained in red (Figure 3.27). The fibroblast influx was very 
dominant 21 days post transplantation. Accumulation of endothelial cells (CD31: green) was 
detected especially on the sides of the trachea that were connected to the dermis of the recipient. 
That area is easier accessible for neovascularization. In generally, allografts had a tendency to show 
more endothelial cells but this could not be quantified (Figure 3.27). 
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Figure 3.27: Fibroblast invasion and neovascularization in allografts on day 14 and 21. 
Experiments were performed as described in Figure 3.25 with specific IF stainings 14 days (A) and 21 days 
(B) after transplantation. Nuclei are highlighted with DAPI staining (blue), fibroblasts with ab against 
α-SMA (red), and endothelium with ab against CD31 (green). Isotype staining visualizes the specificity of 
the used abs. Images were recorded on Axio imager. 
 
3.2.1.4 Analysis of infiltrating lymphocytes 
Another characteristic of BOS is the infiltration of inflammatory cells. At day 14 and 21, syngrafts 
showed no intraluminal CD45+ leukocytes whereas allografts demonstrated an accumulation of 
leukocytes in the lumen that promoted the luminal occlusion. Leukocytes were detected in 
syngrafts, but exclusively in the lamina propria and in the epithelium, and not in the lumen of the 
tracheas (Figure 3.28).  
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Figure 3.28: Inflammatory character of BOS by intraluminal leukocyte influx in allografts on day 21. 
Experiments were performed as described in Figure 3.25 with specific IF staining against leukocytes. 
Tracheas of day 21 after transplantation are shown, exemplarily. Nuclei are highlighted with DAPI staining 
(blue) and leukocytes with ab against CD45 (red). Isotype staining visualizes the specificity of the used abs 
(right). Images were recorded on Axio imager. 
 
To further analyze the composition of the CD45+ leukocytes, staining against CD3+ and galectin3 
were performed. With these markers, T lymphocytes (CD3) and macrophages (galectin3) can be 
distinguished.  
As shown in Figure 3.29, T lymphocytes were detected in syngrafts as well as in allografts. In line 
with the results of the entire leukocyte distribution, no lymphocytes were detected in the lumen of 
syngrafts whereas extensive intraluminal lymphocyte influx was determined in allografts. 
 
Figure 3.29: Invasion of intraluminal T lymphocytes in allografts on day 21. 
Experiments were performed as described in Figure 3.25 with specific IF staining against T lymphocytes. 
Nuclei are highlighted with DAPI staining (blue) and T lymphocytes with ab against CD3 (red). Isotype 
staining visualizes the specificity of the used abs. Images were recorded on Axio imager. 
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Macrophages (galectin3 positive) were observed in the syngrafts and allografts. Allografts revealed 
a clear intraluminal localization of macrophages (Figure 3.30).  
 
Figure 3.30: Invasion of macrophages in allografts on day 21. 
Experiments were performed as described in Figure 3.25 with specific IF staining against macrophages. 
Nucleus is highlighted with DAPI staining (blue), macrophages with ab against galectin3 (red), and 
autofluorescence visualize in green. Isotype staining visualizes the specificity of used abs. Images were 
recorded on Axio imager. 
 
3.2.2 Analysis of the HTT model by flow cytometry 
To further characterize the HTT model, lymph nodes and whole blood from the aorta of syngeneic 
and allogeneic transplanted mice were collected on day 14 and 21 and analyzed for the distribution 
of leukocytes and myeloid cells.  
3.2.2.1 Analysis of lymphocytes in blood and lymph nodes 
Figure 3.31 details the gating strategy to distinguish whole blood lymphocyte subsets by flow 
cytometry, exemplary on day 14. First, lymphocytes were gated according to forward and side 
scatter followed by exclusion of dead and doublet cells, as detailed in the gating strategy in Figure 
3.2ii-iii. Afterwards, CD45+ cells were analyzed for percentage of NK cells (NK.1.1.), 
T lymphocytes (CD3), and B cells (CD19). Furthermore, CD3+ T lymphocytes were further divided 
in their two main subpopulations and percentage of CD4+ and CD8+ T cells were quantified in each 
animal. 
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Figure 3.31: Gating strategy to analyze lymphocyte subsets in blood.  
Blood of allogeneic and syngeneic transplanted animals was collected on day 14 and analyzed for the 
distribution of lymphocyte subsets in whole blood. After separating lymphocytes by forward and side scatter, 
followed by exclusion of dead and doublet cells, all CD45+ cells were chosen. To further distinguish 
subpopulations, the following abs were used: NK1.1 (NK cells), CD3 (T cells), and CD19 (B cells). 
CD3+ T lymphocytes were further distinguished in CD4+ and CD8+ T lymphocytes. Amount of NK, T, and 
B cells are visualized in relation to all lymphocytes. B cells are shown as subgate of pre-gated CD3- and 
NK1.1- cells. CD4+ and CD8+ T lymphocytes are shown in percentage in relation to pre-gated 
CD3+ T lymphocytes. (A) syngeneic and (B) allogeneic transplanted animals on day 14. 
 
To determine the distribution of lymphocyte subsets in lymph nodes (axillary and branchial) of 
syngeneic and allogeneic transplanted animals, the same gating strategy was used as described 
before for whole blood. Figure 3.32 summarizes the gating strategy that was used for lymph nodes 
of transplanted animals, exemplary on day 14.  
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Figure 3.32: Gating strategy to analyze lymphocyte subsets in lymph nodes.  
Lymph nodes of allogeneic and syngeneic transplanted animals were collected on day 14 and analyzed for 
the distribution of lymphocytes by flow cytometry. After separating lymphocytes by forward and side scatter, 
followed by exclusion of dead and doublet cells, all CD45+ cells were chosen. To further distinguish the 
different lymphocyte subpopulations, the following abs were used: NK1.1 (NK cells), CD3 (T cells), and 
CD19 (B cells). CD3+ T cells were further distinguished in CD4+ and CD8+ T cells. Amount of NK, T and 
B cells are visualize in percentages in relation to all lymphocytes. B cells are shown as subgate of pre-gated 
CD3- and NK1.1- cells. CD4+ and CD8+ T cells are shown in percentage in relation to pre-gated 
CD3+ T cells. (A) syngeneic and (B) allogeneic transplanted animals on day 14. 
 
The quantification of leukocyte subsets in blood and lymph nodes of syngeneic and allogeneic 
transplanted animals revealed no significant differences (Figure 3.33). In case of B cells, a 
tendency of increased cell numbers in allografts compared to syngrafts was detected on day 21 
(lymph nodes). Furthermore, in comparison to non-transplanted animals, transplanted ones 
revealed lower percentages of NK cells (lymph nodes) and CD8+ T lymphocytes (lymph nodes) as 
well as higher percentages of CD4+ T cells (blood and lymph nodes), as depicted in Figure 3.33.  
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Figure 3.33: Quantification of lymphocyte subsets in blood and lymph nodes of transplanted mice.  
Blood and lymph nodes were collected of non-transplanted (do), syngeneic, and allogeneic transplanted (d14 
and d21) mice. Flow cytometry analysis was performed to analyze the contribution of NK cells, B cells, and 
CD3+ T lymphocytes which were further subdivided in CD4+ and CD8+ T lymphocytes. (i-iii) Percentage of 
specific cell types in relation to whole lymphocytes. (iv-v) Percentage of CD4+ or CD8+ T cells in relation to 
whole CD3+ T lymphocytes. (vi) Ratio of CD8+ and CD4+ T lymphocytes. Data are shown as percentage of 
specific cell types in blood as well as in lymph nodes. Statistical analysis: Anova with Dunnett's Multiple 
Comparison Test (mean ± SD). *p<0.05 and **p<0.01. 
 
3.2.2.2 Analysis of myeloid cells in blood and lymph nodes 
After analyzing the distribution of lymphocytes, further analysis was performed to detect myeloid 
cells. Figure 3.34 detailed the gating strategy to distinguish myeloid cells in whole blood by flow 
cytometry, exemplary on day 14. First, all leukocytes were gated according to forward and side 
scatter, followed by exclusion of dead and doublet cells. Afterwards, CD45 positive cells were 
gated and subdivided in either cell granularity rich (SSChigh) or cell granularity poor (SSClow) 
CD11b+ myeloid cells. SSChigh and CD11b+ cells were further divided in GR1+ neutrophils or 
GR1- eosinophils. SSClow and CD11b+ cells were further subdivided in CD11c+ and 
GR1- inflammatory or CD11c- and GR1dim resident monocytes.  
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Figure 3.34: Gating strategy to analyze granulocytes and monocytes in blood.  
Blood of allogeneic and syngeneic transplanted animals was collected on day 14 and analyzed for the 
distribution of granulocytes and monocytes in whole blood. Leukocytes were selected based on forward and 
side scatter and CD45+ cells were chosen for further separation in their different subpopulations. 
CD11b+ cells with high granulation were separated in neutrophilic granulocytes by high granulation (SSChigh) 
and high GR-1, whereas eosinophils were separated by high granulation and missing GR-1 expression. 
CD11b+ cells with low granulation (SSClow) were further distinguished in inflammatory (CD11c+ and GR1-) 
and resident (CD11c- and GR1dim) monocytes. Amounts of monocytes, granulocytes, neutrophils, 
eosinophils, and inflammatory and resident monocytes are visualized in percentages in relation to all 
leukocytes. (A) syngeneic and (B) allogeneic transplanted animals on day 14. 
 
Regarding myeloid cells in the draining lymph nodes, the focus was set on DCs. To obtain the 
distribution of CD11c+ DCs in lymph nodes of syngeneic and allogeneic transplanted animals, 
CD45 and CD11c expressing cells that had MHC-II on their surface were defined as DCs. Figure 
3.35 shows the percentage of DCs in relation to all leukocytes in lymph nodes of transplanted 
animals, exemplary on day 14.  
RESULTS 
68 
 
Figure 3.35: Gating strategy to analyze DCs in lymph nodes.  
Lymph nodes of allogeneic and syngeneic transplanted animals were collected on day 14 and analyzed for 
the percentage of DCs in relation to whole leukocytes. Cells were pre-gated on leukocytes by forward and 
side scatter. To exclude dead and doublet cells, the same gating strategy was performed as described in 
Figure 3.2. To visualize DCs in lymph nodes, cells were stained for CD45, CD11c, and MHC-II. Cells which 
were positive for all three markers were counted as DCs. (A) syngeneic and (B) allogeneic transplanted 
animals on day 14. 
 
The quantification of myeloid cells in blood and lymph nodes of syngeneic and allogeneic 
transplanted animals revealed no significant differences. In comparison to non-transplanted 
animals, transplanted ones revealed a slight but not significant decrease in resident monocytes.  
 
Figure 3.36: Quantification of myeloid cells. 
Blood and lymph nodes were collected from non-transplanted (do), syngeneic, and allogeneic transplanted 
(d14 and d21) mice. Flow cytometry analysis was performed to analyze the contribution of myeloid cells. In 
blood, neutrophilic and eosinophilic granulocytes as well as inflammatory and resident monocytes were 
analyzed. Subgroups in the blood of mice are shown as percentage in relation to all pre-gated granulocytes or 
monocytes. To analyze myeloid cells in lymph nodes, DCs were quantified by CD11c and MHC-II surface 
expression. Numbers of DCs are shown in percentage in relation to all leukocytes. Statistical analysis: Anova 
with Dunnett's Multiple Comparison Test (mean ± SD).   
 
In summary, the HTT model was established with allografts revealing the typical BOS phenotype, 
showing epithelial damage, subepithelial and luminal occlusion, and leukocyte influx. Leukocytes 
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and myeloid cells in blood and lymph nodes showed no significant differences between syngeneic 
and allogeneic transplanted animals. 
3.2.3 Analysis of MMP expression in grafts 
To gain insights into the role of MMP-12 and -13 for the development of the BOS phenotype, 
transcript levels of the different MMPs was analyzed in explanted tracheas on day 14. As control, 
data were normalized to tracheas of non-transplanted animals. As shown in Figure 3.37, a clear 
increase in the transcripts of all MMPs between transplanted and non-transplanted animals was 
detected. In contrast, changes in the transcript levels of TIMPs were either increased (TIMP-1) or 
decreased (TIMP-2 and -3) in the transplanted groups. With regards to changes between syngrafts 
and allografts, only MMP-13 expression showed a strong tendency to increase in the allografts 
compared to syngrafts. The other MMPs revealed no clear difference between syngrafts and 
allografts. Slight alterations were also detected in the expression profile of TIMPs. Whereas 
TIMP-1 showed a tendency to increase in allografts, TIMP-2 and -3 revealed a tendency to 
decrease. In summary, all MMPs and TIMPs demonstrated changes in the transcript levels in the 
transplant setting, yet independent of syngeneic or allogeneic except for MMP-13, which was 
increased in the allografts compared to syngrafts. This result indicates that alteration in MMP-13 
expression might not only result from the general transplantation process but rather from the 
rejection process of the allograft.  
 
Figure 3.37: Increased MMP-13 expression in allografts.  
Tracheas of either C57BL/6 (syngraft) or Balb/c (allograft) mice were transplanted in a pouch on the back of 
C57BL/6 mice to mimic the phenotype of BOS. On day 14, tracheas were explanted and the expression of 
MMPs and TIMPs in whole tracheas was analyzed by qRT-PCR. Tracheas of non-transplanted animals were 
used as control. Data are shown as ∆∆CT values of transplanted normalized to non-transplanted tracheas for 
two independent experiments (n = 2). Statistical analysis: Anova with Dunnett's Multiple Comparison Test. 
*p<0.05 and **p<0.01. 
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3.2.4 IHC analysis of MMPs in transplanted tracheas 
After verifying mRNA expression of the selected MMPs in transplanted tracheas, the next aim was 
to localize MMP-12 and -13 proteins in these tracheas. Therefore, IF stainings of paraffin 
embedded tracheas with specific antibodies against MMP-12 and-13 were performed. As shown in 
Figure 3.38 and Figure 3.39, MMP-12 and -13 were detected in non-transplanted as well as in 
transplanted tracheas, consistent with the detection of respective mRNAs.  
MMP-12 expression is shown in red (Figure 3.38). Although MMP-12 could be detected in all 
tracheas, the invading cells in the allografts (right) showed particularly strong MMP-12 staining.  
 
Figure 3.38: MMP-12 protein localization in tracheas before and after transplantation.  
Tracheas were transplanted as described in section 2.2.10 and explanted on day 14. Specific IF staining 
against MMP-12 on paraffin embedded tracheas was performed. Nuclei are highlighted with DAPI staining 
(blue), MMP-12 is shown in red and autofluorescence visualized in green. Images were recorded on Axio 
imager. 
 
Figure 3.39 shows the MMP-13 staining in red in non-transplanted tracheas, syngrafts, and 
allografts. In comparison to non-transplanted tracheas, a stronger MMP-13 staining was determined 
in syngrafts and allografts. As shown before for MMP-12, the invading cells detected in the lumen 
of the trachea were positive for MMP-13.  
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Figure 3.39: MMP-13 protein localization in tracheas before and after transplantation.  
Tracheas were transplanted as described in section 2.2.10 and explanted on day 14. Specific IF staining 
against MMP-13 on paraffin embedded tracheas was implemented. Nuclei are highlighted with DAPI 
staining (blue), MMP-13 is shown in red, and autofluorescence visualized in green. Isotype staining proofed 
the specificity of the used antibodies. Images were recorded on Axio imager. 
 
In summary, MMP-12 and -13 expression was verified in tracheas on mRNA level and protein 
level in syn- and allografts. IF staining visualized MMP-12 and -13 proteins in the invading cells in 
the lumen of the allografts. Co-staining with DC markers like CD11c could not be performed as the 
available antibodies did not work on paraffin embedded sections. 
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3.3 Treatment of BOS phenotype with MMP-13 inhibitor in vivo 
3.3.1 Analysis of lymphocytes and myeloid cells in blood and lymph nodes of MMP-13 
inhibitor-treated allografts 
In a pilot study, the effect of MMP-13 inhibitor treatment for the development of experimental 
BOS was analyzed in vivo. Animals were syn- and allo-transplanted as described in section 2.2.10 
and the MMP-13 inhibitor was administered i.p. every second day until day 14 and 21. Two 
concentrations, 74 µM (25 µg) (2 animals per group) and 296 µM (100 µg) (4 animals per group) 
of MMP-13 inhibitor per animal were tested. NaCl instead of the inhibitor was used as vehicle 
control. For both inhibitor concentrations no weight loss or other side effects were observed. 
To analyze whether the inhibitor had any effect on the leukocyte composition, blood and lymph 
nodes were collected and differences between allogeneic transplanted mice treated with inhibitor or 
NaCl were analyzed as described in section 3.2.2. As shown in Figure 3.40, percentages of 
NK cells in blood but not in lymph nodes of inhibitor-treated mice increased 21 days 
post-transplantation. Furthermore, CD4+ T cells increased after inhibitor treatment whereas CD8+ T 
cells decreased on day 14 and 21 in blood of inhibitor-treated mice. In lymph nodes, both CD4+ and 
CD8+ T lymphocytes showed a tendency to decrease after inhibitor treatment.  
 
Figure 3.40: Quantification of lymphocytes in blood and lymph nodes of transplanted mice treated 
with MMP-13 inhibitor.  
Blood and lymph nodes were collected from allogeneic transplanted (d14 and d21) mice treated with 296 µM 
MMP-13 inhibitor or NaCl. Flow cytometry analysis was performed to analyze the frequency of NK cells, 
B cells, and CD3+ T lymphocytes, which were further subdivided in CD4+ and CD8+ T lymphocytes. (i-iii) 
Percentages of specific cells in relation to whole lymphocytes. (iv-v) Percentages of CD4+ or CD8+ T cells in 
relation to whole CD3+ T lymphocytes. (vi) Ratio of CD8+ to CD4+ T lymphocytes. Data are shown as 
percentages of specific cell types in blood (left column) as well as in lymph nodes (right column). Statistical 
analysis: Anova with Dunnett's Multiple Comparison Test (mean ± SD). *p<0.05.  
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With regard to myeloid cells, no significant differences could be detected in the groups which were 
treated with inhibitor compared to controls.  
 
Figure 3.41: Quantification of myeloid cells after MMP-13 inhibitor treatment.  
Blood and lymph nodes were collected from allogeneic transplanted (d14 and d21) mice treated with 296 µM 
MMP-13 inhibitor or with NaCl. Flow cytometry analysis was performed to analyze the frequency of 
myeloid cells. In blood, neutrophils and eosinophils were analyzed as well as inflammatory monocytes. 
Myeloid subgroups are shown as percentage in relation to all leukocytes. In lymph nodes, DCs were analyzed 
by CD11c and MHC-II surface expression. Data of DCs are shown in percentage in relation to all leukocytes. 
Statistical analysis: Anova with Dunnett's Multiple Comparison Test (mean ± SD). *p<0.05. 
 
In summary, treatment with MMP-13 inhibitor showed a tendency to alter the lymphocyte 
distribution whereas frequencies of myeloid cells remained unchanged. Especially CD8+ T cells 
showed a tendency to decrease in blood and lymph nodes of treated animals. 
3.3.2 IHC analysis of transplanted animals treated with MMP-13 inhibitor 
After collecting blood and lymph nodes from transplanted animals, syngrafts and allografts were 
explanted. H&E staining of the paraffin embedded tracheas revealed, like seen before, a clear 
difference between syngrafts and allografts treated with NaCl (Figure 3.25). Allografts from 
animals that had received NaCl showed the typical destruction of the epithelial layer and the 
luminal occlusion. In contrast, allografts treated with inhibitor revealed a milder luminal occlusion 
and moderate reepithelialization, especially with the higher inhibitor concentration of 296 µM.  
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Figure 3.42: MMP-13 inhibitor treatment in vivo diminishes the development of the BOS phenotype 
moderately.  
Allogeneic transplanted mice were treated with 74 µM (left) or 296 µM (right) MMP-13 inhibitor or with 
equivalent amount of NaCl as control i.p. every second day. Tracheas were explanted on day 14, embedded 
in paraffin, and H&E staining was performed. 
 
As only few animals were treated, quantification was not possible. Whether inhibition of MMP-13 
significantly attenuates the development of experimental BOS must be clarified in the future in 
larger animal studies. 
In summary, this study confirmed the expression of MMP-12 and -13 in BMDCs in vitro and, 
furthermore, clearly demonstrated increased MMP-13 expression in response to the inflammatory 
stimulus LPS on mRNA as well as on activity level. Functional assays with a specific low 
molecular inhibitor of MMP-13 revealed a new role of MMP-13 in MHC-I presentation, 
endocytosis, and cytokine/chemokine release of BMDCs. Inhibition of MMP-13 in BMDCs 
reduced their capacity to activate CD8+ T cells which is likely due to reduced peptide/MHC-I 
presentation by the BMDCs. Treatment of experimental BOS with the specific inhibitor of 
MMP-13 in vivo caused alterations in the lymphocyte distribution in blood and lymph nodes of 
inhibitor-treated animals, concerning NK cells, CD4+, and CD8+ T cells. Moreover, in a pilot study, 
treating allogenic transplanted animals with the inhibitor revealed a milder BOS phenotype with 
regard to epithelial loss and luminal occlusion. These preliminary in vivo experiments require 
validation in a larger animal cohort in the future. 
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 DISCUSSION 
BOS is currently still an incurable condition after lung transplantation, based on a long-term graft 
dysfunction in which both, DCs113,114,229,231,233 and MMPs202-208 are reported to be involved. DCs are 
professional APCs that link the innate and the adaptive immune system and drive the activation of 
the immune response. MMPs are proteases responsible for matrix degradation and involved in 
inflammatory processes, tissue repair121,197, and immunity121 by regulating cytokine/chemokine 
degradation122,156,177,178 and migratory processes175,176.  
In order to identify the connection between DCs and MMPs in the development of BOS, first the 
immunological role of specific MMPs in DCs had to be identified. In the present study the focus 
was set on MMP-12 and -13 as they have already been shown to be expressed in murine pulmonary 
DCs under steady-state conditions171. 
In vitro analysis of BMDCs revealed that MMP-13 transcript level and activity increased in 
response to the inflammatory stimulus LPS, whereas MMP-12 transcript level did not change. The 
induction of MMP-13 suggests that, under inflammatory conditions, BMDCs may need MMP-13 
for specific immunobiological functions to fully act as APCs. To substantiate this hypothesis, 
various functional assays were performed using a specific inhibitor of MMP-13. The results 
suggest an involvement of MMP-13 in endocytosis, peptide presentation via the MHC-I pathway, 
and modulation of the cytokine/chemokine profile of murine BMDCs. Furthermore, the reduced 
capacity of MHC-I presentation after MMP-13 inhibition led to downstream effects, reducing 
CD8+ T lymphocyte activation. In contrast, MMP-13 apparently did not regulated migration or 
maturation of BMDCs.  
To provide further evidence for a potential relevance of MMP-13 in the pathogenesis of BOS, an in 
vivo mouse model (the heterotopic trachea transplant model) was established. Using the murine 
HTT model, an increase in MMP-13 mRNA expression was observed in allografts compared to 
syngrafts. Furthermore, MMP-13 could be localized in explanted tracheas by immunofluorescence 
staining. Based on these promising in vitro results, an in vivo pilot study was initiated whereby 
mice with trachea allografts were treated with the low molecular MMP-13 inhibitor. The results 
from this study provide initial evidence that the treatment with the low molecular MMP-13 
inhibitor alleviates the BOS phenotype compared to vehicle-treated control. Follow-up studies are 
required to substantiate the evidence. 
In summary, this is the first time to the best of my knowledge that a role of MMP-13 in OVA 
endocytosis, MHC-I presentation, and cytokine release of BMDCs was demonstrated. Moreover, 
MMP-13 seems to be important for the communication between DC and the adaptive immune cells 
in that the inhibition of MMP-13 reduced the capacity of BMDCs to activate T lymphocytes. The 
DC-T lymphocyte interplay has important consequences for the regulation of inflammatory 
4
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conditions and preliminary evidence could be provided that MMP-13 inhibition might help to 
attenuate the development or severity of the BOS phenotype. 
4.1 MMP-13 expression by BMDCs in response to inflammatory stimulus 
DCs have various assets that allow them to act as professional APCs. In response to inflammatory 
stimuli, DCs change their phenotype and behavior to act optimal as guardian against invading 
pathogens17-19. Specific MMPs have been reported to be expressed in DCs. Especially MMP-12 and 
-13 were described to be higher expressed in murine pulmonary DCs than in macrophages and 
monocytes under homeostatic conditions171.  
Generation of DCs from bone marrow cells, as used here for the in vitro analysis, is a standard 
method to gain high numbers of murine myeloid DCs97-100. These BMDCs were used in this thesis 
to elucidate potential functions of MMP-12 and -13 in the DC immunobiology. As this was a 
complete new area of MMP biology, it was intended to cover a broad spectrum of assays. Thus, the 
required high cell number and cells with a stable phenotype could be achieved with BMDCs. Based 
on the results obtained here with these in vitro generated BMDCs, selected key processes may be 
studied in primary cells, such as in DCs isolated from the spleen242 or even better from the lung13 in 
the future. This is an important next step, as primary cells, instructed by the surrounding 
environment, likely display somewhat different behavior as the in vitro generated cells. 
The first aim was to analyze alterations in the expression profile of MMP-12 and -13 in BMDCs in 
response to the inflammatory stimulus LPS (section 3.1.2). In line with the literature, MMP-13 
mRNA expression increased significantly due to LPS treatment in BMDCs170. In contrast, no 
significant change was detected in case of murine MMP-12 expression. The lack of difference in 
the MMP-12 gene expression between immature and LPS stimulated mature BMDCs is in line with 
observations of an RNA array study170. As MMPs are expressed as inactive pro-enzymes, the 
activity state of MMPs is even more important than the expression level. Using specific MMP 
activity assays, a significant increase of active MMP-12 and -13 after LPS stimulation was detected 
in BMDCs. In case of MMP-12 measurements, the observed increase might be due to an increase 
in MMP-3 instead of MMP-12, since the assay does not discriminate between these closely related 
MMPs. In case of MMP-13 activity measurements, specificity is assured, as here a pre-separation 
step with a MMP-13 specific antibody is included.  
In summary, LPS stimulation increased MMP-13 mRNA expression as well as activity, supporting 
the hypothesis of an involvement of MMP-13 in DC function. Concerning MMP-12, no alteration 
in mRNA expression was detected and MMP-12 activity could not be measured as no specific 
assay is available. The increase in MMP activity suggests that, under inflammatory conditions, 
BMDCs need MMP-13 for specific functions to fully act as APCs. 
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4.2 Participation of MMP-12 and -13 in the process of cell migration  
MMPs are known to participate in cell migration. Cell migration in general and, specifically, in the 
connection with MMPs, makes an important contribution to various diseases such as cancer, 
myocardial infarction, and hypertension243-249. The importance of MMP-12 for cell migration has 
already been reported for macrophages by MMP-12 knock-out studies172. Shipley and co-workers 
demonstrated that macrophages generated from MMP-12 ko mice have a markedly diminished 
capacity to degrade extracellular matrix components and are unable to penetrate reconstituted 
basement membranes in vitro and in vivo, using elastin and matrigel as target substrates172. 
Furthermore, a higher activity of MMP-12 was reported to correlate with increased fibroblast 
migration. This was demonstrated by the group of Haq et al. who showed, in the fibroblast cell line 
COS7, an increase in MMP-12 activity and migration through collagen IV after transfection with 
MMP-12 variants250. In addition, Sato and colleagues substantiated the importance of MMP-12 for 
fibroblast migration in experimental BOS, using broad-spectrum MMP-inhibitors in two mouse 
models, the orthotopic lung transplantation and the intrapulmonary tracheal transplantation model, 
as well as by wound healing assays in vitro251. As this group used broad-spectrum inhibitors, the 
results cannot allude to a specific contribution of MMP-12 to the migration of fibroblasts in vivo. 
However, this study underlines the general importance of MMPs in the development of BOS. 
Concerning MMP-13, a participation in migration is mainly reported for keratinocytes158 and 
fibroblasts252,253. The role of MMP-13 in keratinocyte migration was shown by Hattori et al. who 
demonstrated a reduced migration in MMP-13 ko cells, using a wound healing assay158. In addition, 
Lecomte and co-workers reported a contribution of MMP-13 in fibroblast migration by showing 
tumor-infiltrating myofibroblasts as main producers of MMP-13 and a diminished cell migration in 
MMP-13 ko cells253.  
Regarding DC biology little is known about the contribution of MMP-12 and -13 for DC migration. 
Most of the studies analyzing the importance of MMPs for DCs reported MMP-9 as crucial for 
migration, studied in murine Langerhans cells254 and BMDCs245, as well as in human DCs246. A 
recent study demonstrated a reduced number of migrating Langerhans cells by using a specific 
MMP-9 blocking antibody254. Furthermore, impaired migration of MMP-9 ko BMDCs through 
tracheal epithelial tight junctions, reported by the group of Ichiyasu et al., substantiates the 
evidence that MMP-9 might participate in DC migration. These results could further be validated in 
human DCs by Chabot and colleagues, who demonstrated a reduced migration of 
monocyte-derived DCs after blocking with a specific MMP-9 antibody. Kis-Toth and co-workers 
reported the importance of MMP-9 in human monocyte-derived CD1a- DCs, using a broad 
spectrum inhibitor255. Conclusively, while MMP-9 was intensively studied in different DC 
subgroups, the role of MMP-12 and -13 for DC migration remains elusive. Therefore, in the present 
study, the impact of MMP-12 and -13 for migration of BMDCs was analyzed (section 3.1.3.2). The 
previously mentioned group of Kis-Toth demonstrated beside MMP-9, a participation of MMP-12 
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in the migration of human CD1a+ monocyte-derived DCs. This subgroup of DCs showed an 
increase in MMP-12 expression in response to LPS treatment and demonstrated a decline in the 
migration capacity by using a broad-spectrum inhibitor255. Using murine BMDCs in the current 
study, no increase in MMP-12 mRNA expression and no alteration in the number of migrated cells 
was detected neither after specific inhibition of MMP-12 nor in MMP-12 ko cells. The differences 
observed, regarding the participation of MMP-12 in DC migration, might be explained by the 
analysis of different DC subgroups and/or the different species in both studies. In addition, the 
group of Kis-Toth used a broad spectrum inhibitor, precluding the assessment of a specific role of 
MMP-12. The observed effects might be attributed to other MMPs, such as MMP-1, -2, -3, -7, -8, -
9, -12, -14, and -26, which are targeted by this inhibitor. 
In the current study, dependent on their target substrate, the influence of MMP-12 inhibition on 
migration was studied using collagen I and IV, whereas the influence of MMP-13 blockade was 
studied using collagen I. As expected, in the absence of the chemoattractant CCL19, no migration 
was detected through collagen I, validating direct migration of BMDCs in this assay. In case of 
collagen IV, 17% ± 8.5% (mean ± SD) of cells migrated in the absent of CCL19. The reason for 
this might be that the very thin collagen IV layer allowed migration without chemoattractant in a 
non-directed way. When comparing LPS-stimulated and non-stimulated cells, LPS-stimulated 
BMDCs showed an increase of migrated cells through collagen I compared to non-stimulated cells. 
This observation is likely due to the induction of the C-C chemokine receptor type 7 (CCR7) which 
is induced during DC maturation and enables the recognition of the ligand CCL19256. In contrast, in 
case of collagen IV, fewer cells migrated after LPS stimulus. The reason for this might be the 
stronger cell adherence after LPS stimulation which leads to a measurable effect only in case of the 
thin collagen IV layer as here the migration time was only four hours instead of 24 hours in 
collagen I. Within the longer time frame the adherence effect might lose its impact on the migration 
outcome.  
As mentioned in section 1.2.4, MMP-12 and -13 have various target substrates. To substantiate the 
observation that MMP-12 or MMP-13 has no major role in the migration of BMDCs, other target 
substrates, such as fibronectin or laminin should be tested in future studies. In addition, to mimic 
tissue conditions more closely, matrigel, a reconstituted basement membrane consisting of a 
combination of different target substrates, could be used. Beside this, one might also envisage that 
MMP-12 or -13 has a subordinated role in the process of migration and MMP-9 being the major 
player. In this scenario, any effect that might emerge by MMP-12 or -13 inhibition would be 
obscured by the still active MMP-9. Pre-treatment with MMP-9 inhibitor might help to reveal such 
presumptive effects of MMP-12 or -13. In the settings used here, neither MMP-12, nor MMP-13 
seems to play a role in the migration of BMDCs.  
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4.3 Participation of MMP-13 in OVA endocytosis  
To the best of my knowledge, to date nothing has been reported about the participation of MMPs in 
the process of endocytosis. Using soluble OVA, inhibition of MMP-13 decreased the capability of 
BMDCs to capture this specific antigen (section 3.1.3.3). As in case of MMP-12 inhibitor the 
vehicle control (DMSO) showed an unexpected effect, MMP-12 inhibitor might be dissolved in 
another dissolvent, e.g. ethanol, for future studies. Here, to sidestep the vehicle effect, MMP-12 ko 
cells were used. These cells showed a reduced uptake of soluble OVA in comparison to wt cells. 
Yet, a phenotypic comparison of the MMP-12 ko and wt cells revealed a clear difference in the 
MHC-II surface expression profile. High MHC-II surface expression is generally associated with a 
mature DC type which takes up less soluble OVA compared to immature DCs with a low MHC-II 
surface expression257. The BMDCs of MMP-12 ko mice showed reduced uptake of soluble OVA 
and simultaneously higher MHC-II surface expression than BMDCs from wt mice. Therefore, the 
reduced endocytosis might be due to the different maturation profile of wt and ko cells after one 
week of cultivation. The different maturation states of wt and ko DCs preclude drawing any 
conclusion regarding an involvement of MMPs in the process of endocytosis. 
In case of the MMP-13 inhibitor, no side effect was detected as the dissolvent was water. Here, 
MMP-13 inhibition significantly reduced the capability of BMDCs to take up soluble OVA. The 
uptake of large amounts of soluble OVA (MFIhigh) in DCs is mainly executed by the mannose 
receptor which mediates cross-presentation of OVA peptides via MHC-I, whereas uptake of small 
amounts of OVA (MFIlow) via micropinocytosis drives OVA into the classical MHC-II 
pathway14,36,258-261. Although mature DCs are reported to poorly take up antigens, recent studies 
demonstrated that mature DCs still perform receptor-mediated endocytosis and phagocytosis262. 
Here, MHC-IIhigh BMDCs took up both, large and low amounts of OVA and both processes were 
decreased by inhibition of MMP-13. These results lead to further interesting research questions 
regarding the precise mechanisms how MMP-13 is involved in antigen uptake. In the future, 
blocking the mannose receptor or pinocytosis can help to discriminate between these two pathways 
and provide insight into the question which pathway of antigen uptake is regulated by MMP-13. 
Mannose receptor independent pathways may be studied using mannose receptor deficient mice263. 
The hypothesis that MMP-13 may regulate the pathway of mannose receptor mediated endocytosis 
is of interest, as some MMPs have already been reported to become activated after mannose 
receptor-ligand interaction. MMP-9 for instance is induced by receptor-mediated signaling 
mechanisms involving the binding of mannosylated ligands to mannose receptors264. Furthermore, 
increased MMP-2 production was reported following human mannose receptor-mediated HIV-1 
entry, published by López-Herrera and colleagues264. In addition, the urokinase plasminogen 
activator receptor–associated protein/endo180, a member of the mannose receptor family, has 
already been reported to serve as a specific cell surface receptor for MMP-13 which, after binding, 
becomes activated by uPA-mediated plasminogen activation265. Based on these research studies, 
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one can assume that the treatment with soluble OVA might increase MMP-13 activity via the 
mannose receptor pathway. The subsequent OVA-mannose receptor complex internalization via 
clathrin-coated pits might further be regulated by the former activated MMP-13 enzymes. This 
might explain the reduced OVA endocytosis upon blocking of MMP-13, but this hypothesis 
remains to be studied in the future.  
Besides this, it will be of importance to study the relevance of MMP-13 for the uptake of other 
antigens, including those with low expression levels or particulate antigens, such as latex beads. 
Studies of phagocytosis by fluorescent bacteria would be another angle to pursue.  
In this study, downstream effects of the reduced endocytosis on T cells were not detected, as no 
cumulative effect was seen when DCs were treated with MMP-13 inhibitor before plus after the 
OVA-uptake. Obviously, despite reduced uptake due to MMP-13 inhibition enough OVA can still 
be captured by BMDCs to provide sufficient antigen presentation to OVA specific T cells. Effects 
on other antigens might be stronger and might result in downstream consequences. This remains to 
be studied in the future. 
4.4 Role of MMP-13 for the phenotype of BMDCs 
While the precise mechanism how MMP-13 regulates the endocytosis of OVA system remains to 
be determined, further analysis clearly demonstrated that CD8+ T cell activation is reduced when 
BMDCs are treated with MMP-13 inhibitor by a mechanism apparently independent of endocytosis 
(section 3.1.3.4). The independency from endocytosis can be assumed as a similar reduction in 
T cell activation was detected when the MMP-13 inhibitor was applied after the endocytosis phase 
was completed. An alteration in the MHC-I surface expression could be one reason for the reduced 
CD8+ T cell activation as MHC–I, but not MHC-II surface expression was found to be reduced 
after MMP-13 inhibition (section 3.1.3.5). Successful T cell activation requires the formation of an 
intact immunological synapse between DCs and T lymphocytes, which is dependent on the 
recognition of the peptide-MHC complex by the specific T cell receptor61. The diminished MHC-I 
surface expression, measured by flow cytometry, might be sufficient to impair formation of a fully 
functional immunological synapse which may explain the decreased CD8+ T cell activation. One 
reason for the reduced MHC-I surface presentation could be an alteration in the MHC-I recycling 
process. Alternatively, MMP-13 might promote BMDCs to efficiently load exogenous peptide onto 
MHC-I via the cross-presentation pathway, and thereby, leading to reduced MHC-I surface 
expression and CD8+ T cell activation after MMP-13 inhibition. The CD8+ T cell line (B3Z) used 
in this study, neither needs cytokine stimulation nor co-stimulatory molecules by DCs. Therefore, it 
is likely that the reduced T cell activation in this system is caused by the reduced MHC-I 
presentation. To further study the mechanism leading to the reduced MHC-I presentation, total 
amount of MHC-I in MMP-13 inhibitor-treated or untreated permeabilized cells might shed light 
on the issue of altered MHC-I recycling as a way to modulate surface MHC-I levels.  
DISCUSSION 
81 
Co-stimulatory molecules such as CD80, CD86, and CD40 are required for efficient T cell 
activation by DCs under physiological conditions20,239. No influence of MMP-13 on these 
maturation markers was detected (section 3.1.3.6). Therefore, the maturation process of BMDCs 
seems to be independent of MMP-13. In contrast, a clear decline in the surface expression of 
CD11c was observed. CD11c binds to complement fragment (iC3b), adhesion molecules and 
matrix proteins. Hence, the group of Sadhu suggested an involvement of CD11c in antigen 
presentation and inflammation266. As a strong CD11c reduction was detected only with high 
inhibitor concentrations it is unlikely to affect antigen presentation in this system.  
To study T cell activation under more physiological conditions, the utilization of OT-I/-II cells 
instead of the T cell lines B3Z and DOBW would be of interest in the future. OT-I/-II cells are 
specific T cells which recognize specific OVA-peptides on either MHC-I or MHC-II like 
B3Z/DOBW cells. The advantage of these primary cells is that they are not immortalized and need 
co-stimulatory and cytokine signals from APCs to get activated, representing more physiological 
conditions. 
4.5 Regulation of BMDC cytokine/chemokine profile by MMP-13 
Several MMPs have been reported to process specific cytokines and modulate chemokine 
gradients. MMP-mediated proteolysis is reported to inactivate chemokines and to generate 
antagonistic or synergistic derivatives267. MMP-13 is reported to process CXCL5, CXCL8, 
CXCL12, and CCL7. While the chemotactic potency of CXCL5 and CXCL8 is increased by 
MMP-13 proteolysis, CXCL12 and CCL7 become inactivated or transformed into an antagonist267. 
Beside these reports, to the best of my knowledge, no other chemokines/cytokines have been 
reported to be regulated by MMP-13. In this study, 18 different cytokines/chemokines were 
analyzed using a Luminex screening assay (section 3.1.3.7). It was observed that cytokines that 
regulate Th1/Th17 cell polarization, such as IL-12p70, IL-23p19, and IL-6 were decreased by 
inhibition of MMP-13, whereas cytokines that affect mainly neutrophils remained unaffected. 
IL-12, which was strongly decreased by inhibition of MMP-13, is known to serve as a critical 
mediator of CD8+ T cell activation69-72 and reduces apoptosis in CD8+ T cells by increasing 
survival and expansion of effector/memory T cell populations76. IL-23, another potent 
pro-inflammatory cytokine, which plays a dominant role in memory T cell response and in 
autoimmune diseases by stimulating a unique T cell subset to produce IL-1777,268, was similarly 
reduced by inhibition of MMP-13. Interestingly, IL-12 and IL-23 share the same p40 subunit which 
they require for secretion69. Along this line, IL-6, which belongs to the same family like IL-12 and 
IL-23 and shows homology to their subunits, was also significantly reduced due to inhibition of 
MMP-13. The homology of the three cytokines and the fact that IL-6 is a downstream factor of 
IL-12 might explain their concerted reduction upon inhibition of MMP-13 as they might exhibit a 
joint processing site. As the Luminex assay does not distinguish between the activation status of 
enzymes, changes in the proteolytic activity of MMP-13 by its inhibition that might further result in 
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modified cytokine activity, as reported before for CXCL5, CXCL8, CXCL12, and CCL7, could not 
be the explanation for the reduced amount of cytokines detected in the current study. Currently, it is 
unknown whether the observed moderations in the secreted amounts of cytokines/chemokines are 
caused on the transcriptional or translational level. Various possibilities might lead to the reduction 
in detected cytokines. MMP-13 might process the cytokines in a way that reduces the binding 
affinity to the capture or detection antibodies. An involvement of MMP-13 in the secretion process 
of IL-12 and IL-23 might be another explanation whereby the reduced MMP-13 activity leads to an 
accumulation inside the cell. Furthermore, it was reported that cross-linking of complement 
receptors results in a potent inhibition of the production of human and mouse IL-1273. Therefore, an 
indirect way of MMP-13 regulating IL-12 or IL-23 secretion via changes in the complement system 
might also be assumed. Of note, previous reports have already linked IL-12 and IL-23 to specific 
MMPs. Godefroy et al. demonstrated an indirect effect of MMP-2 on IL-12p70 via degradation of 
the type-I IFN receptor that inhibited signal transducers and activators of transcription (STAT)1 
phosphorylation and thereby reduced IL-12p35 production269. In line with this, Oriss et al. reported 
MMP-9 as indirect regulator of IL-23 via membrane stem cell factor and receptor tyrosine kinase 
c-kit ligation270. Participation of MMP-13 in similar pathways via alterations of transcription 
factors required for IL-12/-23 production or inhibition might be conceivable. Furthermore, an 
indirect involvement of MMP-13 via activation of other MMPs might be taken into consideration. 
In summary, the inhibition of MMP-13 apparently participates in the process of polarizing the 
T cell response by modulating the cytokine and chemokine profile of DCs. The underlying 
mechanism remains to be determined in the future.  
Although the screening assay covered a wide range of cytokine/chemokines, cytokines that 
promote Th2 polarization, such as IL-4, were not included in the multiplex assay. It would be of 
great interest in the future to determine whether cytokines that promote Th2 polarization are also 
altered by inhibition of MMP-13. 
While pro-inflammatory cytokines decreased after MMP-13 inhibition, CXCL10, an inhibitor of 
neovascularization and hematopoietic progenitor cells increased. Considering future 
pharmaceutical application of MMP-13 inhibitors, the increase of CXCL10 concomitant to the 
decrease in inflammatory cytokines might be advantageous as the inflammatory immune response 
is dampened by reducing vascularization and immune cell supply in vivo271.  
In summary, our data revealed that MMP-13 regulates BMDC cytokine/chemokine profile of 
mainly pro-inflammatory T cell targeting cytokines. Potential consequences of the altered cytokine 
profile on T cells were not studied here, as the used immortalized T cell lines are resilient to 
cytokine changes. However, the strong decrease of specific cytokines gives rise to interesting 
upcoming research questions. The previous mentioned OT-I/-II T cells could be used for these 
analyses. 
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4.6 The relevance of the murine heterotopic trachea transplant model 
The in vitro results using murine BMDC suggested that inhibition of MMP-13 might be a 
promising therapeutic strategy to ameliorate inflammatory processes that are dependent on MHC-I 
antigen presentation and polarization by pro-inflammatory cytokines. These could be 
autoinflammatory disease or graft dysfunction after transplantation, such as in BOS where the 
immune system must be attenuated. 
To provide evidence for a potential relevance of MMP-13 in the pathogenesis of BOS, a mouse 
model of experimental BOS was established (section 3.2.1). The heterotopic trachea transplant 
model is a model described in the literature that allows mimicking the phenotype of BOS in a 
reasonable time frame with acceptable surgical effort. Other models used in the literature to study 
experimental BOS in vivo are the orthotopic tracheal transplantation in mice (introduced by Ikonen 
and colleagues in 2000272), the intrapulmonary tracheal implantation, and the orthotopic lung 
transplantation. In the orthotopic tracheal transplantation model, implanting a segment of a donor 
trachea into the recipient trachea allows studying allotransplant perfusion and a strong role for 
microvasculature in the development of BOS was detected273-275. In the intrapulmonary tracheal 
implantation model a long tracheal segment is placed into the recipient`s lung by pleural incision to 
the intrapulmonary milieu276. Perfusion of the transplanted graft and the possibility to study 
neovascularization from pulmonary circulation are the advantages of this model. Using the 
intrapulmonary tracheal implantation model an importance of MMPs in the pathogenesis of BOS 
was demonstrated in the past277. The fourth model to study BOS in rodents is the orthotopic lung 
transplantation. In this model the whole left or right lung is transplanted and recipient`s artery, 
vein, and main bronchus are connected to the respective vessels and bronchus of the graft. This 
model reproduces the surgical procedure in human lung transplantations with high accuracy. The 
disadvantages are the requirement of high surgical skills and long observation time. In the course of 
the current study, the heterotopic trachea transplant model was established. Although the other 
models introduced above mimic the physiological scenario of BOS more closely, the heterotopic 
trachea transplant model could confirm and reproduce results that were obtained with the 
intrapulmonary and the orthotopic models and support, thereby, the usage of this model. 
Furthermore, the model has been shown to share many of the characteristics of BOS in the clinic in 
that heterotopic tracheal allografts exhibit epithelial damage, leukocyte influx, matrix deposition, 
fibroblast invasion, and luminal occlusion. So far, the greatest gain in knowledge was achieved 
with the help of the heterotopic trachea transplant model, as it provides reliable and reproducible 
results. In summary, the optimal model to study BOS and allograft rejection does not exist. Which 
model suffices rather depends on the research question. For this thesis it was decided to use the 
heterotopic trachea transplant model as has proven to provide reliable and reproducible results 
while being much less invasive and having low infection risk.  
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4.7 MMP-13 in the murine heterotopic trachea transplant (HTT) model 
Previous studies have already provided evidence for an involvement of MMPs, other than MMP-12 
and -13 in the development of BOS in rodent models as well as in patients206-208,233,278. Fernandez 
and co-worker were able to demonstrate the importance of MMP-9 by MMP-9 ko mice studies, 
showing an involvement of MMP-9 in mononuclear cell infiltration, T cell alloreactivity, and 
cytokine/chemokine regulation206. The group of Khatwa reported a relation between MMP-8 
(neutrophil collagenase) and the severity of experimental BOS by showing that MMP-8 is 
important for polymorphonuclear leukocytes migration207. Others reported an increase in MMP-2 
and membrane type 1 MMP activity in experimental BOS208. However, all of these MMPs are 
expressed by a broad spectrum of cells and, as such, these MMPs are not ideal targets for 
pharmaceutical inhibitor therapies. 
Here, using the murine HTT model, an increase in MMP-13 mRNA expression in allografts 
compared to syngrafts was demonstrated (section 3.2.3). Regarding MMP-13, only little has been 
reported about its role in BOS. Using the HTT model, Sato and colleagues demonstrated peaks in 
MMP-3, -9, and -13 mRNA expression in the micro-dissected intraluminal tissue of the allografts 
at day seven, which decreased again over time278. In the current study, the increase in MMP-13 
mRNA expression in allografts compared to syngrafts was verified supporting the idea that 
MMP-13 might participate in the development of experimental BOS. The other MMPs measured in 
the present study, MMP-2, -9, and -12 showed an increase in mRNA expression in both, syngrafts 
and allografts. Therefore, it seems more likely that the induction of these MMPs is due to the 
surgical procedure. Furthermore, MMP-13 could be localized in transplanted tracheas by IF 
staining on paraffin embedded tissue sections, on day 14 and 21. Sato and co-workers also detected 
MMP-13 in the graft lumen in immunofluorescence images278. In contrast to this previous study 
where MMP-13 was no longer detected after day 14, the present study revealed MMP-13 in 
infiltrating cells in the graft lumen still on day 21 using immunofluorescence staining. All the 
previously reported studies206-208 were merely descriptive and did not investigate the possible 
functions of MMP-13.  
The importance of DCs in the development of experimental BOS has already been reported by the 
group of Lambrecht and Kleinjan who showed a denser DC network in allografts compared to 
syngrafts using CD11c, MHC-II, and the specific DC shape as markers of DCs. They further used 
flow cytometry analysis to show a higher accumulation of DC subtypes (CD11c+/MHC-
II+/CD11b+/CD103- or CD11c+/MHC-II+/CD11b-CD103+ subtype) in whole tracheas of allografts 
compared to syngrafts233. Due to the possibility of generating very thin tissue slices (2 µm), 
paraffin embedded tissue sections were used to generate high quality histological stainings. This 
advantage outweighed the disadvantage that the paraffin embedding procedure may cover or alter 
some antibody binding sites which cannot be restored by the boiling procedure. Hence, due to these 
technical limitations, the DC marker (CD11c) could not be used in paraffin embedded tissue. To 
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detect a co-localization of MMP-13 with DCs, new frozen tracheas must be generated and stained 
in the future. However, assuming future validation, the research results of Lambrecht and 
co-workers support the idea of an involvement of DCs in the pathogenesis. 
In a pilot study performed in this thesis, where the MMP-13 inhibitor was applied every second day 
into transplanted mice, an attenuation of the BOS phenotype was observed (section 3.3). Other 
studies already provided hints that experimental BOS is ameliorated in specific MMP ko206 mice or 
after the treatment with broad spectrum inhibitors251,277, exemplifying the importance of MMPs for 
the BOS pathogenesis. Regarding MMP-8 and -9, specific ko mice seem to be protected from 
experimental BOS207. However, the disadvantage of MMP-9 is its broad expression in a variety of 
cell types posing a potential risk of side effects in humans after blocking. Regarding MMP-8, also 
known as neutrophil collagenase, inhibitor treatment mainly blocks the migration of 
polymorphonuclear leukocytes. Thus, even if MMP-8 plays an important role in BOS, it may not 
be sufficient to block only polymorphonuclear leukocyte migration to moderate disease 
progression, as other leukocytes are also involved.  
Concerning human therapies, broad spectrum inhibitors cannot be used due to expected strong side 
effects. Therefore, the MMP-13 specific small molecule inhibitor seems promising. The MMP-13 
inhibitor was used in this thesis instead of ko mice to provide results with translational relevance 
concerning a role of MMP-13 in the development of BOS. Indeed, the in vivo MMP-13 inhibitor 
treatment study revealed promising results with an attenuated BOS phenotype. Following this pilot 
study, a more extent of an animal study must be performed to confirm the in vivo results and to find 
the most effective dose. 
4.8 Conclusion and future direction 
The aim of this thesis was to elucidate the role of MMP-12 and -13 in murine BMDCs and the 
contribution of DCs to the development of experimental BOS.  
Increased mRNA expression and activity of MMP-13 in response to the inflammatory stimulus 
LPS was detected in BMDCs. Functional assays revealed a participation of MMP-13 in OVA 
endocytosis, MHC-I presentation, and cytokine profile of BMDCs whereas an involvement of 
MMP-13 in the migration and maturation was not evident. Observed alterations in the MHC-I 
presentation capability of DCs seemed to have downstream effects concluded from the observation 
of reduced CD8+ T cell activation. In the second part of the thesis, an attempt was undertaken to 
define the relevance of the in vitro findings for the pathogenesis of BOS in vivo. Using the murine 
heterotopic trachea transplant model, an increase of MMP-13 mRNA expression in allografts 
compared to syngrafts was detected, supporting the idea of a role of MMP-13 for BOS 
development. In a pilot treatment study, using the MMP-13 inhibitor, an attenuated BOS phenotype 
was observed in the heterotopic trachea transplant model. The in vitro results together with the 
preliminary findings in experimental BOS provide new insight into the role of MMP-13 in DC 
biology and its potential contribution to the pathogenesis of BOS. 
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Collectively, the findings of the current study identified for the first time an involvement of 
MMP-13 in the immunobiological functions of BMDCs. How exactly MMP-13 regulates 
endocytosis, MHC-I presentation, and the cytokine profile remains to be determined in the future.  
Having established the optimal settings for BMDCs in the different in vitro assays allows 
transferring these assays to sparse primary cell types. This enables future studies on primary DCs, 
which can only be isolated in very low numbers from the lungs. Similarly, using primary T cells in 
the T cell activation assay will allow evaluating the effect of the altered cytokine profile of 
MMP-13 inhibited DCs on T cell polarization. In the current study, this could not be assessed as 
B3Z and DOBW T cells are immortalized and need neither co-stimulatory signals nor cytokines.  
In future in vivo analyses, higher animal numbers will allow reliable quantification of the effects of 
the MMP-13 inhibitor treatment, the quantification of the amount of DCs, and the co-localization 
of DCs with MMP-13 in the allografts. 
Last but not least, it remains an intriguing open question whether a role of MMP-13 can be 
substantiated in human DC biology and in human BOS patients. Due to the lack of a unique DC 
marker, only a limited number of investigations has addressed this issue, showing contradictory 
results. Efforts must be increased to quantify DCs in the lung and bronchoalveolar lavage fluid of 
patients. Regarding a potential role of MMP-13 in DC biology, in vitro experiments, like those 
presented here, should be performed with human DCs. With regards to human biology, a functional 
analog of murine MMP13 may show a similar impact on DC immunobiology. Therefore, additional 
MMPs should be analyzed in parallel to MMP-13 for their contribution to DC biology. 
LITERATURE 
87 
 LITERATURE 
1. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune 
response. Science. Apr 5 1996;272(5258):50-53. 
2. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in 
innate immunity. Science. May 21 1999;284(5418):1313-1318. 
3. Medzhitov R, Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of 
recognition. Cell. Oct 31 1997;91(3):295-298. 
4. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 
1994;12:991-1045. 
5. Rescigno M. Functional specialization of antigen presenting cells in the gastrointestinal 
tract. Curr. Opin. Immunol. Feb 2010;22(1):131-136. 
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. Mar 19 
1998;392(6673):245-252. 
7. Bell D, Young JW, Banchereau J. Dendritic cells. Adv. Immunol. 1999;72:255-324. 
8. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune 
response. Blood. Nov 1 1997;90(9):3245-3287. 
9. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. 
Immunol. 1991;9:271-296. 
10. McWilliam AS, Napoli S, Marsh AM, et al. Dendritic cells are recruited into the airway 
epithelium during the inflammatory response to a broad spectrum of stimuli. J. Exp. Med. 
Dec 1 1996;184(6):2429-2432. 
11. McWilliam AS, Nelson D, Thomas JA, Holt PG. Rapid dendritic cell recruitment is a 
hallmark of the acute inflammatory response at mucosal surfaces. J. Exp. Med. Apr 1 
1994;179(4):1331-1336. 
12. Austyn JM, Kupiec-Weglinski JW, Hankins DF, Morris PJ. Migration patterns of dendritic 
cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within 
marginal zone. J. Exp. Med. Feb 1 1988;167(2):646-651. 
13. Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am. J. Respir. Crit. Care Med. Sep 1 
2005;172(5):530-551. 
14. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and 
the mannose receptor to concentrate macromolecules in the major histocompatibility 
complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. 
Med. Aug 1 1995;182(2):389-400. 
15. Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose 
particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to 
mycobacterial antigens in vivo. J. Exp. Med. Aug 1 1993;178(2):479-488. 
16. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in 
vitro. J. Exp. Med. Aug 1 1993;178(2):509-519. 
17. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing 
machines. Cell. Aug 10 2001;106(3):255-258. 
18. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. 
Rev. Immunol. 2005;23:975-1028. 
19. Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendritic cells in 
growth factor-dependent long-term cultures. J. Exp. Med. Jan 20 1997;185(2):317-328. 
20. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human 
dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus 
interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. Apr 1 
1994;179(4):1109-1118. 
21. Pierre P, Turley SJ, Gatti E, et al. Developmental regulation of MHC class II transport in 
mouse dendritic cells. Nature. Aug 21 1997;388(6644):787-792. 
22. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce 
accumulation of MHC class II complexes on dendritic cells. Nature. Aug 21 
1997;388(6644):782-787. 
5
LITERATURE 
88 
23. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu. Rev. 
Immunol. 2000;18:767-811. 
24. Rescigno M, Granucci F, Citterio S, Foti M, Ricciardi-Castagnoli P. Coordinated events 
during bacteria-induced DC maturation. Immunol. Today. May 1999;20(5):200-203. 
25. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: 
transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. Jan 4 
1999;189(1):169-178. 
26. Hacker H, Mischak H, Miethke T, et al. CpG-DNA-specific activation of antigen-
presenting cells requires stress kinase activity and is preceded by non-specific endocytosis 
and endosomal maturation. EMBO J. Nov 2 1998;17(21):6230-6240. 
27. Hartmann G, Krieg AM. CpG DNA and LPS induce distinct patterns of activation in 
human monocytes. Gene Ther. May 1999;6(5):893-903. 
28. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and 
maturation of human dendritic cells. Proc. Natl. Acad. Sci. U. S. A. Aug 3 
1999;96(16):9305-9310. 
29. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, 
activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 
Mar 1 1999;189(5):821-829. 
30. Bates EE, Ravel O, Dieu MC, et al. Identification and analysis of a novel member of the 
ubiquitin family expressed in dendritic cells and mature B cells. Eur. J. Immunol. Oct 
1997;27(10):2471-2477. 
31. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-
presented peptides. Annu. Rev. Immunol. 1999;17:739-779. 
32. Pamer E, Cresswell P. Mechanisms of MHC class I--restricted antigen processing. Annu. 
Rev. Immunol. 1998;16:323-358. 
33. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major 
histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas 
of lymph nodes. J. Exp. Med. Aug 29 1997;186(5):665-672. 
34. Inaba K, Turley S, Yamaide F, et al. Efficient presentation of phagocytosed cellular 
fragments on the major histocompatibility complex class II products of dendritic cells. J. 
Exp. Med. Dec 7 1998;188(11):2163-2173. 
35. Tan MC, Mommaas AM, Drijfhout JW, et al. Mannose receptor-mediated uptake of 
antigens strongly enhances HLA class II-restricted antigen presentation by cultured 
dendritic cells. Eur. J. Immunol. Sep 1997;27(9):2426-2435. 
36. Engering AJ, Cella M, Fluitsma D, et al. The mannose receptor functions as a high 
capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 
Sep 1997;27(9):2417-2425. 
37. Cresswell P. Invariant chain structure and MHC class II function. Cell. Feb 23 
1996;84(4):505-507. 
38. Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I 
molecules. Curr. Opin. Immunol. Feb 1996;8(1):59-67. 
39. Castellino F, Zhong G, Germain RN. Antigen presentation by MHC class II molecules: 
invariant chain function, protein trafficking, and the molecular basis of diverse determinant 
capture. Hum. Immunol. May 1997;54(2):159-169. 
40. Nijman HW, Kleijmeer MJ, Ossevoort MA, et al. Antigen capture and major 
histocompatibility class II compartments of freshly isolated and cultured human blood 
dendritic cells. J. Exp. Med. Jul 1 1995;182(1):163-174. 
41. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of 
dendritic-cell subsets in vivo. Nat. Rev. Immunol. Jul 2007;7(7):543-555. 
42. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat. 
Rev. Immunol. Aug 2012;12(8):557-569. 
43. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous 
antigens presented on MHC class I molecules. Science. Jan 13 1995;267(5195):243-246. 
44. Houde M, Bertholet S, Gagnon E, et al. Phagosomes are competent organelles for antigen 
cross-presentation. Nature. Sep 25 2003;425(6956):402-406. 
LITERATURE 
89 
45. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-
phagosome fusion defines an MHC class I cross-presentation compartment in dendritic 
cells. Nature. Sep 25 2003;425(6956):397-402. 
46. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of 
cross-presentation and endogenous antigen presentation. Nat. Immunol. May 
2008;9(5):558-566. 
47. Firat E, Saveanu L, Aichele P, et al. The role of endoplasmic reticulum-associated 
aminopeptidase 1 in immunity to infection and in cross-presentation. J. Immunol. Feb 15 
2007;178(4):2241-2248. 
48. Saveanu L, Carroll O, Weimershaus M, et al. IRAP identifies an endosomal compartment 
required for MHC class I cross-presentation. Science. Jul 10 2009;325(5937):213-217. 
49. Shen L, Sigal LJ, Boes M, Rock KL. Important role of cathepsin S in generating peptides 
for TAP-independent MHC class I crosspresentation in vivo. Immunity. Aug 
2004;21(2):155-165. 
50. Bertholet S, Goldszmid R, Morrot A, et al. Leishmania antigens are presented to CD8+ T 
cells by a transporter associated with antigen processing-independent pathway in vitro and 
in vivo. J. Immunol. Sep 15 2006;177(6):3525-3533. 
51. Nair-Gupta P, Blander JM. An updated view of the intracellular mechanisms regulating 
cross-presentation. Front. Immunol. 2013;4:401. 
52. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-
haematopoietic cells requires presentation of exogenous antigen. Nature. Mar 4 
1999;398(6722):77-80. 
53. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen 
presentation to CD4(+) T cells. J. Exp. Med. Jun 16 1997;185(12):2133-2141. 
54. Luther SA, Gulbranson-Judge A, Acha-Orbea H, MacLennan IC. Viral superantigen drives 
extrafollicular and follicular B cell differentiation leading to virus-specific antibody 
production. J. Exp. Med. Feb 3 1997;185(3):551-562. 
55. Caux C, Vanbervliet B, Massacrier C, et al. B70/B7-2 is identical to CD86 and is the major 
functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. Nov 1 
1994;180(5):1841-1847. 
56. Inaba K, Witmer-Pack M, Inaba M, et al. The tissue distribution of the B7-2 costimulator 
in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. 
Exp. Med. Nov 1 1994;180(5):1849-1860. 
57. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge 
between a CD4+ T-helper and a T-killer cell. Nature. Jun 4 1998;393(6684):474-478. 
58. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for 
cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. Jun 4 
1998;393(6684):478-480. 
59. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for 
cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. Jun 4 
1998;393(6684):480-483. 
60. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through 
CD40 cross-linking. J. Exp. Med. Oct 1 1994;180(4):1263-1272. 
61. Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. Annu. Rev. 
Immunol. 2001;19:375-396. 
62. Dubois B, Massacrier C, Vanbervliet B, et al. Critical role of IL-12 in dendritic cell-
induced differentiation of naive B lymphocytes. J. Immunol. Sep 1 1998;161(5):2223-
2231. 
63. Dubois B, Vanbervliet B, Fayette J, et al. Dendritic cells enhance growth and 
differentiation of CD40-activated B lymphocytes. J. Exp. Med. Mar 3 1997;185(5):941-
951. 
64. Geldhof AB, Moser M, De Baetselier P. IL-12-activated NK cells recognize B7 
costimulatory molecules on tumor cells and autologous dendritic cells. Adv. Exp. Med. 
Biol. 1998;451:203-210. 
65. Shah PD. Dendritic cells but not macrophages are targets for immune regulation by natural 
killer cells. Cell. Immunol. Feb 1987;104(2):440-445. 
LITERATURE 
90 
66. Lewis KL, Reizis B. Dendritic cells: arbiters of immunity and immunological tolerance. 
Cold Spring Harb. Perspect. Biol. Aug 2012;4(8):a007401. 
67. Sela U, Olds P, Park A, Schlesinger SJ, Steinman RM. Dendritic cells induce antigen-
specific regulatory T cells that prevent graft versus host disease and persist in mice. J. Exp. 
Med. Nov 21 2011;208(12):2489-2496. 
68. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions 
that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 
1995;13:251-276. 
69. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. 
Nat. Rev. Immunol. Feb 2003;3(2):133-146. 
70. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new 
players in the regulation of T cell responses. Immunity. Nov 2003;19(5):641-644. 
71. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and 
clinical application. Clin. Cancer Res. Aug 15 2007;13(16):4677-4685. 
72. Lee JB, Lee KA, Chang J. Phenotypic changes induced by IL-12 priming regulate effector 
and memory CD8 T cell differentiation. Int. Immunol. Sep 2007;19(9):1039-1048. 
73. Kang BY, Kim E, Kim TS. Regulatory mechanisms and their therapeutic implications of 
interleukin-12 production in immune cells. Cell. Signal. Jun 2005;17(6):665-673. 
74. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation 
of CD40 on dendritic cells triggers production of high levels of interleukin-12 and 
enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. Aug 1 
1996;184(2):747-752. 
75. Koch F, Stanzl U, Jennewein P, et al. High level IL-12 production by murine dendritic 
cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and 
IL-10. J. Exp. Med. Aug 1 1996;184(2):741-746. 
76. Chang J, Cho JH, Lee SW, Choi SY, Ha SJ, Sung YC. IL-12 priming during in vitro 
antigenic stimulation changes properties of CD8 T cells and increases generation of 
effector and memory cells. J. Immunol. Mar 1 2004;172(5):2818-2826. 
77. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is 
composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. Jun 
1 2002;168(11):5699-5708. 
78. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a 
cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 
Nov 2000;13(5):715-725. 
79. Schuijs MJ, Willart MA, Hammad H, Lambrecht BN. Cytokine targets in airway 
inflammation. Curr. Opin. Pharmacol. Jun 2013;13(3):351-361. 
80. Eberlein J, Nguyen TT, Victorino F, Golden-Mason L, Rosen HR, Homann D. 
Comprehensive assessment of chemokine expression profiles by flow cytometry. J. Clin. 
Invest. Mar 2010;120(3):907-923. 
81. Morelli AE, Zahorchak AF, Larregina AT, et al. Cytokine production by mouse myeloid 
dendritic cells in relation to differentiation and terminal maturation induced by 
lipopolysaccharide or CD40 ligation. Blood. Sep 1 2001;98(5):1512-1523. 
82. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. Mar 
2002;2(3):151-161. 
83. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell 
precursors. Annu. Rev. Immunol. 2005;23:275-306. 
84. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for 
distinct subsets of dendritic cells in human peripheral blood. J. Immunol. Dec 1 
2000;165(11):6037-6046. 
85. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic 
cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell 
antigens. J. Exp. Med. Jun 7 2010;207(6):1247-1260. 
86. Zhou T, Chen Y, Hao L, Zhang Y. DC-SIGN and immunoregulation. Cell. Mol. Immunol. 
Aug 2006;3(4):279-283. 
87. Condon TV, Sawyer RT, Fenton MJ, Riches DW. Lung dendritic cells at the innate-
adaptive immune interface. J. Leukoc. Biol. Nov 2011;90(5):883-895. 
LITERATURE 
91 
88. Manh TP, Alexandre Y, Baranek T, Crozat K, Dalod M. Plasmacytoid, conventional, and 
monocyte-derived dendritic cells undergo a profound and convergent genetic 
reprogramming during their maturation. Eur. J. Immunol. Jul 2013;43(7):1706-1715. 
89. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal 
dendritic cells obtained from normal human skin reveals phenotypic and functionally 
distinctive subsets. J. Immunol. Dec 1 1993;151(11):6535-6545. 
90. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent 
immunostimulatory dendritic cells in vitro. J. Exp. Med. Mar 1 1985;161(3):526-546. 
91. Wu L, Li CL, Shortman K. Thymic dendritic cell precursors: relationship to the T 
lymphocyte lineage and phenotype of the dendritic cell progeny. J. Exp. Med. Sep 1 
1996;184(3):903-911. 
92. Vremec D, Shortman K. Dendritic cell subtypes in mouse lymphoid organs: cross-
correlation of surface markers, changes with incubation, and differences among thymus, 
spleen, and lymph nodes. J. Immunol. Jul 15 1997;159(2):565-573. 
93. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally 
mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations 
identified. J. Exp. Med. Nov 1 1996;184(5):1953-1962. 
94. Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells 
in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 
ligand-treated mice. J. Immunol. Sep 1 1997;159(5):2222-2231. 
95. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime 
cytotoxic T cells in vivo. J. Exp. Med. Dec 18 2000;192(12):1685-1696. 
96. Ohteki T, Fukao T, Suzue K, et al. Interleukin 12-dependent interferon gamma production 
by CD8alpha+ lymphoid dendritic cells. J. Exp. Med. Jun 21 1999;189(12):1981-1986. 
97. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from 
mouse bone marrow cultures supplemented with granulocyte/macrophage colony-
stimulating factor. J. Exp. Med. Dec 1 1992;176(6):1693-1702. 
98. Scheicher C, Mehlig M, Zecher R, Reske K. Dendritic cells from mouse bone marrow: in 
vitro differentiation using low doses of recombinant granulocyte-macrophage colony-
stimulating factor. J. Immunol. Methods. Oct 2 1992;154(2):253-264. 
99. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha 
cooperate in the generation of dendritic Langerhans cells. Nature. Nov 19 
1992;360(6401):258-261. 
100. Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells 
among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit 
ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J. Immunol. 
Jun 1 1995;154(11):5851-5861. 
101. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human 
blood. An improved method with special regard to clinical applicability. J. Immunol. 
Methods. Sep 27 1996;196(2):137-151. 
102. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocyte conditioned 
medium is more effective than defined cytokines in mediating the terminal maturation of 
human dendritic cells. Blood. Nov 1 1997;90(9):3640-3646. 
103. Kim SJ, Diamond B. Modulation of tolerogenic dendritic cells and autoimmunity. Semin. 
Cell Dev. Biol. Apr 18 2014. 
104. Mackern-Oberti JP, Vega F, Llanos C, Bueno SM, Kalergis AM. Targeting Dendritic Cell 
Function during Systemic Autoimmunity to Restore Tolerance. Int J Mol Sci. 
2014;15(9):16381-16417. 
105. Specht JM, Wang G, Do MT, et al. Dendritic cells retrovirally transduced with a model 
antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. 
Med. Oct 20 1997;186(8):1213-1221. 
106. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to 
tumors. J. Exp. Med. Oct 20 1997;186(8):1183-1187. 
107. Rogers NM, Ferenbach DA, Isenberg JS, Thomson AW, Hughes J. Dendritic cells and 
macrophages in the kidney: a spectrum of good and evil. Nat Rev Nephrol. Sep 30 2014. 
LITERATURE 
92 
108. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus 
by allogeneic stimulation of blood cells from healthy donors. Cell. Oct 3 1997;91(1):119-
126. 
109. Salazar F, Ghaemmaghami AM. Allergen recognition by innate immune cells: critical role 
of dendritic and epithelial cells. Front. Immunol. 2013;4:356. 
110. D'Hulst A I, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA. Time course of cigarette 
smoke-induced pulmonary inflammation in mice. Eur. Respir. J. Aug 2005;26(2):204-213. 
111. Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels 
RA. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to 
eosinophilic airway inflammation. J. Clin. Invest. Aug 2000;106(4):551-559. 
112. Lynch JP, Mazzone SB, Rogers MJ, et al. The plasmacytoid dendritic cell: at the cross-
roads in asthma. Eur. Respir. J. Jan 2014;43(1):264-275. 
113. Leonard CT, Soccal PM, Singer L, et al. Dendritic cells and macrophages in lung 
allografts: A role in chronic rejection? Am. J. Respir. Crit. Care Med. Apr 2000;161(4 Pt 
1):1349-1354. 
114. Yousem SA, Ray L, Paradis IL, Dauber JA, Griffith BP. Potential role of dendritic cells in 
bronchiolitis obliterans in heart-lung transplantation. Ann. Thorac. Surg. Mar 
1990;49(3):424-428. 
115. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. Sep 27 
2007;449(7161):419-426. 
116. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. 
Proc. Natl. Acad. Sci. U. S. A. Jun 15 1962;48:1014-1022. 
117. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir. Res. 
2001;2(1):10-19. 
118. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: 
biologic activity and clinical implications. J. Clin. Oncol. Mar 2000;18(5):1135-1149. 
119. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. 
Cell Dev. Biol. 2001;17:463-516. 
120. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. 
Crit. Rev. Oral Biol. Med. 1993;4(2):197-250. 
121. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of 
inflammation and innate immunity. Nat. Rev. Immunol. Aug 2004;4(8):617-629. 
122. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and 
TIMPs. Cardiovasc. Res. Feb 15 2006;69(3):562-573. 
123. Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their 
physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol. Chem. Jun 
2003;384(6):863-872. 
124. Song F, Wisithphrom K, Zhou J, Windsor LJ. Matrix metalloproteinase dependent and 
independent collagen degradation. Front. Biosci. 2006;11:3100-3120. 
125. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of 
activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-
site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc. Natl. 
Acad. Sci. U. S. A. Jan 1990;87(1):364-368. 
126. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of 
metalloproteinase activity with potential applicability to the entire matrix metalloproteinase 
gene family. Proc. Natl. Acad. Sci. U. S. A. Jul 1990;87(14):5578-5582. 
127. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. 
Physiol. Rev. Jan 1993;73(1):161-195. 
128. Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by 
triggered human neutrophils. Proc. Natl. Acad. Sci. U. S. A. Jun 1986;83(12):4322-4326. 
129. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: signaling 
pathway to neuronal cell death. Science. Aug 16 2002;297(5584):1186-1190. 
130. Knauper V, Murphy G. Methods for studying activation of matrix metalloproteinases. 
Methods Mol. Biol. 2010;622:233-243. 
131. Clark IM, Cawston TE. Fragments of human fibroblast collagenase. Purification and 
characterization. Biochem. J. Oct 1 1989;263(1):201-206. 
LITERATURE 
93 
132. Kleiner DE, Jr., Tuuttila A, Tryggvason K, Stetler-Stevenson WG. Stability analysis of 
latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of 
metalloproteinases-2 (TIMP-2). Biochemistry. Feb 16 1993;32(6):1583-1592. 
133. Willenbrock F, Crabbe T, Slocombe PM, et al. The activity of the tissue inhibitors of 
metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the 
inhibition of gelatinase A. Biochemistry. Apr 27 1993;32(16):4330-4337. 
134. Heath JK, Reynolds JJ, Meikle MC. Osteopetrotic (grey-lethal) bone produces collagenase 
and TIMP in organ culture: regulation by vitamin A. Biochem. Biophys. Res. Commun. 
May 16 1990;168(3):1171-1176. 
135. Zucker S, Cao J. Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: 
ready for prime time? Cancer Biol. Ther. Dec 2009;8(24):2371-2373. 
136. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic 
metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. Nov 15 
1993;268(32):23824-23829. 
137. Belaaouaj A, Shipley JM, Kobayashi DK, et al. Human macrophage metalloelastase. 
Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. 
J. Biol. Chem. Jun 16 1995;270(24):14568-14575. 
138. Chandler S, Cossins J, Lury J, Wells G. Macrophage metalloelastase degrades matrix and 
myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem. 
Biophys. Res. Commun. Nov 12 1996;228(2):421-429. 
139. Gronski TJ, Jr., Martin RL, Kobayashi DK, et al. Hydrolysis of a broad spectrum of 
extracellular matrix proteins by human macrophage elastase. J. Biol. Chem. May 2 
1997;272(18):12189-12194. 
140. Banda MJ, Rice AG, Griffin GL, Senior RM. Alpha 1-proteinase inhibitor is a neutrophil 
chemoattractant after proteolytic inactivation by macrophage elastase. J. Biol. Chem. Mar 
25 1988;263(9):4481-4484. 
141. Banda MJ, Werb Z. Mouse macrophage elastase. Purification and characterization as a 
metalloproteinase. Biochem. J. Feb 1 1981;193(2):589-605. 
142. Hiller O, Lichte A, Oberpichler A, Kocourek A, Tschesche H. Matrix metalloproteinases 
collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix 
metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J. Biol. 
Chem. Oct 20 2000;275(42):33008-33013. 
143. Koolwijk P, Sidenius N, Peters E, et al. Proteolysis of the urokinase-type plasminogen 
activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. 
Blood. May 15 2001;97(10):3123-3131. 
144. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of 
human collagenase-3. J. Biol. Chem. Jan 19 1996;271(3):1544-1550. 
145. Freije JM, Diez-Itza I, Balbin M, et al. Molecular cloning and expression of collagenase-3, 
a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. Jun 
17 1994;269(24):16766-16773. 
146. Lovejoy B, Welch AR, Carr S, et al. Crystal structures of MMP-1 and -13 reveal the 
structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. Mar 
1999;6(3):217-221. 
147. Gomis-Ruth FX, Gohlke U, Betz M, et al. The helping hand of collagenase-3 (MMP-13): 
2.7 A crystal structure of its C-terminal haemopexin-like domain. J. Mol. Biol. Dec 6 
1996;264(3):556-566. 
148. Welgus HG, Kobayashi DK, Jeffrey JJ. The collagen substrate specificity of rat uterus 
collagenase. J. Biol. Chem. Dec 10 1983;258(23):14162-14165. 
149. Knauper V, Cowell S, Smith B, et al. The role of the C-terminal domain of human 
collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and 
tissue inhibitor of metalloproteinase interaction. J. Biol. Chem. Mar 21 1997;272(12):7608-
7616. 
150. Welgus HG, Grant GA, Sacchettini JC, Roswit WT, Jeffrey JJ. The gelatinolytic activity of 
rat uterus collagenase. J. Biol. Chem. Nov 5 1985;260(25):13601-13606. 
LITERATURE 
94 
151. Lemaitre V, Jungbluth A, Eeckhout Y. The recombinant catalytic domain of mouse 
collagenase-3 depolymerizes type I collagen by cleaving its aminotelopeptides. Biochem. 
Biophys. Res. Commun. Jan 3 1997;230(1):202-205. 
152. Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan 
by collagenase-3 (MMP-13). FEBS Lett. Feb 12 1996;380(1-2):17-20. 
153. Nethery A, O'Grady RL. Interstitial collagenase from rat mammary carcinoma cells: 
interaction with substrates and inhibitors. Invasion Metastasis. 1991;11(5):241-248. 
154. Eeckhout Y, Riccomi H, Cambiaso C, Vaes G, Masson P. Studies on properties common to 
collagen and Clq. Arch. Int. Physiol. Biochim. 1976;84(3):611-612. 
155. Leeman MF, Curran S, Murray GI. The structure, regulation, and function of human matrix 
metalloproteinase-13. Crit. Rev. Biochem. Mol. Biol. 2002;37(3):149-166. 
156. Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. Biochim. Biophys. 
Acta. Aug 2014;1840(8):2571-2580. 
157. Schmidt-Hansen B, Ornas D, Grigorian M, et al. Extracellular S100A4(mts1) stimulates 
invasive growth of mouse endothelial cells and modulates MMP-13 matrix 
metalloproteinase activity. Oncogene. Jul 15 2004;23(32):5487-5495. 
158. Hattori N, Mochizuki S, Kishi K, et al. MMP-13 plays a role in keratinocyte migration, 
angiogenesis, and contraction in mouse skin wound healing. Am. J. Pathol. Aug 
2009;175(2):533-546. 
159. Yamagiwa H, Tokunaga K, Hayami T, et al. Expression of metalloproteinase-13 
(Collagenase-3) is induced during fracture healing in mice. Bone. Aug 1999;25(2):197-
203. 
160. Inada M, Wang Y, Byrne MH, et al. Critical roles for collagenase-3 (Mmp13) in 
development of growth plate cartilage and in endochondral ossification. Proc. Natl. Acad. 
Sci. U. S. A. Dec 7 2004;101(49):17192-17197. 
161. Wahlgren J, Maisi P, Sorsa T, et al. Expression and induction of collagenases (MMP-8 and 
-13) in plasma cells associated with bone-destructive lesions. J. Pathol. Jun 
2001;194(2):217-224. 
162. Westhoff CS, Freudiger D, Petrow P, et al. Characterization of collagenase 3 (matrix 
metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial 
fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum. Jul 1999;42(7):1517-
1527. 
163. Ravanti L, Heino J, Lopez-Otin C, Kahari VM. Induction of collagenase-3 (MMP-13) 
expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 
mitogen-activated protein kinase. J. Biol. Chem. Jan 22 1999;274(4):2446-2455. 
164. Blavier L, Delaisse JM. Matrix metalloproteinases are obligatory for the migration of 
preosteoclasts to the developing marrow cavity of primitive long bones. J. Cell Sci. Dec 
1995;108 ( Pt 12):3649-3659. 
165. Mitchell PG, Magna HA, Reeves LM, et al. Cloning, expression, and type II collagenolytic 
activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Invest. 
Feb 1 1996;97(3):761-768. 
166. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, 
collagenase-3, is expressed and synthesized by human chondrocytes but not by 
synoviocytes. A role in osteoarthritis. J. Clin. Invest. May 1 1996;97(9):2011-2019. 
167. Mao D, Lee JK, VanVickle SJ, Thompson RW. Expression of collagenase-3 (MMP-13) in 
human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem. 
Biophys. Res. Commun. Aug 11 1999;261(3):904-910. 
168. Nagel S, Sandy JD, Meyding-Lamade U, Schwark C, Bartsch JW, Wagner S. Focal 
cerebral ischemia induces changes in both MMP-13 and aggrecan around individual 
neurons. Brain Res. Sep 14 2005;1056(1):43-50. 
169. Botos I, Meyer E, Swanson SM, Lemaitre V, Eeckhout Y, Meyer EF. Structure of 
recombinant mouse collagenase-3 (MMP-13). J. Mol. Biol. Oct 1 1999;292(4):837-844. 
170. Chen Z, Gordon JR, Zhang X, Xiang J. Analysis of the gene expression profiles of 
immature versus mature bone marrow-derived dendritic cells using DNA arrays. Biochem. 
Biophys. Res. Commun. Jan 11 2002;290(1):66-72. 
LITERATURE 
95 
171. Zaslona Z, Wilhelm J, Cakarova L, et al. Transcriptome profiling of primary murine 
monocytes, lung macrophages and lung dendritic cells reveals a distinct expression of 
genes involved in cell trafficking. Respir. Res. 2009;10:2. 
172. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is 
required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. 
Acad. Sci. U. S. A. Apr 30 1996;93(9):3942-3946. 
173. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J. Joint diseases and matrix 
metalloproteinases: a role for MMP-13. Curr. Pharm. Biotechnol. Feb 2008;9(1):47-54. 
174. Stickens D, Behonick DJ, Ortega N, et al. Altered endochondral bone development in 
matrix metalloproteinase 13-deficient mice. Development. Dec 2004;131(23):5883-5895. 
175. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate 
basement membrane transmigration in vitro. J. Immunol. May 1 1995;154(9):4379-4389. 
176. Baratelli FE, Heuze-Vourc'h N, Krysan K, et al. Prostaglandin E2-dependent enhancement 
of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration 
through extracellular matrix. J. Immunol. Nov 1 2004;173(9):5458-5466. 
177. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix 
metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J. 
Immunol. Oct 1 1998;161(7):3340-3346. 
178. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix 
metalloproteinases. J. Biol. Chem. Jun 21 1996;271(25):14657-14660. 
179. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin 
activation by the metalloproteinase matrilysin in innate host defense. Science. Oct 1 
1999;286(5437):113-117. 
180. Saarialho-Kere U, Kerkela E, Jeskanen L, et al. Accumulation of matrilysin (MMP-7) and 
macrophage metalloelastase (MMP-12) in actinic damage. J. Invest. Dermatol. Oct 
1999;113(4):664-672. 
181. Suomela S, Kariniemi AL, Snellman E, Saarialho-Kere U. Metalloelastase (MMP-12) and 
92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in 
psoriatic lesions. Exp. Dermatol. Jun 2001;10(3):175-183. 
182. Matsumoto S, Kobayashi T, Katoh M, et al. Expression and localization of matrix 
metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion 
development. Am. J. Pathol. Jul 1998;153(1):109-119. 
183. Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization 
of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J. 
Clin. Invest. Dec 1 1998;102(11):1900-1910. 
184. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate 
angiostatin: effects on neovascularization. J. Immunol. Dec 15 1998;161(12):6845-6852. 
185. Kerkela E, Bohling T, Herva R, Uria JA, Saarialho-Kere U. Human macrophage 
metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development 
and malignant transformation. Bone. Nov 2001;29(5):487-493. 
186. Belvisi MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the 
pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for 
inhibitors of MMPs? Inflamm. Res. Mar 2003;52(3):95-100. 
187. Nenan S, Boichot E, Lagente V, Bertrand CP. Macrophage elastase (MMP-12): a pro-
inflammatory mediator? Mem. Inst. Oswaldo Cruz. Mar 2005;100 Suppl 1:167-172. 
188. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage 
elastase for cigarette smoke-induced emphysema in mice. Science. Sep 26 
1997;277(5334):2002-2004. 
189. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-
13) genes in arthritis: integration of complex signaling pathways for the recruitment of 
gene-specific transcription factors. Arthritis Res. 2002;4(3):157-164. 
190. Uitto VJ, Airola K, Vaalamo M, et al. Collagenase-3 (matrix metalloproteinase-13) 
expression is induced in oral mucosal epithelium during chronic inflammation. Am. J. 
Pathol. Jun 1998;152(6):1489-1499. 
LITERATURE 
96 
191. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix 
metalloproteinase family members in breast cancer represents a tumor-induced host 
response. Am. J. Pathol. Jul 1996;149(1):273-282. 
192. Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C. Regulation of collagenase-
3 expression in human breast carcinomas is mediated by stromal-epithelial cell 
interactions. Cancer Res. Nov 1 1997;57(21):4882-4888. 
193. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM. 
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of 
the head and neck. Am. J. Pathol. Aug 1997;151(2):499-508. 
194. Airola K, Johansson N, Kariniemi AL, Kahari VM, Saarialho-Kere UK. Human 
collagenase-3 is expressed in malignant squamous epithelium of the skin. J. Invest. 
Dermatol. Aug 1997;109(2):225-231. 
195. Johansson N, Vaalamo M, Grenman S, et al. Collagenase-3 (MMP-13) is expressed by 
tumor cells in invasive vulvar squamous cell carcinomas. Am. J. Pathol. Feb 
1999;154(2):469-480. 
196. Uria JA, Balbin M, Lopez JM, et al. Collagenase-3 (MMP-13) expression in 
chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am. J. Pathol. 
Jul 1998;153(1):91-101. 
197. Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, 
multifarious, and multifaceted. Physiol. Rev. Jan 2007;87(1):69-98. 
198. Nishijima C, Hayakawa I, Matsushita T, et al. Autoantibody against matrix 
metalloproteinase-3 in patients with systemic sclerosis. Clin. Exp. Immunol. Nov 
2004;138(2):357-363. 
199. Demedts IK, Brusselle GG, Bracke KR, Vermaelen KY, Pauwels RA. Matrix 
metalloproteinases in asthma and COPD. Curr. Opin. Pharmacol. Jun 2005;5(3):257-263. 
200. Molet S, Belleguic C, Lena H, et al. Increase in macrophage elastase (MMP-12) in lungs 
from patients with chronic obstructive pulmonary disease. Inflamm. Res. Jan 
2005;54(1):31-36. 
201. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates 
with lung function and airway inflammation in children with cystic fibrosis. Pediatr. 
Pulmonol. Mar 2005;39(3):224-232. 
202. Taghavi S, Krenn K, Jaksch P, Klepetko W, Aharinejad S. Broncho-alveolar lavage matrix 
metalloproteases as a sensitive measure of bronchiolitis obliterans. Am. J. Transplant. Jun 
2005;5(6):1548-1552. 
203. Hubner RH, Meffert S, Mundt U, et al. Matrix metalloproteinase-9 in bronchiolitis 
obliterans syndrome after lung transplantation. Eur. Respir. J. Mar 2005;25(3):494-501. 
204. Chen P, Farivar AS, Mulligan MS, Madtes DK. Tissue inhibitor of metalloproteinase-1 
deficiency abrogates obliterative airway disease after heterotopic tracheal transplantation. 
Am. J. Respir. Cell Mol. Biol. Apr 2006;34(4):464-472. 
205. Beeh KM, Beier J, Kornmann O, Micke P, Buhl R. Sputum levels of metalloproteinase-9 
and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction 
in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. J. 
Heart Lung Transplant. Nov 2001;20(11):1144-1151. 
206. Fernandez FG, Campbell LG, Liu W, et al. Inhibition of obliterative airway disease 
development in murine tracheal allografts by matrix metalloproteinase-9 deficiency. Am. J. 
Transplant. Apr 2005;5(4 Pt 1):671-683. 
207. Khatwa UA, Kleibrink BE, Shapiro SD, Subramaniam M. MMP-8 promotes 
polymorphonuclear cell migration through collagen barriers in obliterative bronchiolitis. J. 
Leukoc. Biol. Jan 2010;87(1):69-77. 
208. Inaki N, Tsunezuka Y, Kawakami K, et al. Increased matrix metalloproteinase-2 and 
membrane type 1 matrix metalloproteinase activity and expression in heterotopically 
transplanted murine tracheas. J. Heart Lung Transplant. Feb 2004;23(2):218-227. 
209. Aurora P, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society 
for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung 
transplantation report--2010. J. Heart Lung Transplant. Oct 2010;29(10):1129-1141. 
LITERATURE 
97 
210. Verleden GM. Chronic allograft rejection (obliterative bronchiolitis). Semin. Respir. Crit. 
Care Med. Oct 2001;22(5):551-558. 
211. Sato M. Chronic lung allograft dysfunction after lung transplantation: the moving target. 
Gen. Thorac. Cardiovasc. Surg. Feb 2013;61(2):67-78. 
212. U.S. Department of Health and Human Services HRaSA, Healthcare Systems Bureau, 
Division of Transplantation, Rockville, MD. Annual Report of the U.S. Organ 
Procurement and Transplantation Network and the Scientific Registry of Transplant 
Recipients: Transplant Data 1999-2008. 2009. 
213. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans 
syndrome after lung transplantation revealed by azithromycin therapy. Eur. Respir. J. Oct 
2008;32(4):832-843. 
214. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am. J. 
Respir. Crit. Care Med. Aug 15 2002;166(4):440-444. 
215. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update 
of the diagnostic criteria. J. Heart Lung Transplant. Mar 2002;21(3):297-310. 
216. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac 
Soc. Jul 2006;3(5):444-449. 
217. Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative 
bronchiolitis lesion after heterotopic transplantation of mouse airways. Am. J. Pathol. Jun 
1993;142(6):1945-1951. 
218. Snyder LD, Palmer SM. Immune mechanisms of lung allograft rejection. Semin. Respir. 
Crit. Care Med. Oct 2006;27(5):534-543. 
219. Neuringer IP, Chalermskulrat W, Aris R. Obliterative bronchiolitis or chronic lung 
allograft rejection: a basic science review. J. Heart Lung Transplant. Jan 2005;24(1):3-19. 
220. Neuringer IP, Mannon RB, Coffman TM, et al. Immune cells in a mouse airway model of 
obliterative bronchiolitis. Am. J. Respir. Cell Mol. Biol. Sep 1998;19(3):379-386. 
221. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the 
classification of pulmonary allograft rejection: Lung Rejection Study Group. J. Heart Lung 
Transplant. Jan 1996;15(1 Pt 1):1-15. 
222. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of 
lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am. J. 
Respir. Crit. Care Med. May 1 2008;177(9):1033-1040. 
223. Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of 
minimal acute rejection after lung transplantation. Transplantation. Nov 27 
2005;80(10):1406-1413. 
224. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development 
of bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. Mar 1999;159(3):829-
833. 
225. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence 
chronic allograft rejection. Transplantation. Feb 15 1995;59(3):313-318. 
226. Kelly K, Hertz MI. Obliterative bronchiolitis. Clin. Chest Med. Jun 1997;18(2):319-338. 
227. Trulock EP. Lung transplantation. Am. J. Respir. Crit. Care Med. Mar 1997;155(3):789-
818. 
228. Grossman EJ, Shilling RA. Bronchiolitis obliterans in lung transplantation: the good, the 
bad, and the future. Transl. Res. Apr 2009;153(4):153-165. 
229. Benichou G. Direct and indirect antigen recognition: the pathways to allograft immune 
rejection. Front. Biosci. May 15 1999;4:D476-480. 
230. Solari MG, Thomson AW. Human dendritic cells and transplant outcome. Transplantation. 
Jun 15 2008;85(11):1513-1522. 
231. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney 
allografts by the addition of donor strain dendritic cells. J. Exp. Med. Jan 1 
1982;155(1):31-41. 
232. Milne DS, Gascoigne AD, Coaker J, et al. Mononuclear phagocyte populations in the 
transplanted human lung. Transplantation. Sep 15 1998;66(5):671-673. 
LITERATURE 
98 
233. KleinJan A, Willart MA, Kuipers H, Coyle AJ, Hoogsteden HC, Lambrecht BN. Inducible 
costimulator blockade prolongs airway luminal patency in a mouse model of obliterative 
bronchiolitis. Transplantation. Nov 27 2008;86(10):1436-1444. 
234. Smith GN, Jr., Mickler EA, Payne KK, et al. Lung transplant metalloproteinase levels are 
elevated prior to bronchiolitis obliterans syndrome. Am. J. Transplant. Jul 2007;7(7):1856-
1861. 
235. Hele DJ, Yacoub MH, Belvisi MG. The heterotopic tracheal allograft as an animal model 
of obliterative bronchiolitis. Respir. Res. 2001;2(3):169-183. 
236. Karttunen J, Sanderson S, Shastri N. Detection of rare antigen-presenting cells by the lacZ 
T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. 
Natl. Acad. Sci. U. S. A. Jul 1 1992;89(13):6020-6024. 
237. Harding CV, Collins DS, Kanagawa O, Unanue ER. Liposome-encapsulated antigens 
engender lysosomal processing for class II MHC presentation and cytosolic processing for 
class I presentation. J. Immunol. Nov 1 1991;147(9):2860-2863. 
238. Grove DA, Xu J, Joodi R, et al. Attenuation of early airway obstruction by mesenchymal 
stem cells in a murine model of heterotopic tracheal transplantation. J. Heart Lung 
Transplant. Mar 2011;30(3):341-350. 
239. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation. Adv. Exp. 
Med. Biol. 1997;417:1-6. 
240. Meunier L, Bohjanen K, Voorhees JJ, Cooper KD. Retinoic acid upregulates human 
Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a 
beta 2 integrin critically involved in T-cell activation. J. Invest. Dermatol. Dec 
1994;103(6):775-779. 
241. Jungraithmayr W, Jang JH, Schrepfer S, Inci I, Weder W. Small animal models of 
experimental obliterative bronchiolitis. Am. J. Respir. Cell Mol. Biol. Jun 2013;48(6):675-
684. 
242. Inaba K, Swiggard WJ, Steinman RM, Romani N, Schuler G. Isolation of dendritic cells. 
Curr. Protoc. Immunol. May 2001;Chapter 3:Unit 3.7. 
243. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction 
of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. Jul 11 
1997;277(5323):225-228. 
244. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor 
invasion. FASEB J. May 1999;13(8):781-792. 
245. Ichiyasu H, McCormack JM, McCarthy KM, Dombkowski D, Preffer FI, Schneeberger 
EE. Matrix metalloproteinase-9-deficient dendritic cells have impaired migration through 
tracheal epithelial tight junctions. Am. J. Respir. Cell Mol. Biol. Jun 2004;30(6):761-770. 
246. Chabot V, Reverdiau P, Iochmann S, et al. CCL5-enhanced human immature dendritic cell 
migration through the basement membrane in vitro depends on matrix metalloproteinase-9. 
J. Leukoc. Biol. Apr 2006;79(4):767-778. 
247. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition 
after myocardial infarction: a new approach to prevent heart failure? Circ. Res. Aug 3 
2001;89(3):201-210. 
248. Zozulya AL, Reinke E, Baiu DC, Karman J, Sandor M, Fabry Z. Dendritic cell 
transmigration through brain microvessel endothelium is regulated by MIP-1alpha 
chemokine and matrix metalloproteinases. J. Immunol. Jan 1 2007;178(1):520-529. 
249. Castro MM, Tanus-Santos JE. Inhibition of matrix metalloproteinases (MMPs) as a 
potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr. 
Drug Targets. Mar 2013;14(3):335-343. 
250. Haq I, Lowrey GE, Kalsheker N, Johnson SR. Matrix metalloproteinase-12 (MMP-12) 
SNP affects MMP activity, lung macrophage infiltration and protects against emphysema 
in COPD. Thorax. Nov 2011;66(11):970-976. 
251. Sato M, Hirayama S, Lara-Guerra H, et al. MMP-dependent migration of extrapulmonary 
myofibroblast progenitors contributing to posttransplant airway fibrosis in the lung. Am. J. 
Transplant. May 2009;9(5):1027-1036. 
252. Burgstaller G, Oehrle B, Koch I, Lindner M, Eickelberg O. Multiplex profiling of cellular 
invasion in 3D cell culture models. PLoS One. 2013;8(5):e63121. 
LITERATURE 
99 
253. Lecomte J, Masset A, Blacher S, et al. Bone marrow-derived myofibroblasts are the 
providers of pro-invasive matrix metalloproteinase 13 in primary tumor. Neoplasia. Oct 
2012;14(10):943-951. 
254. Kobayashi Y, Matsumoto M, Kotani M, Makino T. Possible involvement of matrix 
metalloproteinase-9 in Langerhans cell migration and maturation. J. Immunol. Dec 1 
1999;163(11):5989-5993. 
255. Kis-Toth K, Bacskai I, Gogolak P, Mazlo A, Szatmari I, Rajnavolgyi E. Monocyte-derived 
dendritic cell subpopulations use different types of matrix metalloproteinases inhibited by 
GM6001. Immunobiology. Nov 2013;218(11):1361-1369. 
256. Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. EBI1/CCR7 is a new 
member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. 
Immunol. Sep 15 1998;161(6):3096-3102. 
257. Garrett WS, Chen LM, Kroschewski R, et al. Developmental control of endocytosis in 
dendritic cells by Cdc42. Cell. Aug 4 2000;102(3):325-334. 
258. Watts C, Amigorena S. Antigen traffic pathways in dendritic cells. Traffic. Apr 
2000;1(4):312-317. 
259. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptor-mediated induction of 
dendritic cell maturation and major histocompatibility complex class I-restricted antigen 
presentation after immune complex internalization. J. Exp. Med. Jan 18 1999;189(2):371-
380. 
260. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake 
and intracellular routing in CD4 and CD8 T cell activation. Science. Apr 27 
2007;316(5824):612-616. 
261. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble 
but not of cell-associated antigen for cross-presentation. J. Immunol. Jun 1 
2006;176(11):6770-6776. 
262. Platt CD, Ma JK, Chalouni C, et al. Mature dendritic cells use endocytic receptors to 
capture and present antigens. Proc. Natl. Acad. Sci. U. S. A. Mar 2 2010;107(9):4287-4292. 
263. Lee SJ, Evers S, Roeder D, et al. Mannose receptor-mediated regulation of serum 
glycoprotein homeostasis. Science. Mar 8 2002;295(5561):1898-1901. 
264. Rivera-Marrero CA, Schuyler W, Roser S, Ritzenthaler JD, Newburn SA, Roman J. M. 
tuberculosis induction of matrix metalloproteinase-9: the role of mannose and receptor-
mediated mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol. Mar 2002;282(3):L546-
555. 
265. Engelholm LH, Nielsen BS, Netzel-Arnett S, et al. The urokinase plasminogen activator 
receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase 
plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis. Lab. 
Invest. Oct 2001;81(10):1403-1414. 
266. Sadhu C, Ting HJ, Lipsky B, et al. CD11c/CD18: novel ligands and a role in delayed-type 
hypersensitivity. J. Leukoc. Biol. Jun 2007;81(6):1395-1403. 
267. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases 
and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. Dec 
2007;82(6):1375-1381. 
268. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent 
functions. Nat. Rev. Immunol. Jul 2005;5(7):521-531. 
269. Godefroy E, Manches O, Dreno B, et al. Matrix metalloproteinase-2 conditions human 
dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent 
pathway. Cancer Cell. Mar 8 2011;19(3):333-346. 
270. Oriss TB, Krishnamoorthy N, Raundhal M, et al. Cutting Edge: MMP-9 inhibits IL-23p19 
expression in dendritic cells by targeting membrane stem cell factor affecting lung IL-17 
response. J. Immunol. Jun 15 2014;192(12):5471-5475. 
271. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. Mar 
1997;61(3):246-257. 
272. Ikonen TS, Brazelton TR, Berry GJ, Shorthouse RS, Morris RE. Epithelial re-growth is 
associated with inhibition of obliterative airway disease in orthotopic tracheal allografts in 
non-immunosuppressed rats. Transplantation. Sep 27 2000;70(6):857-863. 
LITERATURE 
100 
273. Jiang X, Khan MA, Tian W, et al. Adenovirus-mediated HIF-1alpha gene transfer 
promotes repair of mouse airway allograft microvasculature and attenuates chronic 
rejection. J. Clin. Invest. Jun 2011;121(6):2336-2349. 
274. Babu AN, Murakawa T, Thurman JM, et al. Microvascular destruction identifies murine 
allografts that cannot be rescued from airway fibrosis. J. Clin. Invest. Dec 
2007;117(12):3774-3785. 
275. Khan MA, Nicolls MR. Complement-mediated microvascular injury leads to chronic 
rejection. Adv. Exp. Med. Biol. 2013;735:233-246. 
276. Dutly AE, Andrade CF, Verkaik R, et al. A novel model for post-transplant obliterative 
airway disease reveals angiogenesis from the pulmonary circulation. Am. J. Transplant. 
Feb 2005;5(2):248-254. 
277. Sato M, Hwang DM, Guan Z, et al. Regression of allograft airway fibrosis: the role of 
MMP-dependent tissue remodeling in obliterative bronchiolitis after lung transplantation. 
Am. J. Pathol. Sep 2011;179(3):1287-1300. 
278. Sato M, Liu M, Anraku M, et al. Allograft airway fibrosis in the pulmonary milieu: a 
disorder of tissue remodeling. Am. J. Transplant. Mar 2008;8(3):517-528. 
 
LIST OF TABLES 
101 
LIST OF TABLES 
Table 2.1: Antibodies for flow cytometry analysis .......................................................................... 15 
Table 2.2: Isotypes for flow cytometry analysis .............................................................................. 15 
Table 2.3: Primary antibodies for immunofluorescence staining ..................................................... 16 
Table 2.4: Isotypes for immunofluorescence staining ...................................................................... 16 
Table 2.5: Secondary antibodies for immunofluorescence staining ................................................. 16 
Table 2.6: Murine cell lines.............................................................................................................. 18 
Table 2.7: Laboratory equipment ..................................................................................................... 19 
Table 2.8: Software .......................................................................................................................... 20 
Table 2.9: Chemicals ........................................................................................................................ 20 
Table 2.10: Consumables ................................................................................................................. 22 
Table 2.11: Kits ................................................................................................................................ 22 
Table 2.12: Enzymes ........................................................................................................................ 22 
Table 2.13: Mouse primer ................................................................................................................ 23 
Table 2.14: DC medium ................................................................................................................... 24 
Table 2.15: T cell medium ............................................................................................................... 24 
Table 2.16: Ab-mix for DCs ............................................................................................................ 27 
Table 2.17: LacZ buffer ................................................................................................................... 28 
Table 2.18: Mastermix for reverse transcription .............................................................................. 29 
Table 2.19: Mastermix for qRT-PCR ............................................................................................... 29 
Table 2.20: Ab-mix for maturation markers .................................................................................... 33 
Table 2.21: Ab-mix for MHC-I presentation ................................................................................... 33 
Table 2.22: Ab-mix for quantification of SIINFEKL-peptide presentation ..................................... 33 
Table 2.23: Ab-mix for myeloid cells .............................................................................................. 34 
Table 2.24: Ab-mix for lymphocytes ............................................................................................... 34 
LIST OF FIGURE 
102 
LIST OF FIGURES 
Figure 1.1: Schematic overview of DC function. ............................................................................... 2 
Figure 1.2: Antigen processing and presentation on MHC-I or MHC-II. .......................................... 4 
Figure 1.3: Basic structure of MMPs. ................................................................................................ 8 
Figure 3.1: Generation of BMDCs in vitro. ..................................................................................... 37 
Figure 3.2: Gating strategy of generated BMDCs. ........................................................................... 38 
Figure 3.3: MMP-12 and -13 expression in unstimulated BMDCs on RNA and protein level. ...... 39 
Figure 3.4: Expression kinetics of MMP-12 and -13 on RNA level. ............................................... 39 
Figure 3.5: Increased MMP-13 expression after inflammatory stimulus. ........................................ 40 
Figure 3.6: Increased active MMP-12 and -13 after LPS stimulation. ............................................. 41 
Figure 3.7: Toxicity measurements of MMP inhibitors using WST-1 assay. .................................. 42 
Figure 3.8: Efficacy of inhibitor for murine MMP-12 or -13 protein. ............................................. 42 
Figure 3.9: Design of the 3D migration assay. ................................................................................. 43 
Figure 3.10: Control setting of the 3D migration assay. .................................................................. 44 
Figure 3.11: No influence of MMP-12 or -13 inhibition on BMDC migration. .............................. 45 
Figure 3.12: Decreased endocytosis of soluble OVA in MMP-12 ko BMDCs................................ 46 
Figure 3.13: Involvement of MMP-13 in endocytosis of soluble OVA in BMDCs......................... 47 
Figure 3.14: No toxic effect of MMP-13 inhibitor on BMDCs, B3Z, or DOBW cells. ................... 48 
Figure 3.15: Decreased capacity of BMDCs to activate B3Z CD8+ T cells by MMP-13  
inhibition. ..................................................................................................................... 50 
Figure 3.16: Inhibition does not affect BMDCs regarding activation of DOBW CD4+ T 
lymphocytes. ................................................................................................................ 51 
Figure 3.17: Involvement of MMP-13 in peptide presentation. ....................................................... 51 
Figure 3.18: Decreased MHC-I surface expression on DCs after MMP-13 inhibition. ................... 52 
Figure 3.19: MMP-13 inhibition does not change the LPS-induced maturation profile of  
BMDCs. ....................................................................................................................... 53 
Figure 3.20: Decreased CD11c surface expression after inhibition of MMP-13. ............................ 53 
Figure 3.21: T cell-targeting cytokines/chemokines in response to LPS and after MMP-13 
inhibition. ..................................................................................................................... 55 
Figure 3.22: Granulocyte-attracting chemokines in response to LPS and after MMP-13  
inhibition. ..................................................................................................................... 56 
Figure 3.23: Monocyte- , memory T cell-, and DC-attracting chemokine in response to LPS and 
after MMP-13 inhibition. ............................................................................................. 57 
Figure 3.24: The heterotopic trachea transplant model. ................................................................... 58 
Figure 3.25: Lumina occlusion and epithelial damage can be detected in the allografts on day 14 
and 21. .......................................................................................................................... 59 
LIST OF FIGURES 
103 
Figure 3.26: Epithelial loss and collagen deposition in explanted tracheas on day 14 and 21. ........ 60 
Figure 3.27: Fibroblast invasion and neovascularization in allografts on day 14 and 21. ............... 61 
Figure 3.28: Inflammatory character of BOS by intraluminal leukocyte influx in allografts on  
day 21. ......................................................................................................................... 62 
Figure 3.29: Invasion of intraluminal T lymphocytes in allografts on day 21. ................................ 62 
Figure 3.30: Invasion of macrophages in allografts on day 21. ....................................................... 63 
Figure 3.31: Gating strategy to analyze lymphocyte subsets in blood. ............................................ 64 
Figure 3.32: Gating strategy to analyze lymphocyte subsets in lymph nodes. ................................. 65 
Figure 3.33: Quantification of lymphocyte subsets in blood and lymph nodes of transplanted  
mice. ............................................................................................................................ 66 
Figure 3.34: Gating strategy to analyze granulocytes and monocytes in blood. .............................. 67 
Figure 3.35: Gating strategy to analyze DCs in lymph nodes. ......................................................... 68 
Figure 3.36: Quantification of myeloid cells.................................................................................... 68 
Figure 3.37: Increased MMP-13 expression in allografts. ............................................................... 69 
Figure 3.38: MMP-12 protein localization in tracheas before and after transplantation. ................. 70 
Figure 3.39: MMP-13 protein localization in tracheas before and after transplantation. ................. 71 
Figure 3.40: Quantification of lymphocytes in blood and lymph nodes of transplanted mice  
treated with MMP-13 inhibitor. ................................................................................... 72 
Figure 3.41: Quantification of myeloid cells after MMP-13 inhibitor treatment. ............................ 73 
Figure 3.42: MMP-13 inhibitor treatment in vivo diminishes the development of the BOS    
phenotype moderately. ................................................................................................. 74 
ABBREVIATIONS 
104 
LIST OF ABBREVIATIONS 
A 
 Ag Antigen 
Anova Analysis of variance 
APC Antigen-presenting cell 
APMA 4-Aminophenylmercuric Acetate  
APS Ammonium peroxodisulfate 
α-SMA Alpha smooth muscle actin 
  B 
 BAL Bronchoalveolar lavage 
BMDC Bone marrow-derived dendritic cell 
BOS Bronchiolitis obliterans syndrome  
bp Base pairs 
BSA Bovine serum albumin 
  C 
 c Concentration  
CCL Chemokine (C-C motif) ligand 
CD Cluster of differentiation 
cDCs Classical dendritic cell 
cDNA Complementary DNA 
CLAD Chronic lung allograft dysfunction  
COPD Chronic obstructive pulmonary disease  
CPRG Chlorophenol red-β-D-galactopyranoside 
CXCL Chemokine (C-X-C motif) ligand 
°C Degrees Celsius 
  
D 
 d Day 
Da Dalton 
DAPI 4',6-diamidino-2-phenylindole 
DC-LAMP DC lysosome-associated membrane protein 
DCs Dendritic cell 
DC-SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
Denat. Denaturated 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Desoxy-nucleotide-tri-phosphate 
dsRNA Double-stranded RNA 
DTT Dithiothreitol 
  E 
 ECM Extracellular matrix 
ABBREVIATIONS 
105 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
  F 
 FBS Fetal bovine serum 
Fc Fragment crystallizable 
FD Fold difference 
FEV1 Forced expiratory volume 1  
FRET Fluorescence resonance energy transfer 
FSC Forward Scatter  
  
G 
 g Gram 
G Gravity 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Gly Glycin 
GM-CSF Granulocyte macrophage colony-stimulating factor 
  H 
 h Hour(s) 
H&E Hematoxylin and eosin 
HEPES N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
HRP Horseradish peroxidase 
HTT Heterotopic trachea transplant  
  I 
 i.p. Intraperitoneal 
ICAM Intercellular adhesion molecules 
IF Immunofluorescence 
IFN Interferon 
IgG Immunoglobulin protein G 
IL Interleukin 
IMPs Smaller inhibitor of metalloproteinase  
  K 
 k Kilo 
KO Knock-out 
  L 
 l Liter 
L Ligand 
LFA Lymphocyte function-associated antigen 
LIMPs Large inhibitor of metalloproteinase  
LIX LPS-induced CXC chemokine 
LPS Lipopolysaccharide 
  
ABBREVIATIONS 
106 
M 
 m Milli 
M Molar 
mA Milli Ampere 
max. Maximum 
mc Monoclonal 
M-CSF Macrophage colony-stimulating factor 
mDC Myeloid dendritic cell 
MgCl2 Magnesiumchlorid 
MHC-I/-II Major histocompatibility complex class I/II 
min Minimum 
min Minute 
ml Milliliter 
MMP Matrix metalloproteinase 
MR Mannose receptor 
mRNA Messenger RNA 
MT-MMP Membrane-type MMP  
µ Micro 
  N 
 n Nano 
NaCl Sodium chloride 
NaOH Natriumhydroxid 
NK  Natural killer  
No Number 
NP40 Nonidet P-40 
  O 
 ON Over night 
OVA Ovalbumin  
  P 
 p Pico 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphatate buffered saline 
pc Polyclonal 
PC Polycarbonate 
PCR Polymerase chain reaction 
pDC Plasmacytoid dendritic cell 
PFA Paraformaldehyde 
PI Propidium iodide  
PS Phospholipid phosphatidylserine  
  Q 
 qRT-PCR Quantitative real-time polymerase chain reaction 
  
  
ABBREVIATIONS 
107 
R 
 RAS Restrictive allograft syndrome 
RIPA Radio-immunoprecipitation assay 
RNA Ribonucleic acid 
rpm Revolutions per minute 
RT Room temperature 
  S 
 s Second 
SDS Sodium dodecyl sulphate 
SNP Single nucleotide polymorphism 
SSC Side Scatter 
STAT Signal Transducers and Activators of Transcription 
  T 
 TAE Tris-acetate-EDTA 
TAP Transporter associated with antigen processing  
TBS Tris-buffered saline 
TBS-T Tris-buffered saline with TWEEN®20 
TCR T cell receptor  
TEMED N,N,N’,N’-Tetramethylenediamine 
TERC Telomerase RNA component 
TERT Telomerase reverse transcriptase 
TGF Transforming growth factor 
Th1/Th2/Th17 T helper cells type 1/2/17 
TIMP Tissue inhibitor of metalloproteinase 
TLR Toll-like receptors 
TNF Tumor necrosis factor 
tPA Tissue-type plasminogen activator  
Tregs Regulatory T cell 
TRIS Tris(hydroxymethyl)-aminomethane 
  U 
 U Unit 
uPA Urokinase type plasminogen activator  
uPAR Urokinase-type plasminogen activator receptor  
  V 
 V Volt 
V Volume 
vs Versus 
  
W 
 W Weight 
WST Water soluble tetrazolium 
WT Wild-type 
 
ACKNOWLEDGEMENT 
108 
ACKNOWLEDGEMENT 
Foremost, I would like to express my special thanks to Prof. Dr. Elfriede Nößner, for her kind 
and excellent supervision, extensive scientific discussions, and encouraging support during the past 
four years.  
I am grateful to Dr. Werner von Wulffen, Dr. Marion Frankenberger, and Prof. Oliver 
Eickelberg for giving me the opportunity to write my thesis in the Comprehensive Pneumology 
Center and the chance to gain interesting experiences at diverse conferences. 
I would also particularly like to thank Heidi Villena-Hermoza for her kind support and for her 
outstanding technical assistance. 
I am grateful to all current and former members of the CPC who supported me during my thesis 
especially, Bettina Oehrle, Ilona Keller, Andrea Schamberger, Dr. Barbara Berschneider, Dr. 
Katharina Heinzelmann, Elisabeth Hennen, Kyra Peters, Katharina Lippl, Ann-Christin 
Beitel, Daniela Dietel, Konstanze Heise, and Deniz Bölükbas for their kind support and for 
technical assistance. 
Furthermore, I want to highlight the friendship of my fellow PhD students. In particular I want to 
thank Bettina Oehrle, Emma Gbandi, Sabine Bartel, Andrea Schamberger, Franziska Uhl, 
Nunja Habel-Ungewitter, Lilia Zvintzou, Ilona Keller, and Murali Sarguru for the fun time in 
and outside the lab. 
Special thanks to Andrea Schamberger for her fussy proofreading of abstracts and her musically 
support in the lab and to Ilona Keller that her office was always open for me. 
Special thanks to Bettina Oehrle for her help during the last four years, for the fun on conferences, 
for carefully proofreading my thesis, more than once, and for simply being the best friend ever!  
I dearly thank my parents for their help, their support and that they are always encouraging me. 
Special thanks to my mother who took care of Nero when I was in the lab and to Amelia and 
Frank Schlott who supported me with Nero in addition.  
My deepest thanks to Fabian who always discussed with me scientific issues, even late at night or 
at the weekends and who always supported me, even he was busy with his own thesis. 
– Thank you for always being there for me.  
EIDESSTATTLICHE VERSICHERUNG 
109 
EIDESSTATTLICHE VERSICHERUNG 
 
Ich, Juliane Bartmann, erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem 
Thema 
 
 
Immunobiological Functions of Matrix Metalloproteinase-13 in Bone Marrow-Derived 
Dendritic Cells and its Contribution to the Pathogenesis of Bronchiolitis Obliterans 
Syndrome 
 
selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und alle 
Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche kenntlich 
gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe. Ich 
erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher Form 
bei einer anderen Stelle zur Erlangung eines akademischen Grades eingereicht wurde.  
 
 
 
 
 
Ort, Datum       Unterschrift 
 
 
 
 
 
 
 
 
 
 
